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ABSTRACT 
 
The British Association for Psychopharmacology guidelines specify the scope and targets 
of treatment for bipolar disorder. The third version is based explicitly on the available 
evidence and presented, like previous Clinical Practice Guidelines, as recommendations 
to aid clinical decision making for practitioners: it may also serve as a source of 
information for patients and carers, and assist audit. The recommendations are presented 
together with a more detailed review of the corresponding evidence. A consensus 
meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and 
considered the strength of evidence and clinical implications. The guidelines were drawn 
up after extensive feedback from these participants. The best evidence from randomized 
controlled trials and, where available, observational studies employing quasi-
experimental designs was used to evaluate treatment options. The strength of 
recommendations has been described using the GRADE approach. The guidelines cover 
the diagnosis of bipolar disorder, clinical management, and strategies for the use of 
medicines: in short-term treatment of episodes, relapse prevention and stopping 
treatment. The use of medication is integrated with a coherent approach to 
psychoeducation and behaviour change. 
 
 
 
Key words: bipolar disorder; treatment; evidence-based guidelines; antipsychotics, 
antidepressants, mood stabilizers, lithium, psychoeducation; Cognitive Behaviour 
Therapy. 
 
Comment [GG1]: HOW MANY 
INTRODUCTION 
 
Bipolar disorder has been and still is a relatively neglected condition. This feeds a 
perception, which we broadly share, that treatment could and should be improved. 
Guidelines provide an opportunity to enhance quality of care by advocating particular 
treatment approaches through systematically derived statements that can help individual 
patients and clinicians to make decisions. They have had an important impact on patterns 
of prescribing for bipolar patients (Bjorklund et al., 2015).  
 
Guideline recommendations are based on evidence. Nevertheless, the principal 
recommendations usually derive from average effects in patient populations. Such 
recommendations may be expected to apply about 70% of the time so we have used 
expressions like “Clinicians should consider…..” in the text. However, there will be 
occasions when adhering to such a recommendation unthinkingly could do more harm 
than good.  
 
We will also describe treatment options in a way that is not prescriptive. They recognise 
that implementation will depend on individual and local circumstances. Options will 
reflect up-to-date evidence and may highlight current uncertainties.  
 
Finally, we make consensus statements, the implications of which should shape and 
inform decision making. 
 
This guideline should be read alongside NICE 2014 Bipolar disorder: assessment and 
management (NICE2014) (https://www.nice.org.uk/guidance/cg185 ), the 
recommendations from which are in places compared with our own. 
  
The quality of the evidence base 
 
Evidence categories (I to IV) traditionally imply a hierarchy from the best evidence, 
based on high quality randomized trials, to the weakest, based on opinion/clinical 
impression (Shekelle et al., 1999).  This approach explicitly downgrades non-
experimental descriptive studies of treatment effects in favour of any RCT; in so doing, it 
confounds design with quality.  
 
Table 1. near here 
In previous editions (Goodwin, 2003; Goodwin, 2009), we ranked individual 
recommendations on the basis of the supporting evidence using this scheme. This can be 
unduly formulaic. For example, weight may be given to positive findings from small, 
inconclusive studies simply because they were randomized trials. Like others (Kessing, 
2015), we have been impressed by new observational data linking treatment exposures 
with clinical outcome. In the past such data would have been rated inferior to RCTs as a 
matter of principle (see Table 1). However, the quality and scale of some routinely 
collected data sets can provide relatively unbiased and reliable evidence for the 
effectiveness and safety of a treatment. While non-randomized, such evidence is more 
convincing than any but the highest quality RCTs, and with superior external validity. In 
addition, the availability of network meta-analysis of RCTs has given us the opportunity 
to re-think how to contextualize the quality of the evidence for an individual drug in the 
overall treatment strategy.  
 
The need for a more flexible appraisal of the evidence has been recognized by the 
Cochrane Collaboration’s GRADE system 
(http://handbook.cochrane.org/chapter_12/12_2.htm). Even though we could not adopt 
the detailed methodology recommended for its full implementation, as a bottom up 
procedure, we followed the spirit of the GRADE approach, top down, to justify the 
quality standard of recommendations in our different treatment sections. We already have 
the major data synthesis conducted for NICE2014, so we did not replicate their efforts. 
The point of the GRADE system is to make the basis for choosing recommendations 
transparent.  
 
Finally we have made many recommendations for standards of care. Standards are 
intended to apply rigidly. Many standards are driven by ethical or clinical consensus 
rather than formal evidence. Where standards are evidence-based, confidence and 
consensus must be very high, requiring that standards be adhered to most of the time.  We 
have phrased such recommendations without qualification and marked (S), so ‘Clinicians 
should …… (S)’.  
 
Throughout, a particular recommendation will imply an estimation of average 
benefit/risk.  In fact, the estimation of potential benefits and harms is not a widely 
understood science. It is very encouraging that the European Medicines Agency has 
allowed pioneering work in recent years to apply decision theory to the approval process 
of new drugs (Phillips et al., 2011). This demonstrates the potential to understand benefit-
risk using quantitative models (Mt-Isa et al., 2014). It is an approach that has also 
informed the estimate of relative harms by drugs that are used ‘recreationally’ (Nutt et al., 
2010). In a better future, such models could be used by doctors or patients who want 
robust estimates of benefits and harms, to inform decisions in an individual case.  For the 
time being, we have made do with opinion based on research evidence, the decisions of 
regulators to approve particular medicines and clinical experience. 
 
METHODOLOGY 
 
This document is the result of an initial meeting held on 9
th
 February 2015.  Expert 
participants were asked to review specific areas in which new data have become available 
from systematic reviews, randomized controlled trials (RCTs) or observational studies. 
After brief presentation, a discussion identified consensus and areas of uncertainty.  A 
narrative literature review was assembled to illustrate the consensus points. This draft 
was circulated to participants. Their feedback was, as far as possible incorporated into the 
final version of the guidelines.  
 
Identification of Relevant Evidence 
 
All the consensus points and the guideline recommendations can be linked to relevant 
evidence through the literature review. As already explained, our methodology did not 
allow for a systematic review of all possible data from primary sources and the recent 
NICE2014 bipolar guideline provided a comprehensive collation of relevant data to about 
two years ago (http://www.nice.org.uk/guidance/cg185). Additional publications were 
identified from MEDLINE searches to December 2015. 
 
STRENGTHS OF EVIDENCE AND RECOMMENDATIONS FOR GUIDELINES 
 
Strengths of Recommendation 
 
Grade of recommendations are shown in Table 2. This approach allows for judgement to 
be made that downgrades some evidence (e.g. results, even if consistent, from small 
clinical trials, where bias is highly likely), and upgrades other findings (e.g. from 
observational studies in large samples with strong quasi-experimental designs). Where 
evidence is sparse, it has been necessary to extrapolate from relevant evidence where it is 
available. Weaker levels of recommendation may cover key areas of practice. 
Recommendations will be starred as in Table 2. 
 
Table 2 near here. 
 
Scope and Target of the Guidelines 
 
The content of the guidelines is relevant for all doctors treating patients with bipolar 
disorder.  We hope that in most cases these will be doctors who are specialists in 
psychiatry.  However we have also written the guidelines to help inform general 
practitioners, patients and their families, and other health care professionals involved in 
the management of patients with bipolar disorder.  
 
Clinical psychologists and other colleagues providing psychotherapy to patients with 
bipolar disorder are a particularly important group who need to understand and 
acknowledge the complementary roles for patients of medication and psychological 
treatment.  
 
We have emphasized our interest in evidence. However, we could not review all the 
relevant literature in the detail required to give a fully comprehensive text. Even distilling 
the evidence and summarising points of consensus, relating mainly to medical 
management of bipolar disorder, does not result in a format that is particularly brief or 
easy to use. Accordingly, the document consists of two parts. Part 1 abstracts the key 
recommendations (and some of the key points of evidence) and can inform everyday 
practice. Part 2 indicates consensus points that emerged and briefly summarises the 
evidence. The structure and content are broadly but not precisely aligned between Parts 1 
and 2. 
 
Finally, in Part I, we identified a list of quality standards for audit based on our most 
important recommendations. 
  
Nomenclature 
 
In this manuscript, we will avoid, where possible, the use of generic terms for drugs 
based on indication and instead prefer to use descriptions of mode of action. The 
Neuroscience based Nomenclature (NbN) is a new system to promote the description and 
classification of psychotropic drugs in this way. It aims to provide an app-based update of 
relevant and specific scientific, regulatory and clinical information, to support rational 
prescribing (https://www.ecnp.eu/projects-initiatives/nomenclature.aspx ). The use of a 
pharmacologically driven nomenclature, which highlights pharmacological targets and 
modes of action, helps clinicians to make informed choices (for example by combining 
two different targets or adding a complementary mode of action). It is a work in progress, 
and the voluntary suppression of the familiar terms antipsychotic, antidepressant and 
anticonvulsant can only be partial.  When we use the term antidepressant, for example, it 
should be understood that we are referring to drugs used in the treatment of unipolar 
depression. The problem is, of course, that not all the drugs used for unipolar depression 
are currently described as antidepressants and antidepressants are not active specifically 
in depression. Thus, antipsychotics are effective in psychosis, mania and, in some cases, 
depression, and anticonvulsants are effective in epilepsy but also mania and depression. 
NbN will give us a larger vocabulary and a better grasp of what our medicines actually do 
if we make the necessary effort.  
 
 
CAVEATS 
 
We are committed to the principle of basing recommendations on the best possible 
evidence and, for treatment efficacy, this will usually be evidence from randomized 
controlled trials (RCTs). However, there are important limitations to such evidence. We 
highlight these limitations here so what follows is informed by this perspective. 
 
Drug treatment trials  
 
Drug trials are usually conducted by companies seeking to register new compounds. Such 
trials are now usually of good quality: matched placebo medication, randomized and 
concealed allocation, blinded treatment and pre-specified analysis plans. Nevertheless, it 
is often stated that sponsor (allegiance) bias influences the outcome of clinical trials of 
new medicines (in favour of the sponsored product). One important explanation for this 
global conclusion is that company sponsored studies may more often be placebo 
controlled than independent studies, and will tend to have larger effect sizes for that 
reason. Indeed, for dopamine antagonists and serotonin reuptake inhibitors there were no 
differences in effect size between industry supported and non-industry supported trials 
when the designs were similar (Lundh et al., 2012). The unthinking position that 
companies can fix the results of their studies to inflate positive effects is wrong, and is 
not the main reason we should treat such studies with caution. 
 
In fact, sponsors can only easily influence outcomes by biasing the design of the study: 
for example, choice of dose, comparator or unblinding (if adverse reactions are obvious). 
Unblinding could lead to inflation of effect sizes by biasing assessment. Measures of 
blinding should be included in all such studies for patients and raters, but are often 
omitted or not reported. This potential problem should be kept in mind when examining 
the coherence of network meta-analyses which include placebo as the main comparator. 
 
The reporting of adverse reactions in clinical trials is also less systematic than it could be, 
and has often relied on ambiguous tick-box categories to capture usually subjective 
complaints. The controversy arising from how self harm or suicidality should be 
identified as an adverse reaction has been particularly problematic(Gibbons et al., 2015; 
Posner et al., 2007). This means that the balance between benefits and harms can be 
difficult to assess from trial data. In describing outcomes that patients may experience 
themselves or that may be detectable by observation we will refer to “adverse reactions”; 
“adverse effects” are unwanted, measured consequences of drug treatment (Aronson, 
2013).  
 
Sponsor bias is also confused with publication bias. There is no doubt that the way 
industry-supported data was published has been a major problem in past decades. This 
mainly took the form of over-stating product advantages and cherry picking for 
publication the most positive trials or the most positive outcome measures. Non-
publication of negative results was also very common. This is now partially corrected by 
trial registration and disclosure of ‘negative’ studies by companies. In addition, full 
disclosure of all analysed data has long been required by the regulatory authorities and 
this information is usually accessible if not actually published. 
 
The quality and reproducibility of individual trials is critical. As a rule, companies must 
convince regulators that new drugs are better than placebo.  Can they recruit 
representative patients into the necessary trials?  While the patients recruited into 
company trials meet diagnostic criteria for BD, the list of inclusion/exclusion criteria is 
often so long as to render the resulting sample highly atypical, and not representative of 
the most ill patients with multiple co-morbidities we actually see in practice.  The 
exclusion of patients with co-morbid substance misuse in trials of mania and of patients 
with suicidality in bipolar depression has the highest impact (Hoertel et al., 2013). This is 
compounded by heterogeneous rates of recruitment and associated with heterogeneous 
results across sites in multi-centre trials. In acute studies, high placebo response rates at 
some sites will drown out efficacy signals at others with lower placebo responses 
(Yatham et al., 2015b). In addition, many acute treatment studies in psychiatry are only 
6-8 weeks in duration and the artificial nature of clinical trial procedures and the 
difficulties of recruitment mean dropout rates are high. This severely reduces the power 
to detect effects, so trial methodology is probably as likely to under-estimate drug effect 
as to magnify it.  
 
Substantial drop out rates are common even in quite short-term RCTs. The right to drop 
out of studies is actually emphasized in the information given to participants in trials! 
However, high attrition rates have negative consequences for the power to detect effects 
and obviously defeat the purpose of longer-term studies. The effect is sometimes 
described as a bias, and NICE2014 heavily downgrades many of the RCTs for the 
medication of bipolar disorder on this basis. We have not taken the same view, because it 
is clearly a limitation of RCTs in general, but when particularly severe, it must limit the 
validity and generalizability of any conclusions (Leon et al., 2006). 
 
Finally, outcomes in acute treatment studies are often rating scale scores, which are 
arbitrary counts of symptoms and their severity. These are measures rarely used by 
clinicians because they are tedious to obtain by interview.  They are intermediate 
measures suspended between biomarkers, which can prove a drug has had the predicted 
pharmacological effect, and real outcomes relevant to patients (for example return to 
work). Real outcomes are too distal to provide sensitivity in a short clinical trial.  
 
For all these reasons, caution is required in extrapolating the results of such trials to 
practice, whether or not presented as a meta-analysis.  
 
Independent trials have often been less well-resourced and small scale, but may lack the 
stigma attaching to industry sponsorship. The results of such trials have the potential to 
be very misleading due to the whole range of potential biases. However, where quality is 
maintained and sample size is reasonable, they can offer important independent support 
to prove efficacy.  They may also recruit patients in a less distorted way than commercial 
clinical research organizations and so generalize more convincingly. Positive studies of 
this kind have been particularly important in shaping some of our recommendations (e.g. 
the use of lithium and lamotrigine).  
 
One final consideration is that when small trials are negative, caution is required in 
claiming that the trial proves lack of efficacy: underpowered studies by definition run a 
high risk of type II statistical error. 
 
In conclusion, RCTs provide an important evidence base for all medical practice. Effect 
sizes in psychiatry, in common with the rest of medicine, are moderate (Leucht et al., 
2012) but deliver worthwhile patient benefit. Nihilism about the results of RCTs should 
be avoided. However, RCTs are essentially experiments; their results are most plausible 
when confirmed by large scale, independent, pragmatic RCTs conducted in real world 
patient samples. There are few examples of such trials in psychiatry.  More relevant 
currently are pharmaco-epidemiological studies using quasi-experimental designs. In 
such studies patients can act as their own controls before, during and after treatment, 
patient numbers can be very large and observation periods can be long. Furthermore, the 
measured outcomes can be objective and highly clinically relevant: admission to hospital, 
suicide, acts of violence etc. Such studies are crucial in supporting our recommendations 
for the long-term use of drugs in bipolar disorder. 
 
 
Psychotherapy trials 
 
Psychotherapy trials pose difficulties for evidence-based practice that have not been 
sufficiently recognized. The choice of a fair comparison treatment is much more 
challenging than for medicines. It is often simply ducked by using a poorly specified 
‘treatment as usual’ (TAU) condition. While this may be defensible in a pragmatic study 
of effectiveness, it creates problems of interpretation for a proof of concept or efficacy 
study. If, as is commonly the case, the active treatment is superior to TAU, no specificity 
can be claimed for its content. The alternative ‘waiting list’ control group is also 
problematic because any superiority for an active treatment may be due to (or amplified 
by) a waiting list’s expected nocebo effect. Hence, many positive trials of particular 
therapies are pseudo-specific, in the sense that we do not know what elements of the 
psychotherapy are actually effective.  
 
The collection of ‘adverse reactions’ to psychological treatment also appears to be 
unsystematic and hence under-appreciated (Nutt and Sharpe, 2008).  
 
These inherent problems require an approach to refining best practice based on 
meticulous trial design and execution and sequential refinement of the psychotherapy 
content. Biomarkers or more experimental designs could also inform treatment 
development in psychotherapy trials (Button and Munafo, 2015). Unfortunately, 
development funding is often not available in the way that is taken for granted for the 
development of new drugs by industry.  
 
As a corollary of limited funding, psychotherapy trials are often small scale and suffer 
from all the disadvantages of similar, independent trials of medicines. Moreover, 
psychotherapy trials may be particularly subject to allegiance bias. This will mean that 
investigators are heavily invested professionally in showing that ‘their’ treatment works. 
This may consciously or unconsciously influence how trials are designed, treatments 
delivered and results described.  It can also influence how results are analysed, if 
statistical methods are not pre-specified. Publication in a high profile journal or 
endorsement in a guideline will increase the demand for workshops and training that may 
remunerate a provider personally, and will be used to demonstrate impact by their 
employing institution. Thus, declaration of interest should be taken seriously in the 
publication of psychosocial interventions (Dragioti et al., 2015). Given a strong appetite 
from patients for psychological solutions, there is a prevailing pressure to reach positive 
but premature judgements. 
 
Publication bias is objectively as important a problem for psychotherapy trials as for drug 
trials (Flint et al., 2015). However, there is not the safeguard that is provided by the 
formal disclosure of negative studies in the regulation of drug treatments.  
 
Meta-analysis cannot resolve uncertainty where the methodology of the individual RCTs 
is flawed.  In the case of bipolar disorder, the paucity of research in psychological and 
psychosocial treatments is as regrettable as for the other domains of treatment. Future 
studies that can avoid the mistakes of the past and present can therefore be 
enthusiastically anticipated. For now, we have favoured caution in interpreting the 
findings from trials of psychosocial interventions. Just as for drug treatments, more large-
scale data with harder outcomes (admission to hospital, offending) would be very 
welcome, but is not currently available. 
 
Relapse prevention trial designs 
 
These studies are required by The European Medicines Agency (EMA) as proof of 
continuing efficacy for drugs shown to be effective in short-term studies of acute illness. 
They offer a further proof of acute efficacy since they take patients who have recovered 
while taking a particular active treatment and randomize to continue that treatment or be 
switched to placebo. If patients on placebo relapse to the same pole as the index episode, 
this is taken as further evidence that the drug worked acutely. 
 
If these studies are extended over one or even two years, there must be a point at which 
we can infer further that the drug-placebo difference represents prevention of new 
episodes. Since there is no clear discontinuity in the boundary between preventing relapse 
of the original episode and the prevention of new episodes, perhaps they are essentially 
different sides of the same coin?  Relapse prevention studies have been interpreted in that 
way in previous BAP guidelines. However, it is recognized that much of the difference 
between active treatment arms and placebo are due to early events, and dropout rates tend 
to be very high. Retention of patients in a 1-2 year study may be as low as 10%. Hence, 
interpretation of such studies, except in relation to acute efficacy may be questionable.  
 
It may also be objected that such studies are ‘enriched’ with patients who have 
preferentially responded to the drug under investigation. Clearly this is true, but in actual 
practice this may often reflect the clinical question a psychiatrist asks: what will happen 
if I discontinue the drug? Knowing that there will be a risk of relapse is useful and 
informs clinical practice. This is really the only experimental evidence that supports the 
belief that what gets patients well will often keep them well. Relapse prevention studies 
underline that lesson, and offer us more safety data than are available in acute studies.  
 
Finally, the definition of relapse in relapse prevention studies requires care. Acute 
withdrawal of a drug may lead to subjective changes and effects on sleep, which are often 
the mirror image of adverse reactions to taking the drug (for example vivid dreams after 
withdrawal of drugs that suppress REM sleep).  Withdrawal reactions of this kind by 
definition immediately follow drug discontinuation and are relatively transient. However, 
in theory, withdrawal effects could be mistaken for relapse; if so, this must result in an 
excess of cases of very early relapse which are artefactual.  Studies in which such an 
effect is observed are very difficult to interpret.  More subtly, such effects could lead to 
unblinding and bias the assessment of patients later in the course of follow up.  
 
On the other hand, drug withdrawal effects may also trigger an excess of true cases of 
early relapse compared with untreated patients. At present such an effect has only been 
convincingly shown with lithium, where it is a clinically important phenomenon (Suppes 
et al., 1991; Goodwin, 1994)). In theory, such effects might be more likely with those 
treatments that most modify the risk of relapse and act most proximal to the brain 
mechanisms involved in, for example, the onset of mania. 
 NICE2014 effectively discounted much of the longer term data generated by relapse-
prevention studies. In contrast, we accept them for what they are while recognizing their 
limitations. Further where randomized data and high quality naturalistic data support the 
same the conclusions, then those findings are likely to be of particular validity and should 
clearly influence treatment recommendations. 
 
Choice of treatment and network meta-analysis 
 
We are impressed by the power of network meta-analysis for understanding treatment 
efficacy and we will refer to such analyses in supporting the use of medicines to treat 
different aspects of bipolar disorder. The principle is to use all the available data that 
meets quality standards and include all trials where medicines are compared directly or 
indirectly via a common comparator (often placebo) (Cipriani et al., 2013b). This can 
identify when a data set is internally consistent (A beats B, B beats C, so A should also 
beat C). Where there is consistency between comparisons with placebo on one hand, and 
active comparators on the other, it is less likely that effects have been biased by 
unblinding. In our view, this is probably the most important current test that RCTs are 
indeed reliable and provide a secure evidence base for clinical decision making. In 
GRADE terminology, a coherent network supports strong ranking for treatment 
recommendations based on RCTs; a sparse or unstable network does not. 
 
Network meta-analysis can also provide a kind of league table to rank different medicines 
against each other (and against placebo). Such findings have strongly influenced the 
NICE recommendations for the treatment of mania and depression. However, confidence 
intervals around the rankings were wide. As we argue in the preceding paragraph, 
practice can be underpinned by the knowledge that the efficacy of the treatment choices 
has been established in RCTs with a coherent network. It does not follow that practice be 
dominated by evidence that one effective treatment is, on average, slightly better than 
another. In addition, extrapolating from average effects in RCTs and meta-analyses to 
what might work amongst a range of effective treatments in a given individual requires 
experience and judgement. Previous history of response, willingness to adhere to a 
treatment, potential benefits and risks given an individual’s personal situation all have a 
bearing on therapeutic outcome. 
 
The key to success with individual patients is cautious but confident prescribing of 
adequate doses and monitoring of effects, both positive and negative. Moreover, drug 
choice is an important clinical freedom in developing treatment with the individual 
patient in relation to both efficacy and adverse reactions. While NICE2014 is at pains to 
emphasize the need to respect patient choice, as are we, they are less liberal in what 
choices they actually sanction. 
PART 1. GUIDELINES  
 
In making recommendations that will be of practical value to clinicians who treat patients 
with bipolar disorder, we stand on the consensus view of the evidence reviewed in the 
accompanying document. The clinical practice guideline developed by NICE2014, has 
also been considered. We have sometimes reached different conclusions. These 
differences result from different weights placed on the available evidence. Differences of 
opinion, of course, are most likely to occur when the evidence is less than compelling. 
 
Along with grading of specific recommendations for a strategy or individual treatment, 
the guideline includes statements, the implications of which should also influence 
practice. The strength of the evidence is rated as in Table 1 (and may relate to RCTs or 
observational findings).  
 
Currently, medication remains the key to successful practice for most patients in the long 
term. The objective is to achieve a personalized choice of medicine (effective and well 
tolerated), informed adherence and an understanding of illness course shared with the 
patient and all most involved in their care.  This needs to be established as early as 
possible in patients who present with severe illness. 
 
FUNDAMENTALS OF PATIENT MANAGEMENT 
 
1. Diagnosis 
 
Clinicians should make accurate diagnoses of hypomania, mania and depression 
(Standard of Care, (S)). Individual episodes may display mixed features of the opposite 
pole (Category I evidence, (I)). 
 
Consider the identification of the core symptoms of mania or depression against a check 
list as in DSM-5 to improve confidence in, and the reliability of diagnosis (S). There is a 
new requirement in DSM-5 for an observable increase in energy and activity in addition 
to subjective mood elevation for hypomania and mania.  Practice may also be made more 
comprehensive with a patient-completed screening instrument (Category IV evidence, 
(IV)). 
 
Failure to use some form of structured record increases the likelihood that bipolar 
disorder will be missed and/or confused with another diagnosis (Category II evidence, 
(II)). 
 
The term hypomania should be used as defined in DSM-5, where it is confined to elated 
states WITHOUT significant functional impairment (S).  
 
Be careful not to dismiss or minimize mood elevation when it is the cause of disturbed 
behavior; personality problems or situational disturbance should be invoked only if mania 
(or hypomania) is absent (IV).  
 
Bipolar patients may present with depression, especially in adolescence (I). Ask about a 
history of distinct periods of elated, excited or irritable mood of any duration and a family 
history of mania in all patients with depression (S). 
 
Anxiety disorders are highly co-morbid with bipolar disorder (I) from a lifetime 
perspective.  Anxiety symptoms are often persistent between episodes and may contribute 
to mood instability (I). 
 
Anxiety disorders are associated with increased illness burden and poor outcome (I): they 
require assessment and treatment (S). 
 
Stimulant drugs may mimic manic symptoms (II). A drug-induced state, including 
psychosis, should wane with the clearance of the offending drug (II): use 5 half-lives as 
the relevant interval (and the longest half-life stated in a range).  Levodopa and 
corticosteroids are the most common prescribed medications associated with secondary 
mania (I). 
 
More commonly, alcohol and/or drug use is co-morbid with manic or depressive mood 
change (I). The mood state will then significantly outlast the drugged state and a 
diagnosis of bipolar disorder can be made (S).  
 
Borderline personality disorder is an important diagnosis that may either be confused 
with or be co-morbid with bipolar disorder. Reliable diagnosis of either condition can 
only be achieved by using operational criteria properly (S). 
 
Organic conditions, such as thyroid disease, multiple sclerosis or any lesion(s) involving 
right-sided sub-cortical or cortical areas may be associated with secondary mania (II) and 
should be considered in the differential diagnosis (S). These conditions are most likely to 
occur in the elderly (I). 
 
The diagnosis of bipolar disorder in childhood has been controversial. The narrow 
definition of the condition, now endorsed in DSM-5 and described in the latest NICE 
guideline (NICE2014), recognizes unequivocal euphoria and an episodic course as the 
defining characteristics in pre-pubertal children (S). One should not make the diagnosis 
in children or young people unless there has been a period of prospective longitudinal 
monitoring by appropriately experienced clinicians taking into account the child or young 
person’s educational and social functioning (S).  
 
Within many child and adolescent services, bipolar disorder may well be missed and the 
challenge is to enhance its recognition. The approach to diagnosis in children is poorly 
operationalized: diagnostic instruments are available that could aid clinical practice (II). 
 
The so-called broad bipolar phenotype of childhood has been replaced by a new 
diagnosis in DSM-5: disruptive mood dysregulation disorder (DMDD). This is not a 
bipolar diagnosis and is likely to be rather common in comparison with bipolar disorder, 
which is rare in prepubescent children (I). 
 Following puberty, the familiar adult criteria can be used with increasing confidence 
(IV).   
 
Bipolar symptoms such as irritability or aggression may appear, with the benefit of 
hindsight, to be misdiagnosed by clinicians when a patient is first seen (I).  In fact, 
diagnosis can only be reliable after a clear-cut episode of (hypo)mania (S). 
 
 
2. Access to services and the safety of the patient and others  
 
Specialized services for bipolar patients of all ages have not been a priority for the NHS, 
and so provision is variable and too often poor (IV). 
 
Early intervention is a highly desirable objective in the management of young people 
with bipolar disorder (S). There are numerous systemic barriers to its provision and 
development in UK services (IV). This is an urgent problem.  
 
When mania is diagnosed, always consider admission to hospital or intensive community 
management (S). The particular risks to the patient and others will be the result of poor 
judgment and associated actions in areas of work, personal relationships, alcohol/drug 
use, spending, driving and sexual activity (I).  
 
Always try to obtain third party information if in any doubt when making a risk 
assessment (S). 
 
When any patient is in a mixed state or depressed, ask about suicidal ideation, intention 
to act on these ideas and extent of plans, means or preparation for suicide (S). Social 
isolation, substance use, psychosis (especially with command hallucinations), personality 
disorder, family history of suicide, recent exposure to suicide and any prior suicide 
attempts may all increase the risk (I).  
 
The increased incidence of completed suicide soon after an assessment in bipolar patients 
(I), suggests that current practice may under-estimate suicide risk (IV).  
 
Bipolar patients may be vulnerable to exploitation or violence when in an abnormal 
mental state, which may make admission more desirable (IV). The risk of violence and 
offending more generally (by the patient) is also increased in bipolar disorder (I) and 
assessment should address this risk (S).  
 
Carefully document your decisions in formulating a care plan (S). 
 
The fractionation of clinical services, for example between in and out patients, 
‘assessment’ and ‘treatment’ runs counter to the needs of bipolar patients in all stages of 
their treatment but particularly in managing follow up (IV). Premature discharge to 
primary care can further dilute the treatment package available in the early stages of 
managing the illness (IV). 
 
3. Enhanced care 
 
a) Establish and maintain a therapeutic alliance  
 
A doctor should take responsibility for diagnosis, physical examination, investigations 
and explanation of the medical plan of management (S). Communicate clearly and 
honestly what you think (S). Take the time to listen to what is bothering the patient (S). 
 
Very disorganized psychotic patients with bipolar disorder will have social needs that 
merit assertive management (IV).  
 
b) Educate the patient and his or her family about the disorder 
 
Doctors, patients and carers tend to bring different experiences and beliefs to the 
therapeutic relationship (II) and make different estimates of future risks. Make use of 
evidence to address poor insight, the seriousness of the illness, reluctance to give up the 
experience of hypomania or mania, the risk of relapse and the benefit of therapeutic 
engagement (II). 
 
c) Enhance treatment adherence  
 
Treatment adherence is often poor, particularly in younger patients early in the illness 
course (I). 
 
While respecting patient preferences, education about the illness after an acute episode 
should include information on the potential benefits and risks of medication and 
emphasize the need to continue on it long-term (S).  
 
The known tolerability and safety of available medicines should guide prescribing: 
inform patients about possible adverse reactions and monitor their possible emergence 
(S). Make the reduction of adverse reactions a priority - by using different scheduling 
(e.g. by prescribing all sedative medicines at bed time), alternative formulations or lower 
dosages (Category III evidence, (III)).  Patience may be required to establish that lower 
doses are effective (IV). 
  
d) Promote awareness of stressors, sleep disturbance, early signs of relapse, and 
regular patterns of activity. 
 
Sleep disruption is often the final common pathway triggering manic episodes and is also 
associated with depression: stressors that lead to reduced sleep may contribute to relapse 
(II).  
 
Regular patterns of daily activities should be promoted (II). Identify and try to modify 
habitual, very irregular patterns of activity, which are common in patients with bipolar 
disorder: consider using diaries or apps to self-monitor mood or activities (III).  
 
Since alcohol and drug use are associated with a poor outcome, they require assessment, 
appropriate advice and treatment (S). 
 
Help the patient, family members, and significant others recognize emerging symptoms 
of manic or depressive episodes so that they may know when to request early intervention 
(S).  
 
A consistent long-term flexible alliance between the patient, the patient’s family and key 
members of a psychiatric team, including an effective, appropriately trained psychiatrist, 
is the ideal arrangement for outpatient care. The input of family members may also 
enhance the patient’s treatment adherence (S). 
 
e) Evaluate and manage functional impairments  
 
Full functional recovery seldom occurs within twelve weeks following the remission of 
mood symptoms (I). Advise the patient in scheduling respite from work or other 
responsibilities when necessary (S). Discourage major life decisions being made while in 
a depressive or manic state (S). 
 
Patients may experience considerable difficulty performing at the level for which their 
education has prepared them (I). Manage patient expectations of their capacity to work 
(S).  
 
Consider the needs of carers and children of patients with bipolar disorder: provide 
information about local or national support groups (S). 
 
f) Consider physical health in clinical assessment and treatment planning 
 
Bipolar patients have premature mortality, owing partly to cardiovascular disease (I). In 
large part this is driven by weight gain. Weight and other relevant risk factors should be 
monitored at least annually and treatment offered appropriately (S).  
 
Consult BAP guideline on management of weight gain and metabolic disturbances 
associated with psychosis and antipsychotic drug treatment (S). 
 
g) Consider the use of alcohol and drugs (including caffeine) 
 
The use of alcohol or drugs may be excessive. Quantify their consumption and discuss 
setting targets for reducing harm (S). Caffeine (in coffee and other drinks) may 
significantly disturb sleep and exacerbate anxiety symptoms in sensitive individuals (III). 
 
h) Consider risks for various adverse outcomes, including self harm, suicide, 
victimization, violence and criminality. 
 
Bipolar patients are at substantially increased risks of self harm, suicide, victimization, 
violence and criminality (I).  
 
Risk factors whose modification could reduce the risks of suicide and criminal outcomes 
include comorbid drug and alcohol use disorders and illness severity (II).   
 
i) Increase the focus of care planning in women of child-bearing potential 
 
The postpartum period is one of very high risk for relapse in women with bipolar disorder 
(I).  Psychosis or mania is a particular risk for bipolar I disorder: it is increased further by 
a previous post-partum episode. Depression is a substantial risk for both bipolar I and II 
disorder. Women need to decide about using medication in pregnancy and during 
breastfeeding (or whether to breast feed), bearing in mind the very high risk of severe 
illness at this time (S). See section on special situations below. 
 
 
TREATMENT OF DIFFERENT PHASES OF BIPOLAR ILLNESS 
 
Prescribers should be aware of the limitations imposed by licences for different 
medicines and potential safety concerns documented in product descriptions (S). 
Marketing authorizations are primarily designed to limit the actions of companies, NOT 
clinicians. Accordingly, ‘Off label’ prescribing of licensed medicines is implied by some 
of the recommendations incorporated below. However, seek expert advice if unsure about 
the efficacy or safety of any individual medicine or its use in combination (S).  
 
Residual symptoms predict eventual relapse (II), so the objective of short term treatment 
is remission of symptoms (S). 
 
We have not specified doses in this section. See Annex for additional information about 
individual medicines and relevant Product Information Sheets. 
 
1. Acute Manic Episodes  
 
Choice of an initial treatment  
 
Most patients with mania will require short-term treatment with medicine(s) in an 
appropriate clinical setting (I).  The evidence from network meta-analysis of many RCTs 
is coherent and supports efficacy of a range of different medicines (I). Thus, comparisons 
in RCTs include many indirect (placebo) and direct comparisons; this reduces the risk 
that unblinding and other bias has significantly distorted the results in individual studies. 
Choice of medicine should respect the balance between the benefit of efficacy and the 
harm of short-term adverse reactions or adverse effects in an individual with mania. 
 
No psychotherapy currently provides an alternative strategy for management. 
 
a) For patients not already taking long-term treatment for bipolar disorder 
 
For severe manic episodes, consider oral administration of a dopamine antagonist when 
seeking rapid anti-manic effect (****). Systematic comparison of data from clinical trials 
suggests that haloperidol, olanzapine, risperidone and quetiapine are particularly effective 
in short-term reduction of symptoms. Valproate is an alternative treatment with less risk 
of adverse motor reactions but should not be used for women of child bearing potential 
because of its unacceptable risk to the foetus of teratogenesis and impaired intellectual 
development. Aripiprazole, other dopamine antagonists and partial agonists, 
carbamazepine and lithium are also options. 
  
Where an agitated patient requires parenteral treatment to control behaviour without their 
full consent, the use of dopamine antagonists/partial agonists and GABA modulators 
(benzodiazepines) should follow established protocols (S). The lowest doses necessary 
should be used (S). Do not escalate the dose of dopamine antagonists simply to obtain a 
sedative effect (S). 
 
For less ill, non-psychotic manic patients or for hypomania, treatment can be extrapolated 
from practice in mania (IV). 
 
To promote sleep for agitated overactive patients in the short term, consider adjunctive 
treatment with GABA modulating drugs (***).  
 
When possible, treatment selection should be guided by a patient’s previous experiences 
and preferences especially if expressed in the form of an advance directive under the 
Mental Capacity Act 2005 (S) or an advance statement. 
 
Antidepressant drugs (i.e. drugs approved for the treatment of unipolar depression) 
should usually be tapered and discontinued in a manic episode (**). 
 
If successful treatment has been initiated for mania, long-term treatment should be 
considered (see below) (S). 
 
b) For patients who suffer a manic episode while taking long-term treatment. 
 
If the current presentation is due to inadequate symptom control, ensure that the highest 
well-tolerated dose of the current treatment is offered (S). For a dopamine antagonist or 
partial agonist, or valproate raising the dose may be sufficient to control manic symptoms 
(IV). 
 
For lithium, check whether serum concentrations are within the usual target range; 
consider aiming for a higher serum concentration within the target range (0.6 - 0.8 
mmol/l (or mEq/l)); concentrations of 0.8-1.0 mmol/l may be more effective but carry a 
greater risk of harm if continued long term (I).  
 If the patient is taking lithium, consider adding a dopamine antagonist or partial agonist, 
or valproate, as in a) above (****).  In general, follow the same principles as for a first 
episode or an episode occurring off short-term treatment. 
 
If the current episode is due to poor adherence, establish the cause and offer appropriate 
intervention (S). For example, if non-adherence is associated with an adverse reaction, 
consider dose reduction, assuming the adverse effect is dose related, or a switch to a more 
tolerable alternative regimen. If poor adherence is deliberate, and not related to 
tolerability, use of lithium long term may not be indicated due to the risk of ‘withdrawal’ 
mania and depression (I). 
 
c) If symptoms are inadequately controlled with optimized doses of the first-line 
medicine and/or mania is very severe, add another medicine. 
 
Consider the combination of lithium or valproate with a dopamine antagonist/partial 
agonist (****).   
 
Consider clozapine in more refractory illness (**).   
 
Electroconvulsive therapy (ECT) may be considered for patients whose mania is 
particularly severe or treatment-resistant, those who express a preference for ECT and 
patients with severe mania during pregnancy (***).   
 
d) The presence of mixed features in a manic or hypomanic episode 
 
DSM-5 encourages the identification of mixed features rather than a ‘mixed episode’ (as 
in DSM-IV). The implications for treatment are uncertain. Existing data from secondary 
analysis of trials for mixed episodes, suggest that treatment as for mania is appropriate 
(I). 
 
e) Assess contribution of substance use to a manic or hypomanic episode and 
consider if medically assisted withdrawal is required (S).   
 
f) Discontinuation of short-term treatments 
 
Drug discontinuation should be planned in relation to the need for long-term maintenance 
treatment (S). Many medicines shown to be effective for the treatment of mania have also 
been shown to be effective in relapse prevention (I).  
 
Medicines only used for the acute treatment of mania, may be reduced in dose and 
discontinued (tapering over four weeks or more) after full remission of symptoms has 
been achieved (IV). Remission will often occur within three months (I) but mood stability 
may require six months or more to achieve. 
 
Any medication used adjunctively for symptomatic effect to promote sleep or sedation 
should be discontinued as soon as symptoms improve (S).  
 
 
2.  Acute Depressive episode 
 
The evidence from network meta-analysis of available RCTs supports the efficacy of a 
limited range of individual medicines with different pharmacology and different weights 
of evidence. In particular, there is uncertainty (and difference of opinion) over the option 
of choosing antidepressants (i.e. drugs shown to be effective in major depressive episodes 
with a unipolar course) (IV). 
 
Most of the evidence concerns patients with a bipolar I illness course; however, 
extrapolation to bipolar II disorder appears logical (IV).   
 
a) For patients not already taking long-term treatment for bipolar disorder 
 
Consider quetiapine, lurasidone or olanzapine (***). Dopamine antagonists have the 
inherent advantage of being anti-manic treatments (I). 
 
Antidepressants (meaning drugs for a major depressive episode in a unipolar illness 
course) have not been adequately studied in bipolar disorder. Only the combination of 
fluoxetine with olanzapine has support as a specific treatment (***). The common use of 
other antidepressants in patients with bipolar disorder is an extrapolation from effects 
established in a unipolar illness course. When considered, they should be co-prescribed 
with a drug for mania (e.g. dopamine antagonists, lithium, valproate) in patients with a 
history of mania (S).  
 
Consider initial treatment with lamotrigine, with the necessary incremental dosing 
schedule, usually as an addition to agents preventing recurrence of mania (****). 
 
Consider ECT for patients with high suicidal risk, treatment resistance, psychosis, severe 
depression during pregnancy or life-threatening inanition (***). Consider simplifying 
pre-existing polypharmacy, which may have raised the seizure threshold. It is very 
unusual for ECT to be used under mental health legislation without a patient's consent; 
fears that this may occur should be allayed 
 
When depressive symptoms are less severe, and despite limited evidence, lithium may be 
considered, especially as a prelude to long-term treatment (**). 
 
Consider family-focused, cognitive behavior therapy or interpersonal rhythm therapy as 
an additional treatment, when available, since these may shorten the acute episode (**). 
 
b) For patients who suffer a depressive episode while taking long-term treatment 
 
Ensure that the current choice of long-term treatments is likely to protect the patient from 
manic relapse (e.g. lithium, valproate, dopamine receptor antagonist/partial agonist 
drugs), by checking adequate doses of medicines and/or serum concentrations of lithium 
within the usual target range (S). Address current stressors, if any (S). 
 
If the patient fails to respond to optimization of long-term treatment, and especially if 
depressive symptoms are significant, initiate treatment as above. See also section on 
treatment-resistant depression below. 
 
c) Choice of drug for a depressive episode 
 
Treatment preference cannot be securely based on the current database of RCTs (IV). The 
available network meta-analyses may not be stable because rankings are strongly 
influenced by inclusion criteria and indirect comparisons sometimes contradict the 
findings from direct comparisons.  
 
There is a risk of a switch to mania or mood instability during treatment for depression 
(I). While this will often reflect the natural history of the disorder, it may be increased by 
monotherapy with antidepressants. The dual action monoamine re-uptake inhibitors 
(venlafaxine, duloxetine, amitriptyline and imipramine)(II)) carry a greater risk of 
precipitating a switch to mania than single action drugs (especially selective serotonin 
reuptake inhibitors) (II). 
 
Antidepressant drugs appear unlikely to induce mania when used in combination with a 
drug for mania (I).  
 
In bipolar II disorder, if an antidepressant is prescribed as monotherapy, any increase in 
dose should be gradual and there should be vigilance for and early management of any 
adverse reactions such as hypomania, mixed states or agitation (IV). 
 
In contrast to the common use of antidepressants, audit data suggest that lamotrigine is 
too little used outside specialist centres, given its efficacy in bipolar I, and suitability for 
bipolar II disorder. 
 
If successful treatment has been initiated for depression de novo in a bipolar illness 
course, long-term treatment should be considered (see below) (S). 
 
d) Tapered discontinuation of antidepressant drugs may be considered after full 
remission of symptoms (IV).  
 
Depressive episodes that remit in bipolar disorder tend to be shorter than in unipolar 
disorder (I); in the absence of strong data for maintenance efficacy, consider 
discontinuation of antidepressants after as little as twelve weeks in remission (*). 
 
Longer treatment with antidepressants is justified if patients relapse on their withdrawal 
(IV). 
 e) Treatment of resistant depression 
 
Relative or even marked treatment resistance may occur in depressed bipolar patients (I). 
This would mean failure to respond not just to an antidepressant but also quetiapine, 
olanzapine, lurasidone and lamotrigine singly and in combination. There is very little 
information from trials on the treatment of such refractory bipolar patients. ECT is an 
option (***). Augmentation strategies may be translated from experience in unipolar 
patients (*; see BAP guideline on the use of antidepressants: Management when initial 
treatment fails), but not before evidence-based bipolar options have been exhausted. 
Adequate anti-manic cover with lithium, valproate or a dopamine antagonist/partial 
agonist will be necessary (S). 
 
Choice of initial treatment: psychosocial treatments. 
 
There is very little evidence of efficacy of psychological treatments alone (without 
pharmacotherapy) in the treatment of acute bipolar depression.  
 
Recommendations for psychotherapy alone (as in NICE2014, for example) are surprising 
and based on very low quality data (*). More evidence is needed that this is really an 
effective approach (IV). 
 
3. Long-term treatment 
 
a) Prevention of new episodes 
 
Consider long-term treatment following a single severe manic episode (i.e. diagnosis of 
bipolar I disorder) (***).  
 
However, without active acceptance of the need for long-term treatment, adherence may 
be poor (I). Consider a wider package of treatment offering enhanced psychoeducation, 
motivational and family support especially in the early stages of illness to promote 
behaviour change and adherence to medication (***). 
 
When a patient has accepted treatment for several years and remains well, they should be 
advised to continue indefinitely, because the risks of relapse remain high (***). 
 
Consider extrapolating the advice for bipolar I to bipolar II disorder, given increasing 
evidence for common efficacy from clinical trials (**). 
 
b) Options for long-term treatment 
At present the preferred strategy is for continuous rather than intermittent treatment with 
oral medicines to prevent new mood episodes.  The network meta-analysis of available 
RCTs with relapse prevention designs support the efficacy of a limited range of 
individual medicines with different pharmacology and different weights of evidence: 
lithium, olanzapine, quetiapine, risperidone LAI (long acting injection) and valproate 
(albeit marginally) prevented manic relapse. Only lamotrigine, lithium and quetiapine 
were convincingly shown to prevent depressive relapse. Lurasidone also prevents relapse 
to depression. 
 
Relatively few patients remain in such trials for as long as 6 months, but lithium is 
exceptional in having strong evidence for relapse prevention from RCTs in which 
patients were not enriched for an acute response to lithium (I). 
 
Most of the evidence concerns patients with a bipolar I illness course; however, 
extrapolation to bipolar II disorder appears logical (IV).   
 
Short-term add ons (e.g. GABA modulators or dopamine antagonists/partial agonists) are 
necessary when an acute stressor is imminent or present, early symptoms of relapse 
(especially insomnia) are present or anxiety becomes prominent (IV). Consider supplying 
these medicines prospectively to patients with instructions how to use at their discretion 
(*).  Higher doses of long-term treatments may also be effective, instead of add-ons (*). 
 
Since the optimum long-term treatment strategy is not established, clinicians and patients 
are encouraged to participate in clinical trials designed to answer key therapeutic 
questions (S).  
 
c) Choice of long-term medicines 
 
In addition to the relapse prevention RCTs, naturalistic data, allowing comparison of 
rates of hospital admission on and off treatment over four years, are strongly supportive 
of efficacy for lithium> valproate>olanzapine>lamotrigine>quetiapine>carbamazepine 
(I).   
 
Consider lithium as initial monotherapy (****). 
 
Lithium monotherapy is effective against both manic, depressive and mixed relapse (I), 
has better evidence for prevention of new episodes than other agents (I) and a more 
substantial evidence base documenting the risks of prolonged exposure (I). Lithium is 
associated with a reduced risk of suicide in patients with bipolar disorder in RCTs and in 
both self harm and suicide in observational studies (I). 
 
Biochemical monitoring of lithium treatment, including plasma lithium concentrations, is 
a standard of care (S); the target range is 0.6-0.8 mmol/l.  Lithium concentrations above 
0.8 mmol/l are associated with an increased risk of renal impairment especially in women 
(I). 
 
Clinicians should know that NICE2014 recommended monitoring lithium concentrations 
at 3 monthly intervals for the first year of treatment in otherwise healthy patients, and 6 
monthly thereafter (S). 
 
Consider other options if lithium is ineffective, poorly tolerated or if patients are unlikely 
to be adherent: valproate, dopamine antagonists/partial agonists (S).  
 
Valproate is often accorded an equivalent place to lithium as a ‘mood stabilizer’. It has a 
weaker evidence base from RCTs, but upgraded naturalistic data supports its position 
ahead of other options (I). Safety concerns in women have already been noted. 
 
Additional evidence for efficacy of specific treatments comes, as already indicated, from 
trials in which patients have responded favourably to a particular medication in an acute 
indication.  Accordingly, in an individual patient, if a medicine leads to prompt remission 
from the most recent manic or depressive episode, this may be considered evidence in 
favour of its long-term use as monotherapy (IV).  Because effective in the short term, this 
may lead to preferential use of dopamine antagonists; active consideration of lithium as a 
better alternative should be promoted (IV). 
 
Carbamazepine is less effective in maintenance treatment than lithium but may 
sometimes be used as monotherapy if lithium is ineffective and especially in patients who 
do not show the classical pattern of episodic euphoric mania (II). It appears to be almost 
exclusively effective against manic relapse (I). Be aware of the pharmacokinetic 
interactions that are a particular problem with carbamazepine. Oxcarbazepine may be 
considered by extrapolation because of its lower potential for such interactions (I). 
 
Consider long acting (“depot”) formulations if prophylaxis against recurrence of mania is 
required and adherence to oral medication is erratic or injection preferred (**). Various 
long-acting injectable (LAI) dopamine antagonist/partial agonists are available, including 
fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone 
microspheres, paliperidone palmitate, and aripiprazole monohydrate. Only risperidone 
has RCT support (II). Use of other options will represent extrapolation from oral efficacy 
or class effect of dopamine antagonists/partial agonists and clinical experience (IV). 
 
Lamotrigine and quetiapine may be considered as monotherapy in bipolar II disorder 
(***).  In bipolar I disorder, lamotrigine will usually require combination with an anti-
manic long-term agent (IV).  
 
d) If the patient fails to respond to monotherapy and continues to experience 
sub-threshold depressive symptoms or relapses, consider long term combination 
treatment (GRADE: variable for different combinations). 
 
When the burden of disease is mania, it may be logical to combine two predominantly 
anti-manic agents (e.g. lithium, valproate, a dopamine antagonist or a dopamine partial 
agonist) (IV). When the burden is depressive, a combination of lithium, lamotrigine, 
quetiapine, lurasidone or olanzapine may be more appropriate (IV).  
 
The role of antidepressants in long-term treatment is not established by controlled trials; 
nevertheless they appear to be used effectively in a minority of patients in the long term 
(**). 
 Consider continuation of clozapine if effective in refractory mania (**). 
 
Maintenance ECT may be considered for patients who respond to ECT during an acute 
episode but respond poorly to all oral agents (*). 
 
Consider adjunctive psychotherapy to address subthreshold symptoms (**; see (h)). 
 
 
e) If rapid cycling poses particular long-term management problems 
 
Identify and treat conditions such as hypothyroidism or substance use that may contribute 
to cycling (**). 
 
Consider tapering and discontinuing antidepressants that may contribute to cycling (*). 
  
There are no specific treatments for rapid cycling. As an often disabling expression of 
bipolar disorder, many patients require combinations of medicines. Evaluate anti-cycling 
effects over periods of 6 months or more by tracking mood states longitudinally.  
Discontinue ineffective treatments to avoid unnecessary polypharmacy (*). 
 
f) Discontinuation of long-term treatment  
 
Following discontinuation of medicines, the risk of relapse remains, even after years of 
sustained remission (II). Accordingly, if discontinuation is considered, it should be 
accompanied by an informed assessment of the potential dangers (S). 
 
Discontinuation of any medicine should normally be tapered over at least 4 weeks and 
preferably longer (S). Early relapse to mania is an early risk of abrupt lithium 
discontinuation (I). 
 
Discontinuation of medicines should not lead to withdrawal of services to patients; short-
term care and monitoring will still be required if medication is discontinued together with 
a management plan to recognise and treat early warning signs of future relapse to mania 
or depression (S). 
 
h) Specific psychosocial interventions 
 
Psychosocial interventions may enhance care, reduce subthreshold symptoms and reduce 
risk of relapse (II). Psychoeducation is a component of good clinical practice, because 
clinical communication cannot be effective without it (S); it is formally supported by 
manualized approaches tested formally in clinical trials (****). 
 
A number of differently named therapies (Family focused therapy, Cognitive behavior 
therapy, Interpersonal Social Rhythm therapy) have also been studied in relapse 
prevention. It is striking that they share many elements with each other and with 
psychoeducation.  Psychological interventions appear to be more successful with patients 
early in their illness course (I). 
 
The functional impairments of bipolar patients may merit cognitive and functional 
remediation strategies (II). 
 
User groups can provide useful support and information about bipolar disorder and its 
treatment (IV). 
 
Table 3 near here 
 
4. Treatment of alcohol use disorder  
 
See BAP’s Evidence based guidelines for the pharmacological management of substance 
abuse, harmful use, addiction and co-morbidity. In heavy drinkers, modest reductions in 
consumption may result in substantial health gains (I). 
 
Offer naltrexone or nalmefene as part of a behavioural programme to help patients reduce 
their alcohol consumption (**). 
 
Offer acamprosate if naltrexone has not been effective to help patients remain abstinent 
(*). 
 
Consider disulfiram if patient wants abstinence and if acamprosate and naltrexone have 
failed. The patient must be able to understand the risks of taking disulfiram and have their 
mood monitored (*). 
 
5. Treatment of co-morbid borderline personality disorder 
 
 
In co-morbid patients both disorders may require treatment. Hence, avoid a polarizing 
choice between medication (usually required for bipolar disorder) and psychological 
treatment (the preferred approach to borderline problems) (S).  
 
In the absence of relevant evidence, there is no reason to withdraw or withhold 
appropriate treatment for bipolar disorder or borderline personality disorder. Although 
the place of pharmacotherapy for borderline symptoms is based on limited evidence, the 
shared symptom of mood instability may be appropriately treated by medicines (e.g. 
lamotrigine, lithium, olanzapine, risperidone, aripiprazole and quetiapine) and borderline 
symptoms improved (*). 
 
6. Treatment of anxiety and other co-morbid disorders 
 
Consider treatment along the lines suggested by BAP guidelines for the treatment of 
anxiety disorders, attention deficit hyperactivity disorder and substance use disorders (*). 
Care in the use of antidepressants is required (S). 
 7. Treatment in special situations 
 
In children and young people 
 
For mania 
 
Consider aripiprazole as first line because it is licensed in adolescents (over 13 years) 
with bipolar I disorder (***). Otherwise refer to adult recommendations; there is some 
primary evidence that olanzapine, quetiapine, and risperidone are efficacious in 
adolescents (**). 
 
Refer to the British National Formulary (BNF) for Children to modify drug doses (S). Be 
aware of the increased potential for a range of adverse reactions, particularly weight gain 
(S). 
 
For bipolar depression 
 
Consider medicines and psychological treatments largely by extrapolation from data in 
adults (*). 
 
Drugs for depression may induce switch to mania more frequently in children and young 
people than adults (II). 
 
The need for long-term treatment should be considered in young people because of the 
potentially disruptive effect of relapse and mood instability on cognitive and emotional 
development (S). 
 
 
In elderly people 
 
Consider lower doses of psychotropic medicines of all classes for all phases of treatment 
when adverse reactions or effects are evident with conventional dosing (check the SPC 
for prescribing recommendations) (*). 
 
In women and pregnancy 
 
Women who may become pregnant.  
There is a risk of teratogenicity from valproate and carbamazepine (I). The risk/benefit 
for valproate contraindicates its use in women of child bearing potential under normal 
circumstances (I). 
 
Concerns about lithium and cardiac malformation appear to have been disproportionate 
(II). 
 
Since as many as 50% of pregnancies currently occur unplanned, access to family 
planning advice should be ensured whenever feasible (S). 
 
Women who are pregnant.  
Low or no risk of teratogenesis appears to be associated with dopamine 
antagonists/partial agonists, antidepressants, lamotrigine and lithium. However, risks 
from new compounds are usually unknown and always justify caution. Any teratogenic 
risk putatively associated with the use of medicines should be considered in the poorly 
appreciated context of a relatively high, age-related, baseline risk for congenital 
malformations and spontaneous abortion and confounding by indication (S).  
 
Women are not protected from relapse by pregnancy. Discontinuation of medicines risks 
destabilising mood (IV). Hence, the possible risks of medicines to the foetus needs to be 
balanced with the risk of mental illness in the mother and its effects on the health of the 
baby (S).  
 
Many psychotropic drugs used to treat bipolar disorder can cause neonatal symptoms (II 
& III). Neonates should be monitored for possible adverse reactions in the hours and days 
following birth (S) 
 
Women are at high risk of relapse to mania or depression following childbirth (I). 
Vigilance is essential and effective prophylactic treatment should always be considered 
and usually recommended (S). 
 
Adverse reactions attributed to maternal psychotropic medicines have been sporadically 
reported in breast-fed infants but the prevalence is unclear (III).  
 
Women who continue to take psychotropic medication after childbirth should choose 
between breast and bottle feeding after a full explanation of the relevant benefits and 
harms (S). If a mother takes medication and breast feeds, the infant should be monitored 
for possible adverse reactions (S). 
 
There are regular reports of adverse outcomes in the development of the children of 
women treated with antidepressants or other psychotropic drugs. Too often such studies 
appear inadequately controlled for confounding by indication. Accordingly, claims that 
drugs used in pregnancy cause adverse behavioural outcomes should be treated 
cautiously. 
 
NICE has published perinatal guidelines relevant to these recommendations 
(http://pathways.nice.org.uk/pathways/antenatal-and-postnatal-mental-health). 
 
 
PART 2. CONSENSUS POINTS AND REVIEW 
 
FUNDAMENTALS OF PATIENT MANAGEMENT 
 
1. Diagnosis and psychopathology 
 
 DSM-5 criteria provide the appropriate schema for diagnosis of Bipolar 
Disorder. DSM-5 mania defines bipolar I Disorder (S). 
 Hypomania is not associated with significant functional impairment. With major 
depression, a history of hypomania defines bipolar II disorder (S).  
 Hypomania and mania apparently precipitated by antidepressants or stimulants 
does not disallow the diagnosis of bipolar disorder (IV). 
 Incidence per lifetime is, together, about 1% for bipolar I and conservatively 
defined DSM-5 bipolar II disorder (I). Other Specified Bipolar and Related 
Disorders add a further 2-3% of bipolar diagnoses in adults. 
 Bipolar I disorder is highly heritable (up to 80%) and caused by many common 
genetic variations of small effect.  
  Bipolar I disorder (mania) occurs rarely in pre-pubertal children, but its 
improved diagnosis in children and young adults is an important priority(S).  
 Relapse in bipolar I and bipolar II disorder occurs with a higher frequency than 
in unipolar depression (I). 
 The clinical presentation of major depression is similar for unipolar and bipolar 
patients. Suicide, deliberate self harm and violence are important risk outcomes 
across the life span for bipolar patients (I).  
 Anxiety disorders are the commonest co-morbid conditions in bipolar disorder (I) 
but are often missed or ignored (IV).  
 Alcohol use is common in bipolar disorder (I). Drug use is more relevant to 
younger patients with mania (I).  Established addictive problems should be 
assessed and treated (S).  
 Delay in diagnosis occurs because the illness may start non-specifically, the 
diagnosis of mood elevation is missed or symptoms are attributed to substance 
use or personality disturbance (II).  
 There is an unexplained resistance on the part of some clinicians to diagnose 
bipolar disorder even when the syndrome of mania has clearly been present (IV). 
Key uncertainties 
 Severity of mania, presence of psychotic features and mixed features may all 
influence outcome but are poorly characterised in relation to treatment response.  
 The diagnosis of hypomania in DSM-5 sets an arbitrary minimum time 
requirement of 4 days. Many more cases of ‘unipolar’ major depression appear to 
have had shorter periods of hypomania or simply hypomanic symptoms, so 
approaching or meeting criteria for ‘other Specified Bipolar and Related 
Disorders’. 
  DSM-5 encourages the use of ‘mixed feature’ specifiers for individual episodes 
to capture symptoms of the opposite pole of the illness. The relationship between 
MDD with mixed features and bipolar disorder is uncertain. It may be more 
common in the presence of co-morbid borderline personality disorder (II). 
 The mechanisms linking bipolar states to self harm or other violent acts (for 
example, impulsivity, disinhibition, inducing or exacerbating low mood via 
alcohol/drugs) are poorly understood.  
 DSM-5 has introduced a new syndrome (disruptive mood dysregulation disorder 
or DMDD) to capture a childhood syndrome, which may have nothing to do with 
bipolar disorder, but is classified as a mood disorder. 
 
Reliable diagnosis was arguably the major achievement of the last century in psychiatry. 
It depends upon the use of operational criteria to define cases, and its most important 
framework is provided by DSM-IV (American Psychiatric Association, 1994) and DSM-
5 (American Psychiatric Association, 2013). We will recommend DSM-5 criteria in this 
text. However, some of the changes in diagnostic sub-typing with specifiers will have 
uncertain implications for current treatments. We also recognize that in clinical practice 
the precise use of research criteria may be too exacting a standard. It is however, the 
standard to which we should aspire.  
 
Reliability of diagnosis, especially for mania, is high under optimal conditions. The use 
of checklists and standardised interviews could ensure improved diagnosis under ordinary 
clinical conditions (Hiller et al., 1993). However, we recognize that field trials for DSM-
5 showed only average reliability for bipolar diagnoses (Freedman et al., 2013). Practice 
may also be made more comprehensive with a patient-completed screening instrument 
like the Mood Disorders Questionnaire (MDQ) (Hirschfeld et al., 2003), the 
Hypomania/Mania Symptom Checklist (HCL-32) (Meyer et al., 2007) or the 
Computerized Adaptive Technology for Mental Health (CAT-MH) (Achtyes et al., 
2015). 
 
 Bipolar disorder is, at present, the most commonly used term to describe serial elevations 
of mood usually along with intercurrent depressions of mood.  Descriptions consistent 
with Bipolar Disorder exist since antiquity but Kraepelin first used the term manic-
depressive psychosis to include all cases of affective psychosis. Patients with unipolar, 
commonly psychotic depression were included in the diagnosis whether or not they had 
experienced mania.  The central emphasis on mania and thus on bipolarity emerged 
relatively recently.  Bipolar I disorder is defined by episodes of mania and also, usually, 
depression.  The incidence of bipolar I disorder is estimated between 2-21 per 100,000, 
per year.  Differences in reported rates are probably due to the definition of cases.  
Differences based on first admissions to hospital, which is a proxy estimate of severity, 
show figures that are less variable and, on average, represent a rate of about 3-4 people 
per 100,000 per year.  Incidence per life-time of bipolar disorder is approximately 0.5%-
1% for Bipolar I disorder (I, (Angst and Sellaro, 2000; Lloyd and Jones, 2002; 
Merikangas et al., 2007)).  
 
Bipolar II disorder is characterised by episodes of hypomania and, invariably, major 
depression. As defined by DSM-IV, its lifetime incidence has also been described as 
about 1% (I, (Angst, 1998; Merikangas et al., 2007).  This estimate depends on where the 
boundary between bipolar II and sub-threshold bipolarity is drawn. A figure nearer 0.5% 
may be more appropriate (Merikangas and Lamers, 2012) giving 1% as the figure for 
lifetime diagnosis if bipolar I and II combined. 
 
Bipolar I disorder is prominent in secondary care because it is a highly prevalent rather 
than a highly incident condition.  It follows a relapsing, often chronic course, with an 
average 8 episodes over the 10 years following diagnosis.  The rate of relapse is higher 
than that seen in unipolar disorder of comparable severity (I, (Winokur et al., 1993; Angst 
and Preisig, 1995)). 
 
The known aetiology of bipolar disorder is primarily genetic with estimated heritability 
as high as 0.93 (I, (Potash and DePaulo, 2000; Kieseppa et al., 2004)).  This means it is 
one of the most heritable disorders in medicine. Genome-wide association (GWA) studies 
have now been conducted on sufficiently large samples to give complete confidence in a 
growing number of specific genes. These small effects when combined can now account 
for about 20% of the heritability (Cross-Disorder Group of the Psychiatric Genomics et 
al., 2013). Bipolar disorder is highly polygenic so leaving little room for causation by 
rare genes of large effect. Genetic effects are not susceptible to errors of reverse 
causation, otherwise common in observational epidemiological studies. Therefore, these 
positive findings confirm that the DSM diagnosis has some biological validity. However, 
there is clear evidence of overlap with risk genes for both schizophrenia and major 
depression. This genetic architecture was predicted by the elevated rates of bipolar 
disorder, unipolar depression, and psychosis in first-degree relatives of bipolar patients 
(Gershon et al., 1982). Compared with schizophrenia, there is weaker evidence for 
presumed environmental aetiologies such as obstetric complications or inner city 
residence (I, (Bain et al., 2000; Browne et al., 2000; Lloyd and Jones, 2002)).  
 
Factors such as early abuse and neglect are elevated in bipolar disorder and increase the 
risks for other co-morbid psychiatric disorders; this probably worsens the course of 
bipolar illness (II, (Leverich et al., 2002)). Abuse and neglect are also associated with 
impairments of memory and executive function in bipolar patients (Savitz et al., 2008) 
and may increase the risk of psychosis (Read et al., 2005).  
 
The overlap of risk genes for bipolar I disorder with those for ADHD is apparently 
negligible, even though current significant alleles account for about 20% of the risk of 
each disorder separately (Cross-Disorder Group of the Psychiatric Genomics et al., 2013). 
This is perhaps the first example of where genetics may eventually guide psychiatric 
diagnosis (see below). 
 
The differential diagnosis of elated states in Bipolar Disorder 
Mania defines bipolar I disorder. DSM-IV criteria for mania, which form the basis for 
most of the studies cited in these guidelines, are as follows (American Psychiatric 
Association, 1994): 
 
1 A distinct period of abnormally and persistently elevated, expansive, or irritable 
mood, lasting at least 1 week (or any duration if hospitalisation is necessary). 
 
2 During the period of mood disturbance, three (or more) of the following 
symptoms have persisted (four if the mood is only irritable) and have been present 
to a significant degree: 
 
a. inflated self-esteem or grandiosity 
b. decreased need for sleep (e.g. feels rested after only 3 hours of sleep) 
c. more talkative than usual or pressure to keep talking 
d. flight of ideas or subjective experience that thoughts are racing 
e. distractibility (i.e. attention too easily drawn to unimportant or irrelevant 
external stimuli) 
f. increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation 
g. excessive involvement in pleasurable activities that have a high potential 
for painful consequences (e.g. engaging in unrestrained buying sprees, 
sexual indiscretions, or foolish business investments) 
 
3 The symptoms do not meet criteria for a Mixed Episode. 
 
4 The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others, 
or to necessitate hospitalisation to prevent harm or self or others, or there are 
psychotic features. 
 
5 The symptoms are not due to the direct physiological effects of a substance (e.g. a 
drug of abuse, a medication, or other treatment) or a general medical condition 
(e.g. hyperthyroidism). 
 DSM-5 (American Psychiatric Association, 2013) has modified Criterion 1 by adding the 
requirement for increased activity/energy as a core symptom of mood elevation. This 
represents an effort to reduce over-diagnosis of bipolar disorder driven by subjective 
report, and increase specificity (Suppes et al., 2014). 
 
The symptoms must be present for one week and/or require hospital admission.  Most 
critically, the criteria include a judgement that function is impaired. Admission to 
hospital obviously defines loss of function and autonomy quasi objectively.  Less obvious 
impairment will require identification of failure in normal working and personal 
relationships and judgement. Intelligent patients may be very difficult to assess from this 
point of view without corroborating evidence from third parties.  The contribution this 
makes to misdiagnosis will be considered below. This definition of mania underpins the 
distinction made between bipolar I disorder and milder elated subtypes. Psychotic mania 
is usually regarded as reflecting severity rather than a subtype.  Thus, psychotic 
symptoms wax and wane within individual subjects and are not invariably present from 
one episode to another.  As a rule, psychotic symptoms in mania are mood congruent and 
represent an extension of grandiose interpretations, paranoid ideation or heightened 
awareness.  They are relatively common (McElroy et al., 1996; Dunayevich and Keck, 
2000). However, in a study of over 500 patients with mania, only 20% had a presentation 
dominated by psychosis (Sato et al., 2002). This may mean that such symptoms can often 
be missed in routine clinical practice. 
 
In a minority of cases, symptoms seem to be mood incongruent and in some cases this is 
diagnosed as schizo-affective disorder.  Strictly defined schizo-affective disorder 
(according to DSM-IV and 5) is relatively uncommon in clinical samples because 
patients must meet diagnostic criteria for both bipolar disorder and schizophrenia 
simultaneously. It may also be unreliable (II, (Maj et al., 2000)). The meaning of a 
schizo-affective diagnosis also remains controversial. It may represent forms of illness in 
some sense intermediate between the two Kraepelinian psychosis types, so supporting the 
unity of psychotic states, or it may be the co-occurrence of the two different disorders (II, 
(Kendell, 1987; Kendell and Gourlay, 1970)).  Genetic findings are increasingly 
supportive of the former view (Craddock and Owen, 2010).  
 
Although euphoric mania is the classic type of presentation, a significant number of cases 
of mania are far from euphoric and may have a mixture of different symptom dimensions.  
These dysphoric presentations require diagnostic expertise for detection. The most 
striking example is where patients meet the criteria for both mania and depression 
simultaneously as was required for the diagnosis of a mixed state in DSM-IV.  However, 
some significant admixture of dysphoric (depressive) symptoms occurs in many manic 
episodes. Factor analyses of the symptoms of manic patients have been relatively 
consistent in suggesting that the atypical features of depressive mood, irritable 
aggression, and psychosis load on separate uncorrelated factors (II, (Cassidy et al., 1998; 
Sato et al., 2002)). This agreement suggests the potential to distinguish several relatively 
separate syndromes among manic patients.  Subsequent analysis has confirmed that there 
are at least two mixed mania presentations. One has a dominant mood of severe 
depression with labile periods of pressured irritable hostility and paranoia, but a complete 
absence of euphoria or humour. The second has a true mixture of affects with periods of 
classical euphoria switching frequently to moderately depressed mood with anxiety and 
irritability (II, (Cassidy et al., 2001)).  These putative subtypes are not identified by 
existing diagnostic criteria and hence are not distinguished in treatment studies. The 
change in approach to mixed states in DSM-5 is discussed below. 
 
Severity of mania, presence of psychotic features and the admixture of depressive 
symptoms may all influence outcome but are also poorly characterised in relation to 
treatment response. Future advice on acute treatment may take account of differential 
effects of medicines on the common symptom dimensions. However, at present, only 
severity, especially expressed as over-activity, imposes itself on current treatment 
options.   
 
With DSM-5, it is now accepted that mania associated with antidepressant treatment 
should usually be regarded as defining bipolar disorder, except when the symptoms are 
reliably locked in time to exposure to a specific antidepressant, like other drug-induced 
psychoses as discussed below (IV, opinion of the consensus group).  
 
The diagnosis of hypomania  
Both the use of the term and the criteria for hypomania have been controversial. Its 
definition has been crucial to the diagnosis of elated states outside bipolar I disorder.  
DSM-IV recognised core symptoms of hypomania as a checklist like that for mania itself; 
DSM-5 has modified Criterion 1 by adding the requirement for increased activity/energy 
as a core symptom of mood elevation in line with its new definition of mania (see above). 
This is intended to make diagnosis more reliable, but will thereby exclude individuals 
with purely subjective experiences of mood elevation from a bipolar II diagnosis. 
 
The time requirement is for four days of symptoms. Patients must display observable but 
not impaired change in function.  This will include mood elevations and increases in 
energy that are often positively valued by individuals with bipolar disorder.  In contrast 
ICD-10 chooses a slightly different set of symptoms and requires for hypomania, “some 
interference with personal functioning”.  Essentially hypomania under this definition is 
mild mania and should not include DSM-5 cases of hypomania.  ICD-10 hypomania 
contributes little but confusion to current classification because it tends to encourage the 
use of the term for frankly manic states (IV, (Goodwin, 2002)).  
 
There is continuing interest in the extension of a bipolar diagnosis to a spectrum of cases 
with less severe elated states. Bipolar disorder NOS is a DSM-IV category that includes 
any of the following:(1) recurrent subthreshold hypomania in the presence of intercurrent 
major depression, (2) recurrent (at least two episodes) hypomania in the absence of 
recurrent major depression with or without subthreshold major depression, and (3) 
recurrent subthreshold hypomania in the absence of intercurrent major depression with or 
without subthreshold major depression. The number of required symptoms for a 
determination of subthreshold hypomania is confined to 2 criterion B symptoms (from 
the DSM-IV requirement of 3, or 4 if the mood is only irritable) to retain the core features 
of hypomania in the subthreshold definition. DSM-5 has changed the ‘Bipolar NOS’ 
grouping to ‘Other Specified Bipolar and Related Disorder’ but covers the same still ill-
defined group of disorders; they have a 2.4% community lifetime incidence (Merikangas 
et al., 2007). 
 
In fact, on the basis of symptom endorsement over a life time in clinic samples, (Cassano 
et al., 2004) have suggested that mood elevation forms a continuous bridge between 
unipolar and bipolar disorder.  The intensity of illness, either depressive or manic, 
increased in parallel and simply showed a higher baseline of elated experience for the 
bipolar group compared to the unipolar cases. If there is indeed no qualitative break 
between unipolar and bipolar disorder, the question becomes one of calibration. At what 
point on this continuum of experience does mood elevation influence treatment choice?   
 
DSM-5 has introduced the concept of a mixed features specifier (see below), which 
formalizes the identification of manic symptoms in depressive episodes (Angst et al., 
2011). These proposed diagnoses still do not yet have clear implications for treatment. 
However, to call such cases bipolar would increase the temptation for treatment choices 
to be extrapolated from bipolar I/II data. 
 
The differential diagnosis of depressed states in Bipolar Disorder 
Major depression in the context of bipolar disorder is similar to major depression arising 
in a unipolar illness course, when severity is comparable. Within episodes of depression, 
grades of intensity – mild moderate and severe – should be distinguished.  The use of a 
scale such as the Inventory of Depressive Symptomatology (IDS) or Quick Inventory of 
Depressive Symptomatology (QIDS), which maps to the diagnostic features, gives a 
severity estimate. The QIDS, in particular, is useful in its self-administered form (Rush et 
al., 2003).  
 
Bipolar patients may be more likely to demonstrate psychomotor-retarded melancholic 
and atypical depressive features and to have had previous episodes of psychotic 
depression (II, (Mitchell et al., 2001)).  Retarded or psychotic depression, particularly in 
young people, should raise the suspicion of a bipolar illness course.  Indeed, there are a 
number of other clinical features suggesting a bipolar illness, such as 'atypical' depressive 
features (hypersomnia, hyperphagia, and leaden paralysis), pathological guilt and lability 
of mood, but none can convey a categorical certainty. There may be scope for the 
development of such features as a measure of probability that an episode of depression is 
the manifestation of bipolar disorder in the absence of evidence of mood elevation 
(Mitchell et al., 2008). 
 
Poor outcomes in bipolar disorder 
 
Deliberate self harm and completed suicide are important risks in bipolar disorder and are 
associated with depression and mixed states (I, (ten Have et al., 2002; Black et al., 
1987a)). For patients identified by admission to hospital, absolute rates of suicide are 
about 0.4% per year (Tondo et al., 2003). This is 20 fold greater than population rates and 
translates into risks at long term follow-up between 3-6% (I, (Chesney et al., 2014; 
Crump et al., 2013), which are amongst the highest for any psychiatric disorder.  The 
increased odds of self harm and suicide compared with sibling controls, arguably a more 
relevant comparison, is still 6-8 fold (Webb et al., 2014). 
 
The risk of violent and non-violent crime is also elevated in bipolar patients, especially 
males. The increase compared with sibling controls is 2-4 fold. This risk may not be as 
widely appreciated as the risk for suicide, but offending is actually a more common 
outcome and thus associated with a higher absolute risk. Rates of violent crime in male 
patients were 8% and, for non-violent crime, 18% in one population cohort study, with 
most of these patients committing their crimes within 5 years of diagnosis (Webb et al., 
2014). 
 
Suicide has always received more attention than other adverse outcomes. The risk of 
suicide is highest early in the course of the illness (Hoyer et al., 2000). Suicide is 
independently associated with male gender, previous self harm, alcohol and drug use 
disorders, and previous criminality (Webb, 2014). An early review identified 
hopelessness at index admission as another risk factor (Hawton et al., 2005). A longer list 
of possible contributory factors emerges from a broad review of the literature (Pompili et 
al., 2013); the contribution of individual risks is poorly quantified and many are likely to 
be confounded.  
 
The lifetime prevalence of non-fatal suicidal behaviour (self harm or attempted suicide) 
in those with bipolar disorder is approximately 30% (Chen and Dilsaver, 1996; Tondo et 
al., 2003) and may be as high as 50% in secondary care samples (Valtonen et al., 2005).  
A recent Swedish population study estimated rates of hospital-presenting self harm at 
10% in male patients and 14% in female patients (Webb et al., 2014). Studies have shown 
that a wider range of factors are associated with self harm than suicide itself, presumably 
because the former is a more common outcome.  These factors include mixed states, 
rapid cycling, alcohol and drug use, comorbid anxiety, a positive family history of 
suicide, and, possibly, early abuse or a bipolar II diagnosis (Hawton et al., 2005; Schaffer 
et al., 2015). Bipolar patients have the highest rate of suicide of all psychiatric disorders.  
In addition, independent associations have been found for female gender, previous 
criminality, parental psychiatric disorders and low family income (Webb et al., 2014).  
Aggression and impulsivity may also be associated with suicide attempts (Oquendo et al., 
2000; Oquendo et al., 2004).      
 
Specifiers in DSM-5 
 
DSM-5 has introduced a device to recognize the heterogeneity of episodes in bipolar 
disorder in the form of specifiers.  These can be used with any primary diagnosis (mania, 
hypomania, depression) to enrich the clinical description. 
 
The mixed features specifier  
In DSM-IV, a mixed episode was defined as requiring the full syndrome of mania and 
major depression to be present simultaneously for at least 1 week. In practice this proved 
to be a rare diagnosis, although it was widely recognized that symptoms from the 
opposite pole might be present in a bipolar episode: this has already been discussed above 
for mania. DSM-5 has dropped the category ‘mixed episode’ and introduced a new 
feature to the diagnosis of a primary manic, hypomanic or depressive episode: the mixed 
feature specifier. A specifier requires the presence of three symptoms from a list 
restricted to those symptoms unique to the pole in question. Thus a manic episode can be 
said to have mixed features (of depression) if there are three or more of subjective 
depression, worry, self-reproach/guilt, negative evaluation of self, hopelessness, suicidal 
ideation or behaviour, anhedonia, fatigue or psychomotor retardation.  
 
The BRIDGE study of over 5000 adults with a major depressive episode identified 47.0% 
(95% CI, 45.7%-48.3%) as meeting the bipolarity specifier criteria. Associations (odds 
ratio > 2; P <.001) with bipolarity were observed for family history of mania/hypomania, 
multiple past mood episodes and comorbid substance use disorder (Angst et al., 2011). 
 
This change may have important implications for clinical care, education, and research in 
the future (Vieta and Valenti, 2013). For the moment, we do not know whether a more 
precise categorization of episodes in this way will influence indications for treatment. A 
particular potential confusion is the possibility to add a mixed feature specifier to a 
depressive episode in a unipolar illness course. This appears to be most likely when there 
is a co-morbid borderline diagnosis (Perugi et al., 2015). 
 
Rapid cycling specifier 
Patients with four or more episodes of depression, mania, mixed state or hypomania in 
the preceding 12 months are conventionally described as showing rapid cycling.  Rapid 
cycling is another specifier. It conflates patients with frequent illnesses allowing 
remission between episodes with those who cycle continuously (or switch continually) 
from one polarity to the other without euthymia (II, (Maj et al., 1999)). The lifetime risk 
of rapid cycling is around 16% and it is weakly associated with female gender, bipolar II 
disorder, current hypothyroidism and a poor response to lithium (especially the 
depressive component) (II-III, (Calabrese et al., 2001)).  Rapid cycling obviously implies 
temporal severity and it may often be difficult to treat. In 30-40% of cases it may be 
preceded by exposure to antidepressants, and worsened by treatment with antidepressants 
(see below: treatment of depression), but there is no proof of a causal relationship.  
 
NICE2014 has chosen not to make specific recommendations for treatment of rapid 
cycling bipolar disorder, commenting “Offer people with rapid cycling bipolar disorder 
the same interventions as people with other types of bipolar disorder because there is 
currently no strong evidence to suggest that people with rapid cycling bipolar disorder 
should be treated differently.”  This is understandable given the paucity of evidence and 
we agree with their conclusion.   
 
Other specifiers in DSM-5 
Other specifiers that may be included in the description of a relevant episode are anxious 
distress, mood congruent psychotic features, mood incongruent psychotic features, 
catatonia, peripartum onset, seasonal pattern and for a depressive episode, melancholic 
feature or atypical features. Their value either for research or clinical practice remains to 
be established. 
 
Predominant polarity 
Although not included in DSM-5 as a course specifier, the majority of patients with 
bipolar disorder have a tendency to develop more episodes of one pole over the other. 
This has relevant clinical and therapeutic implications and can be clinically useful in 
planning drug and psychological treatment (Carvalho et al., 2015; Colom et al., 2006). 
 
Gender 
Women with Bipolar disorder have a slightly different profile of illness on average from 
men. The differences include more rapid cycling, a more seasonal pattern, more and 
longer depressive episodes, more mixed and dysphoric mania, more bipolar II cases, 
more comorbidity with medical disorders (e.g. thyroid disease, migraine, obesity) and 
anxiety disorders, less substance abuse, fewer completed suicides and later onset 
(Diflorio and Jones, 2010). Except for the implications of pregnancy and childbirth, such 
differences do not carry implications for treatment. 
 
Co-morbidity 
Co-morbidity of bipolar disorder with a range of other psychiatric conditions poses 
problems of two diametrically different kinds. First, non-specific psychological 
symptoms and disturbed behaviour may be the harbinger of bipolar disorder in young 
people. Diagnostic uncertainty or the wrong diagnosis at the very early stages of the 
illness can delay its accurate recognition (I, (Lish et al., 1994)).  Secondly, in the 
presence of recognised bipolar disorder, co-morbid conditions may contribute to poor 
treatment response and outcome.  
 
Anxiety disorders and persistent anxiety symptoms 
Community samples show replicated, high lifetime co-morbidities of Bipolar I disorder 
with a range of anxiety related disorders and substance use (I, (Kessler et al., 1997; 
Merikangas et al., 2007)).  Lifetime rates are extremely high in some estimates: as many 
as 90% of bipolar I patients reported at some time to have had an anxiety disorder in the 
influential US National co-morbidity survey (I-II, (Freeman et al., 2002; Merikangas et 
al., 2007)).  The most recent meta-analysis of 40 studies, including 14,914 individuals 
from North America, Europe, Australia, South America, and Asia, suggested a more 
conservative lifetime prevalence of anxiety disorders of about 45% (95% CI 40–51) 
(Pavlova et al., 2015). 
 
This raises the question of how to view anxiety symptoms within the behavioural 
phenotype in bipolar disorder. The earliest symptoms that a patient experiences may be 
those of anxiety but the dominant picture subsequently may be mania and depression.  On 
the other hand, anxiety is not uncommon between acute episodes and in bipolar 
depression. Mixed affective states can be misdiagnosed as anxiety and vice versa. 
 
Where the anxiety disorder dominates the outcome, this must clearly influence 
evaluations of successful treatments. Anxiety disorder co-morbidity is associated with a 
range of worse outcomes in bipolar disorder such as worse functioning, poorer quality of 
life, increased suicide rates, rapid cycling and the transition from unipolar to bipolar 
depression (Fagiolini et al., 2007; Simon et al., 2004) and yet has received little specific 
attention in developing treatments. For adequate assessment, anxiety should be regularly 
monitored (in addition to the usual focus on depression and mania). 
 
In fact anxiety in bipolar disorder may have particular features that should influence 
approaches to treatment development. There is scope to improve assessment to consider 
bipolar-specific features like anxiety-provoking mental imagery (Hales et al., 2011; Ivins 
et al., 2014) because this may amplify the expectation of future threat. Mental imagery 
involves “seeing in the mind’s eye”. While this may relate to intrusive past events (‘flash 
backs’ as in PTSD) it is also relevant as a ‘flash forward’ experience. Previously suicidal 
patients may, for example, vividly simulating a future outcome such as jumping off a cliff 
(Hales et al., 2011). Such experience can be asked about in assessment (in addition to the 
content of verbal thoughts) (Di Simplicio et al., 2012).  
 
 
Alcohol and drug use 
As with anxiety, excessive use of alcohol or drugs is so common in bipolar patients that 
there seems to be a shared vulnerability to either or both outcomes. Experimental studies 
even suggest how this may arise for alcohol dependence (Yip et al., 2012). The risk of 
alcohol dependence is, therefore, another common (and clinically significant) co-
morbidity of bipolar I and perhaps to a lesser extent bipolar II disorder. Drug, especially 
stimulant, use is more relevant to younger patients with bipolar II disorder and is 
associated with poorer outcome. It can confound the diagnosis and makes engagement 
with treatment more difficult (I, (Strakowski et al., 2000)).  Indeed, mania appears to be 
induced by a range of stimulant drugs. Where elated states are sustained and meet criteria 
for mania, a diagnosis of ‘drug induced psychosis’ is likely to be wrong and a diagnosis 
of Bipolar disorder more useful. A true drug-induced psychosis should either wane with 
the clearance of the offending drug or be a transient effect associated with drug 
withdrawal (see definition of Substance-induced psychotic disorder in DSM-IV).   
 
Levodopa and corticosteroids are the most common prescribed medications associated 
with secondary mania (I-II, (Young et al., 1997; Brown et al., 2002; Brown et al., 1999)).  
 
It is an important principle that bipolar patients with significant alcohol or other drug use 
should have these issues appropriately assessed and treated, and consideration given to 
involving the specialist addictions service, or dual diagnosis team, if available.  There is 
evidence that effective treatment of substance use can improve compliance and bipolar 
outcomes (Ib, (Salloum and Thase, 2000)).   
 
Caffeine is an obvious but often over-looked drug which may contribute to sleep 
disturbance, anxiety and perhaps mood elevation in bipolar patients. Sensitivity to 
caffeine, related to its actions at the Adenosine A2 receptor, appear to be genetically 
determined and modulated by a common polymorphism (Urry and Landolt, 2015). The 
importance of caffeine in bipolar patients is poorly documented by formal research. 
Systematic recording of caffeine consumption and efforts to cut down may be helpful in 
vulnerable individuals. 
 
Gambling, over-spending and shop lifting 
Gambling has an increased prevalence in bipolar patients (Jones et al., 2015a), and may 
be a major clinical problem. There is evidence that gambling is in part a way to regulate 
mood but mood elevation also enhances enjoyment (Lloyd et al., 2010). There is limited 
evidence that lithium may have an independent effect in problem gamblers (Rogers and 
Goodwin, 2005) again pointing to a shared vulnerability. There has been little formal 
study of the management of problem gambling in bipolar patients. 
 
Overspending and shoplifting can also be problems for people with bipolar disorder 
compared to other disorders and the general population even between manic and 
depressive episodes (Blanco et al., 2008). The mechanism is unclear but it can be a 
significant problem for clinical management. 
 
 
Personality disorder 
Personality disorder may be an important accompaniment of Bipolar disorder, although 
the categorical approach to personality disturbance has important limitations (Blacker and 
Tsuang, 1992). As with the co-morbidities already described, the greater risk probably 
lies in allowing a personality diagnosis to blind the clinician to bipolar disorder, rather 
than vice versa. DSM-5 retains borderline, obsessive-compulsive, avoidant, schizotypal, 
antisocial and narcissistic personality disorders, but also recognizes dependent, histrionic, 
paranoid and schizotypal. The borderline diagnosis is the most critical for confusion with 
bipolar disorder. Histrionic personality disorder falls in the so-called ‘dramatic’ or cluster 
B grouping with borderline, narcissistic and antisocial disorders; it is also not uncommon 
in bipolar disorder, but has received little clinical attention. 
 
Borderline personality disorder may be co-morbid in as many as 20% of bipolar I and II 
cases. The dual diagnosis is associated with worse outcomes: hospitalisation (Colom et 
al., 2000), suicidal ideation and deliberate self harm (Leverich et al., 2003), increased 
service utilisation (Lembke et al., 2003), substance abuse (Kay et al., 2002), poor 
symptomatic outcome (George et al., 2003) and worse adherence & treatment response 
(Colom et al., 2000; Bieling et al., 2007).  
 
The relatively high rate of co-morbidity is problematic because clinicians usually seek to 
make an exclusive diagnosis of one or other disorder. Moreover, they appear to try and 
do so without really enquiring systematically about borderline symptoms in particular 
(Saunders et al., 2015). Finally, even if there is a systematic enquiry about symptoms, 
there is a potentially confusing overlap between borderline symptoms, bipolar spectrum 
and rapid cycling bipolar disorder.  
 
The key symptoms that distinguish the borderline diagnosis are the pervasive presence of 
efforts to avoid real or imagined abandonment, unstable and intense personal 
relationships, an unstable image of self and chronic feelings of emptiness. The defining 
feature of bipolar disorder is (hypo)mania, which is not satisfied by identifying simply 
the anger which is such a strong feature colouring the presentation of borderline patients. 
The diagnoses can only be made by systematic enquiry about symptoms and construction 
of the longitudinal course of the illness. Symptoms in bipolar disorder are episodic and in 
borderline patients pervasive and enduring. It is a grave clinical error to interpret bipolar 
episodes as pervasive and personality driven if they are not. Early abuse and neglect is 
common in psychiatric patients in general and not diagnostic of borderline personality 
disorder, as widely believed (Saunders et al., 2015). 
 
Organic conditions  
Organic conditions, such as thyroid disease, multiple sclerosis, neurosyphilis or any 
lesion(s) involving right-sided sub-cortical or cortical areas may be associated with 
secondary mania (II-III, (Cummings and Mendez, 1984; Mendez, 2000; Strakowski et al., 
1994)) and should be considered in the differential diagnosis. Secondary mania is 
commonest in older patients (Dols et al., 2014). 
 
Early diagnosis of bipolar disorder 
The early diagnosis of bipolar disorder may not be easy. The delay described in surveys 
of patients with bipolar disorder is, on average, a decade (I, (Lish et al., 1994)). A number 
of factors contribute. In part it will be because, as noticed in the previous section, the first 
developments may be non-specific anxiety, depression or substance use.  Bipolar disorder 
cannot be diagnosed if an episode of (hypo)mania has not yet occurred, and it would be 
unhelpful to say that a diagnosis has been missed in these circumstances. 
Notwithstanding such reservations, the diagnosis of (hypo)mania or sub-syndromal mood 
elevation may indeed often be missed in young adults. Misdiagnosis contributes to the 
problems for patients and their families when accepted diagnostic criteria are either not 
applied or ignored.  In young patients, generally, behavioural disturbance may be 
interpreted as the maturational tensions of adolescence. Alternatively, ‘personality’ 
diagnoses are still perhaps too readily employed (III, e.g. (Tyrer and Brittlebank, 1993)). 
To miss a diagnosis of a treatable condition may be harmful. Second opinions from 
bipolar specialists are potentially helpful.  
 
Finally, before the expression of frank (hypo)mania, a significant number of bipolar 
patients diagnosed with unipolar depression may run into difficulties because of 
inadequate or inappropriate treatment. In addition to morbidity, the failure to diagnose 
bipolar disorder appears to incur significant additional costs (McCombs et al., 2007). Any 
patient who is being treated for depression should be asked if they have a personal history 
of abnormal mood elevation of any duration or a family history of affective disorder (D, 
opinion of consensus group). 
 
Diagnosis of bipolar disorder in children 
It is fully accepted that Bipolar I disorder can present before puberty and should be 
diagnosed as such. It is a relatively rare condition and its recognition should rest on the 
detection of the symptoms of mania - specifically euphoria and grandiosity and never 
simply irritability. Most studies of childhood bipolar disorder have been conducted in the 
absence of empirically supported guidelines for determining the presence of the manic 
syndrome, which poses real operational problems for definition in children. For example, 
what constitutes grandiosity at age 8 versus age 15 and at what point does silliness and 
laughing, usually associated with normal childhood behavior, become indicative of 
mania?  NICE2014 recommends that the diagnosis of mania in a person under 18 years of 
age requires a distinct period of abnormally and persistently elevated or expansive 
mood.  Plus, there has to be a change in the person’s normal pattern of behaviour that is 
not developmentally appropriate and which is associated with impairment. Therefore, the 
condition is episodic, not chronic. It is quite likely that mania is more often mis-
diagnosed than over-diagnosed in the UK context. It is very important clinically to 
recognize that the first presentation is often depression; so those with recurrent 
depression, or with treatment-resistant depression may have bipolar disorder. Because it 
is proportionally more common in young people (unipolar depression tending to a later 
incidence) it may often be a diagnosis that is over-looked. 
 
NICE2014 recommends that “Diagnosis of bipolar disorder in children or young people 
should be made only after a period of intensive, prospective longitudinal monitoring by a 
healthcare professional or multidisciplinary team trained and experienced in the 
assessment, diagnosis and management of bipolar disorder in children and young people, 
and in collaboration with the child or young person’s parents or carers”. It should take 
into account the child or young person’s educational and social functioning. The group 
endorse this as a standard of care. However, it should not be an injunction that simply 
delays diagnosis (and appropriate treatment) when diagnostic criteria are already, clearly 
met. 
 
There is some consistency in reports of the prevalence of bipolar diagnoses in young 
people in different countries. The average rate for age 7-21 years was 1.8% (95% CI, 
1.1%-3.0%). This is probably higher than appreciated (Van Meter et al., 2011). The 
developmental trajectory is still to be established definitively by prospective studies. 
People of above average ability are over-represented in bipolar cohorts (MacCabe et al., 
2010). 
 
Diagnosis became controversial because ‘childhood bipolar’ diagnoses became 
increasingly common in some services in North America (II, (Geller et al., 1995)), but 
generally not in the rest of the world (II, (Wals et al., 2001)). In North America rates of 
diagnosis increased forty-fold in children and young people in a decade (Blader and 
Carlson, 2007; Moreno et al., 2007). The desire to move diagnosis earlier in the life 
history is entirely understandable. Unfortunately to do so inevitably risks sacrificing 
specificity to sensitivity. At the risk of over-simplification, softening the diagnosis of 
bipolar disorder to allow irritability and chronicity risks confounding with more common 
problems such as ADHD and oppositional disorder. Indeed, these disorders were usually 
described as very commonly comorbid with childhood bipolar diagnoses in US case 
series. Affective instability is undoubtedly a component of what troubles many children, 
but it does not allow ‘early diagnosis’ of true bipolar disorder.  
 
DSM-5 moved to diffuse the problem of diagnosing overactive children with emotional 
instability as ‘bipolar’ by inventing the diagnosis of Disruptive Mood Dysregulation 
Disorder (DMDD). This is accordingly defined by severe recurrent temper outbursts 
manifested as verbal rages and/or behaviourally (physical aggression toward people or 
property) that are grossly out of proportion in intensity or duration to the situation or 
provocation. It is required to be inconsistent with developmental and to occur frequently 
(on average, three or more times per week). It appears to have links in later life with 
depression, a common outcome at follow up. However, it remains questionable whether 
this is really a diagnosis that merits classification as a mood disorder, rather than as a 
particularly severe form or variant of oppositional defiant disorder or ADHD. The 
separation from the latter is a potential source of confusion in the coming years.  
 
It is now clear that clinical assessment should be supported by structured assessment 
tools to increase reliability and validity of diagnosis (Youngstrom and Van Meter, 2015). 
Instruments exist for the children themselves, parents and teachers. The detection of 
mania is more reliable on the basis of mothers’ reports than either the children themselves 
or teachers (Youngstrom et al., 2015). This has implications for the assessment of young 
people who have left home and for whom parental evidence may be lacking.  
 
2. Access to services and the safety of the patient and others  
 
 The Department of Health’s ‘National Service Framework’ in the UK set a 
template for specialist mental health clinical services to focus on ‘psychosis’; this 
remains broadly unchanged with a consequent lack of understanding among 
policymakers of the need for high quality specialised services for bipolar patients 
(IV), either in relation to early intervention or to provision of adult services. 
 This contrasts with the approach to schizophrenia even though the burden of 
disease for bipolar I disorder is comparable with schizophrenia (I). 
 Mania is usually a medical emergency 
 Assessment should be offered by a trained psychiatrist with an understanding of 
both the medicines and psychological treatments available for the management of 
bipolar disorder (S).   
 Patients should have access to early intervention, which must include the option 
of hospital admission (S).     
 Appropriate use of legal powers of detention is essential for the successful 
management of risk in some patients with acute mania and severe depression (S).     
 Consistent outpatient follow up is necessary and many individual patients may 
require complex interventions in community settings (S).  
 Risk assessment has poor positive predictive value for adverse outcomes and 
should not be over-emphasized in management (I). 
 There is an increased incidence of completed suicide soon after an assessment in 
bipolar patients (I), which suggests that current practice under-estimates suicide 
risk (IV).  
 
 
Early intervention 
 
Early detection and intervention is an increasing aspiration for mental health services. In 
the UK, the development of all mental health services has been distorted by an emphasis 
on psychosis and, in early intervention, psychosis has also been the paradigm focus. This 
could imply that a significant proportion of manic patients will be seen and treated, but 
actual practice appears to be inconsistent. A psychosis criterion will usually exclude 
patients with bipolar I disorder who present with depression until they become manic and 
will completely exclude bipolar II cases. 
 
The illness model proposed for schizophrenia was based on two related ideas. First to 
reduce duration of untreated psychosis and provide a service that was geared to treating 
younger people; avoiding stigma was a key element. The secondary purpose was inspired 
by the idea of a prodromal presentation and early intervention to prevent onset of 
syndromal illness. There is an inherent contradiction for these two approaches being 
pursued by the same service. Earlier detection of established illness implies diagnostic 
confidence and an earlier choice of evidence based treatments. In contrast, a prodrome is 
likely to be a relatively non-specific predictor of subsequent illness, in the absence of a 
diagnostic biomarker. Hence, there would be tolerance of diagnostic uncertainty, and no 
established approach to treatment.  
 
Early presentations with affective disorder pose the same dilemma. The necessary 
diagnostic tools to identify bipolarity in the prodrome are under active investigation 
(Howes et al., 2011; Youngstrom et al., 2015). However, we lack the necessary service 
structure to deliver any clinical programme.  
 
One version of a staging model for bipolar disorder is shown in Fig. 1. An important 
caveat is that staging implies predictable progression (most classically in the context of a 
cancer diagnosis) and bipolar illness course is much less predictable. Indeed the high 
rates of symptomatic diagnoses in young people suggest the outcome can be benign in a 
significant number of individuals assessed as teenagers (Tijssen et al., 2010). 
 
FIGURE 1 near here 
 
There is a reluctance to make a diagnosis in young people with bipolar disorder, which is 
to some extent reinforced by NICE2014.  Thus, NICE recommendations place an 
emphasis on specialist and detailed assessment. Much as this may always be desirable, it 
may be unnecessary if symptoms and history are obvious. If detailed assessment is not 
available, one result is likely to be failure to intervene in a way that might engage 
younger people with bipolar disorder at a time when treatment has most potential to be 
both effective and efficient (Kessing et al., 2013; Jones et al., 2015b). The first symptoms 
of bipolar disorder commonly occur in the teenage years, with a mean age of onset by age 
20 but many diagnoses are not made before the age of 30 (Fig. 1). 
 
First and early episodes 
 
Early-onset bipolar patients are about twice as likely to present with depression as mania 
(see Fig 1 and (Biffin et al., 2009)). Depression with psychosis in young people may 
predict subsequent bipolar disorder (Tohen et al., 2012). Highly recurrent illness and a 
family history may also raise the index of suspicion that a young person with a depressive 
episode has bipolar disorder. The use of antidepressants (i.e. drugs for unipolar 
depression) in these patients appears to be quite common. There is very little controlled 
data, but the findings from large naturalistic studies suggest that a patient whose 
diagnosis subsequently changes to bipolar is more likely to receive multiple treatments 
for their first depressive episode and so may be relatively treatment-resistant (Goodwin, 
2012). This may be a further clue to diagnosis. Additionally, the drugs themselves may 
increase the risk of manic switch or mood instability. In either case, they do not lend 
strong support to the use of antidepressants for unipolar depression in bipolar cases (see 
later).  
 
Even where the diagnosis can be made with confidence there is a dearth of evidence 
concerning the optimal management of a first syndromal episode. The key objective must 
be to prevent recurrence and the accrual of disability in young people because they tend 
to have poor clinical outcomes (Coryell et al., 2013). The optimal treatment choices or 
combinations are not established; the available data to be reviewed below concern mature 
patients. 
 
Any acute episode, regardless of polarity, should receive active treatment. Mania, in 
particular, is a relative emergency because of the important personal and social 
consequences that result from the errors of judgement that are intrinsic to a highly 
elevated mood state. The complexity of bipolar disorder makes it desirable that 
assessment should be offered by a trained psychiatrist with an understanding of both the 
medicines and psychological treatments available for the management of bipolar 
disorder.  Patients should have access to early intervention within an episode, which must 
include the option of hospital admission.   
 
Appropriate use of legal powers of detention is essential for the successful management 
of some patients with acute mania and psychotic depression.  Patients who are unlikely to 
co-operate with treatment because of difficulties in accepting their diagnosis, who use 
drugs, or in whom violence, risk taking or self harm complicate their mood change may 
require complex, community-based interventions, although the optimal approach remains 
controversial (Burns et al., 2002).  
 
 
Risk assessment in bipolar disorder 
 
There has been considerable emphasis in mental health policy and corresponding 
research interest in risk assessment in the UK and other high income countries. This 
approach is problematic if it is based on the notion of accurate prediction – the predictive 
value of assessment scales for suicide and violent risk are currently poor to moderate, and 
the ability of these tools to identify high risk groups is uncertain. For outcomes with very 
low base rates such as suicide, risk factors will only be weakly predictive of the event, 
and most suicides will occur in patients who, in statistical terms, are at low risk (Powell 
et al., 2000); this is also called the prevention paradox. Therefore, the idea that high risk 
groups can be appropriately targeted in providing services is a fallacy. 
 
All bipolar patients are at risk of suicide, especially if admitted to hospital, when their 
first episode is depressive, if prone to recurrent depression and mixed states, have co-
morbid anxiety (Harris and Barraclough, 1997; Schaffer et al., 2015) or comorbid drug 
and alcohol use disorders (Webb et al., 2014). The logical approach is to provide good 
long-term clinical care to as many of them as possible.  
 
One area where suicide risk assessment needs to be examined more carefully is in self-
harm patients with bipolar disorder presenting to hospital. Here the subsequent risk of 
suicide is high in the following year particularly (Tidemalm et al., 2008), and therefore 
risk assessment really may enable more effective targeting of those that need enhanced 
follow-up. This is important because risk may be under-estimated in bipolar patients. 
Thus, in a large survey of suicides in the UK, more than 60% of the bipolar group were in 
contact with services the week prior to suicide but were assessed as low risk (Clements et 
al., 2013). A diagnosis of bipolar disorder should modify an optimistic risk assessment of 
a symptomatic patient. 
 
Concerns about the risk of violence by psychiatric patients (not necessarily bipolar 
patients), has led to a proliferation of often very lengthy assessment schedules. A 
systematic review of the better known instruments suggest that they perform quite well at 
predicting individuals at low risk of offending, but the positive predictive value for those 
who will offend is not strong (Fazel et al., 2012). Thus, there is little evidence to support 
the routine use of the current set of commonly used instruments in bipolar disorder. New 
instruments will have to be assessed on their own merits, using multiple measures of 
performance. They need to be scalable, evidence-based, and not lead to patient harms (as 
positive predictive values will be low). 
In conclusion, the central purpose of risk assessment should be clinical diagnosis and 
estimation of severity of depression. For suicide and violence risk, beyond identifying 
comorbid substance abuse and past history of self harm and criminality, further 
quantification of risk is unlikely to help plan treatment and services. Many suicides occur 
in the first year after a serious episode of self harm, so reinforcing the need for attention 
to this clinical context and to early treatment engagement. Prisoners represent another 
high risk group who merit the same consideration (Fazel and Seewald, 2012; Fazel et al., 
2013).  
 The potential for the prevention of suicide and violent offending 
 
The most important perspective for risk assessment is the potential for successful long-
term treatment to reduce suicide risks by preventing new episodes or reducing chronic 
symptoms. Suicide has never been the primary outcome measure for a clinical trial in 
bipolar disorder, because in practice observable rates are too low. However, naturalistic 
studies have long suggested that suicide rates are lower in patients who receive long-term 
treatment (Angst et al., 2002). Furthermore lithium may have particular efficacy. This 
conclusion is again based largely on naturalistic comparison of patient cohorts on and off 
lithium, but the findings from different centres are consistent and the treatment effect is 
very large (I, (Tondo et al., 2001; Toffol et al., 2015)). One short-term RCT also found 
suicides and attempted suicides to be associated with carbamazepine and not lithium 
treatment (Ib, (Thies-Flechtner et al., 1996)). Indeed, meta-analysis of all the randomized 
controlled data for lithium suggests an important effect on suicide in studies which are 
individually inconclusive because of inadequate power (I, (Cipriani et al., 2013a)). An 
emerging study of a large Swedish data base which allows within subject comparisons on 
and off treatment in a so-called quasi-experimental design, has confirmed lithium’s effect 
in reducing suicide attempts by 30%; the same effect was not seen with valproate (Song 
et al.). Both lithium and valproate treatment were associated with 90% reduction in 
completed suicide. 
 
There is also recent evidence that treatment may be effective in reducing the rate of 
violent crime in patients with bipolar disorder. The data again comes from record linkage 
of medications and outcome. Dopamine antagonists halved the rates of offending in 
bipolar disorder and schizophrenia. Drugs for relapse prevention (‘mood stabilizers’ so 
lithium and valproate mainly) had an equally potent effect in bipolar disorder (but not in 
schizophrenia) (Fazel et al., 2014). These results are impressive because the events are 
relatively common, effect sizes are so large and the outcomes so important. As already 
emphasized in relation to data quality, they move the argument for benefit to a 
completely different level, compared with effects on symptoms or even symptomatic 
relapse. Consequently we have upgraded them in assessing the evidence supporting the 
use of medications in the long term. 
 
The National Confidential Inquiry data for England and Wales (1997-2006) included 
1243 bipolar patients (10% of the sample) who had died from suicide, and been in contact 
with mental health services in the previous 12 months (Clements et al., 2013). They make 
sobering reading. Only 390 (31%) were adherent with medication at time of death. This is 
an important measure of how ineffective management strategies currently are for our 
patients. Only 13 (about 3%) died by poisoning with prescribed drugs, so the benefit/risk 
potential appears favourable.  The challenge appears to be the delivery of effective 
treatment. 
 
The need for a service model 
 
The neglect of the specific needs of bipolar patients in UK government policy (Morriss et 
al., 2002) justifies our restating the obvious in the previous paragraphs. The term bipolar 
disorder or manic depression was given no special consideration (and entirely omitted 
from the glossary of key terms) in the National Service Framework for mental disorders 
in the United Kingdom (Department of Health, 1999). It remains a monolithic social 
model of mental illness, which is inappropriate to bipolar disorder (Goodwin and Geddes, 
2007).  
 
The complexity of the disorder, the resulting need for specialist and expert care and the 
potential for preventing bad outcomes by early treatment all argue for a concerted effort 
to improve treatment. The recent NICE guideline implied that this objective could be 
achieved by the appropriate deployment of existing services. We are very sceptical. In 
our view, a separate, serious effort to extend early intervention to young people with 
affective disorder, with appropriate identified funding, is long overdue. The absence of 
early stage specificity has led to pioneering approaches to youth mental health services in 
Australia, where distress rather than a diagnostic criterion applies, and bipolar patients 
can, in principle, make appropriate access (McGorry et al., 2007). 
 
In addition to the lack of focus on bipolar disorder, and certainly contributing to making 
it worse, is the traditional fault line between child and adolescent services and adult 
services. This falls at exactly the point where continuity is most obviously needed for 
young people developing severe psychiatric disorder (IV). 
 
Nevertheless, there remains a need for better quality evidence on which to argue for an 
improved approach to care. According to an analysis for the charity MQ, funding for 
research on bipolar disorder has been about one third that for schizophrenia in the decade 
to 2013 (http://www.joinmq.org/pages/mental-health-research-funding-landscape-report 
).  It is hardly surprising that our knowledge base is less than it might be: this must 
change. 
 
The best service model? 
The single most relevant study concerned bipolar patients discharged from inpatient care 
for their first, second or third episode of bipolar disorder in Denmark (Kessing et al., 
2013); they were randomized to either specialised or standard care.  The specialized care 
reduced re-admission over the subsequent 6 years by about 20%. This approach would 
not necessarily be cost effective for less severely ill patients, but it translates into very 
appreciable cost savings in a group of patients at high risk of relapse and re-admission.  
 
The key ingredients of expert care appear to have been psychoeducation (based on the 
Barcelona model (Colom and Vieta, 2006)), an algorithmic psychopharmacology (based 
on the previous BAP Guidelines) and continuity/consistency of care. A critical ingredient 
of psychoeducation is likely to be active monitoring for signs of relapse to mania and this 
approach should be a standard of care (Morriss et al., 2007).  The system in Denmark is 
broadly comparable to the UK, so these results may well generalize. They deserve very 
serious consideration in arguing for a better future in the care of bipolar patients. 
 
In the USA, a collaborative care model has been proposed involving a key worker to keep 
close contact with the patient, encourage adherence to treatment algorithms and 
guidelines and follow up in the case of non-attendance. Two similar studies showed small 
positive effects on a number of outcomes (Bauer et al., 2006a; Bauer et al., 2006b; Simon 
et al., 2006).  This may have been mediated in part by improved adherence in the 
collaborative care arms of the studies (Bauer et al., 2009). Finally collaborative care 
focused on physical health improved blood pressure in a small RCT (Kilbourne et al., 
2013). The lessons of these findings are less easy to translate to the UK because primary 
care and community provision is usually so limited in the USA and so there is the 
potential for a much bigger impact of service outreach. This was the lesson previously 
drawn from systematic comparisons of community care models for schizophrenia, which 
outside the USA had less if any impact on outcomes (Fiander et al., 2003). 
 
Finally one negative or failed trial (Crowe et al., 2012) has the possible lesson that 
collaborative care needs to be an integral part of a service, rather than an add-on that risks 
disrupting the continuity of the core service provision.   
 
NICE2014 published evidence from patients that supported employment initiatives are 
highly relevant to improving social outcomes. There are a few specific issues like risks of 
overspending, recklessness that may require some safeguards, undesirability of shift work 
for some bipolar disorder patients and the ability to take time off relatively quickly if 
early signs of mania or depression emerge. Psychiatrists and other professionals should 
be aware of these issues when counselling return to usual employment as well. 
 
In conclusion, very little work has pragmatically addressed the best model of service 
delivery for bipolar patients. Our conclusions are summarized alongside those reached by 
NICE (2014) in Table 1. The NICE approach essentially proposes that generic NHS care 
can be readily extrapolated to the needs of bipolar patients who require admission and 
access to secondary care services.  
 
 
Table 5. NEAR HERE 
 
Our primary conclusion is that we really do require more evidence of what works at the 
systems level. In Table 5 most of the recommendations by NICE2014 are not based on 
formal evidence, certainly for applicability to bipolar disorder. Instead they appear 
largely driven by what is currently provided in theory by psychosis-orientated NHS 
services. However, it appears a priori self-evident that services should be led by 
specialists with expertise in guideline-based psychopharmacology, there should be 
continuity of care and psychosocial management should be informed by and apply 
lessons from psychoeducation.  
 
Recent further fractionation of clinical services, for example between in and out patients, 
‘assessment’ and ‘treatment’ is a recent concern. It runs counter to the needs of bipolar 
patients in all stages of their treatment but particularly in managing follow up. Premature 
discharge to primary care can further dilute the treatment package available in the early 
stages of managing the illness (IV). 
 
 
3. Enhanced clinical care  
 
 Enhancement of patient care can be achieved by structured interventions based 
on psychoeducation (II). This has the potential to complement and inform 
treatment with medicines, not replace it (IV).  
 While, the evidence for efficacy in preventing relapse comes from mature patient 
samples, the same approach can inform early assessment and intervention with 
young people (IV). 
 We support NICE’s assertion that assessment and management of bipolar 
disorder should ideally involve partners, families and carers. 
 Bipolar patients are at high risk of cardiovascular, metabolic and respiratory 
disease: there should be an annual auditable check for hypertension, central 
obesity, raised blood glucose, and dyslipidaemia annually (S). 
 Assess consumption of alcohol and drugs. Drinking up to 14 units of alcohol per 
week represents lower risk drinking levels for men and women (<1% increase in 
excess mortality). High risk drinking (10% excess mortality) is 35 units or over 
per week. 
 
 Bipolar patients may have a particular problem with the use of tobacco (I). 
Treatment with effective nicotine substitutes will often be indicated (IV). 
 
Key uncertainty 
 The optimal approaches to enhanced care are evolving rapidly with the rapid 
development of self-monitoring and instruction from mobile apps.  
 
As noticed in the previous section, the services in which care is delivered clearly 
constrain what is possible. However, good individual clinical practice is a commonplace 
but essential objective. Psychiatrists must take responsibility for diagnosis, physical 
examination, investigations and explanation of the medical plan of management. They 
must communicate clearly and effectively. A therapeutic alliance between doctor and 
patient is essential for the management of any complex chronic condition, which bipolar 
disorder certainly is.  
 
The role of structured psychological treatment in the management of bipolar disorder 
remains at an experimental and exploratory level.  However, the findings are already 
important because they suggest that enhanced care can improve outcomes in bipolar I 
and, probably, bipolar II patients.  Broadly speaking the interventions that have been 
offered in bipolar disorder are pragmatically directed to identified clinical problems.  
They do not depend on specific models of psychopathology.  There is also appreciable 
overlap in content of the different approaches although it is conventional to consider 
them under separate headings. The following general principles are important. 
 
1) Bipolar disorder is a long-term problem, so psychological treatments should 
produce enduring behavioural change. Acute effects of any psychological 
approach need also to be considered in the longer term.  
2) We endorse the NICE statement on caregiver involvement. In essence, partners, 
families and carers can contribute significantly to the assessment process, the 
management of acute episodes, the promotion of long-term recovery and the 
prevention of relapse. This has the further implication that carers may benefit 
from information and support to improve how they achieve these objectives. 
 
 
Knowledge (or ‘Psychoeducation’) 
There is a consensus that good clinical management of patients with bipolar disorder 
involves an appreciable educational component for both patients and their relatives.  The 
objective of acquiring knowledge about the illness is prevention of relapse. Successful 
long-term management involves a high degree of patient involvement and autonomous 
judgement about return of symptoms etc.  It is essential to address the seriousness of the 
illness, any reluctance to give up the experience of hypomania or mania, the risk of 
relapse and the benefit of therapeutic engagement (IV). For patients to know what to do, 
and why, appears usually to be an essential prelude to actually doing it. 
 
One option is to provide a formal group course, the efficacy of which was shown in a 
randomized controlled trial (II, (Colom et al., 2003)). This compared psychoeducation 
with an equivalent group experience in which the content was simply unstructured 
supportive discussion. The use of an appropriate control intervention gives this trial 
particular credibility and the benefits of psychoeducation appear to be sustained because 
mood episodes of all types were reduced over a 5 year follow up of the original trial 
participants (Colom et al., 2009). The effect size compared to other psychoeducation 
RCTs makes it an optimistic outlier (Bond and Anderson, 2015).  Nevertheless, the 
findings described previously from Denmark over six years may also underline the 
potential for long clinically relevant effects in patients with recent illness onset (Kessing 
et al., 2013). Comparison with other alternatives, notably CBT (see also below), has also 
illustrated the economy of a more educational approach (Parikh et al., 2012). 
 
Despite our endorsement, virtually as a standard of care, negative or just marginally 
positive findings have been common in trials of psychoeducation. Pellegrinelli et al 
(2013) failed to show any difference in clinical outcomes for 16 psychoeducation versus 
non-psychoeducation sessions using the Barcelona manual; a slightly different 
psychoeducational approach run in UK mental health teams failed to separate 
convincingly from treatment as usual (Lobban et al., 2010). A related, more sustained 
intervention (the Life Goals program) showed minor effects on manic symptoms over 2 
years (Simon et al., 2006) but more substantial gains in function (not reduced symptoms) 
over 3 years (Bauer et al., 2006b). These failed or marginally positive trials indicate the 
methodological challenge to future treatment development.   
 
Failure to find a difference between groups is associated with higher proportions of 
patients with more previous episodes (Scott et al., 2007). Age appears not to vary 
between studies of adult patients, so intensity rather than length of illness appears to be 
the limiting factor. Clearly, lack of efficacy in large numbers of patients with more 
recurrent illness represents a challenge to understand the failure of existing approaches 
and an unmet need to develop better treatment approaches in the future. 
 
The key ingredients of all psychotherapies so far found useful for bipolar disorder 
(including psychoeducation) are as follows (Miklowitz et al., 2008): 
 
1. Monitor moods and early warning signs 
2. Recognize and manage stress triggers and interpersonal conflicts 
3. Develop relapse prevention plans 
4. Stabilize sleep/wake rhythms and daily routines 
5. Encourage medication adherence 
6. Reduce self-stigmatization 
7. Reduce alcohol or drug use (including caffeine in sensitive individuals) 
 
The involvement of carers/family is highlighted in family-focused treatment for younger 
patients, which has similar ingredients (Geddes and Miklowitz, 2013). In fact, these 
elements are also commonly present in treatments formally described in clinical trials as 
something other than psychoeducation (e.g. cognitive behaviour therapy (CBT) and inter-
personal social rhythm therapy (IPSRT)), which is a source of confusion. The role of 
CBT will be considered in a little more detail in relation to the treatment of bipolar 
depression and relapse prevention. 
 
 
Optimal delivery of psychoeducation 
 
The group format may not be culturally generalizable, so individual or family, rather than 
group approaches to psychoeducation, are also likely to be helpful and can inform 
ordinary practice. Facilitated use of a 5 session psychoeducational package increased 
comprehension of the principles and practice of self-management compared with self-
instruction (Miklowitz et al., 2012).  
 
Current practice also favours didactic teaching, live or by video, written materials or 
guided internet searching for high quality material (e.g. the National Electronic library for 
mental health: http://www.nelh.nhs.uk/). There is also an explosion of self-help apps, 
most still of rather low quality (Nicholas et al., 2015), that may incorporate personal 
mood and activity monitoring on mobile devices. The approach has enormous intuitive 
appeal, but systematic examination of the effects of self-monitoring has not led to 
immediate proof of concept (Faurholt-Jepsen et al., 2015). Such individual, rather than 
group approaches, includes the use of auto-didactic on line psychoeducation (Barnes et 
al., 2011): to see this in action visit http://www.beatingbipolar.org. The possibility of 
recording therapy sessions on patients’ phones for subsequent review also has the 
potential to enhance patient care. This is an area likely to see major advances in the 
coming years and, hopefully, clarification of what really helps. 
 
A time very early in the illness course may not be the most propitious for patient 
acceptability; however, it may be a critical period for the greatest impact of behavioural 
change on clinical outcome. Thus, the goals of education need to be sustained and 
incremental. There also needs to be a shared and consistent approach across mental health 
disciplines. Psychoeducation also appears to offer an approach to intervention in the early 
stages of the disorder before diagnosis is necessarily established and medicines are 
indicated.  
 
Adherence to medicines  
As we will review, there is good evidence that long-term treatment is effective in 
preventing relapse in bipolar disorder. However, adherence to prescribed medicines is 
poor in most chronic illness (I, (Horne et al., 2013)). Bipolar disorder is no exception (II, 
(Johnson and McFarland, 1996; Lingam and Scott, 2002; Scott and Pope, 2002)). The 
simplest framework for understanding adherence weighs the perceived need for treatment 
against concerns about its possible effects (Clatworthy et al., 2009). Understanding need 
will necessarily be a matter for education and personal experience. Adverse reactions are 
a major consideration given the limitations of existing medicines and should be 
minimised by all possible means. These include once daily administration (e.g. at bed 
time), switching between formulations and dose adjustments. Other efforts to improve 
adherence such as user-friendly packaging, monitoring of pill taking, delivery of supplies 
of medicine may contribute to successful treatment in certain individuals. 
 
The motivation to take tablets is heavily dependent upon the attitudes, beliefs and 
perceptions of risk shown by patients and their carers. These cultural factors may often 
divide clinical staff from patients. Pragmatic motivational interviewing to improve 
adherence to prescribed medicines has already been shown to be moderately effective in 
patients with psychosis. The best-known early study included a sub-group with bipolar 
disorder (II, (Kemp et al., 1998)).  Since non-adherence with treatment occurs in up to 
50% of most clinical samples (Scott and Pope, 2002), the development of a focused and 
generally applicable approach to this problem would be welcome.  The published 
methodology emphasises the involvement of a third party and there is clearly a potential 
role here for pharmacists who occupy an advisory role for patients in other contexts. 
Where barriers to adherence are identified and targeted interventions delivered, 
adherence is more likely to improve (Staring et al., 2010). Patient-related factors include 
younger age, male gender, low educational level, alcohol and drug use. Disorder-related 
factors include severity, insight and lack of awareness of illness.  And treatment-related 
factors are obviously adverse reactions to medications and perceived lack of efficacy. To 
improve adherence, clinical practice should address the underlying causes of non-
adherence within the overall frame work of psychoeducation (Leclerc et al., 2013). If the 
bottom line for adherence is the balance between the perceived necessity of drug 
treatment and concerns about it, this should inform clinical efforts to improve it. 
 
Clinical trials, in bipolar disorder as in other conditions, are likely directly to enhance 
patient care (I, (Ashcroft, 2000)). We believe that participation per se in well-designed 
clinical trials is a benefit for both doctors and patients. To put it bluntly, a controlled 
experiment is likely to be better than participation in the uncontrolled experiment that is 
ordinary practice. Furthermore the results from trials will eventually enhance the 
evidence base for improving patient care. Participation in trials is potentially related to 
adherence and hence we make the point here 
 
Awareness of stressors, sleep disturbance and early signs of relapse, and regular 
patterns of activity. 
Manic relapse in particular may follow a relatively stereotyped course in individual 
patients.  Sleep disturbance is perhaps the most commonly described final common 
pathway to mania (II, (Wehr et al., 1987)).  The sleep of bipolar patients between 
episodes is often disturbed in a very similar way to that of patients with primary insomnia 
(Harvey et al., 2005).  Despite this, formal trials to improve sleep in bipolar disorder are 
only just beginning. Pilot data suggest effects of CBT for insomnia generalize to bipolar 
symptoms (Harvey et al., 2015).  
 
The more usual emphasis is on tell tale signs and symptoms of relapse; this may take the 
form of particular impulses and preoccupations which accompany or even precede it. 
Efforts to train patients on individual scripts which access their own experience and 
enable them to take evasive action appears to be effective in avoiding new episodes of 
mania (II, (Perry et al., 1999)).  This approach was less successful with episodes of 
depression.  The original intensive trial involved up to 12 sessions of training and there is 
a need to know whether a more dilute approach or one focused uniquely on personal 
scripts for relapse into mania would be more widely applicable. The involvement of 
family members with experience of previous episodes may be helpful (Reinares et al., 
2008). 
 
Interpersonal social rhythms therapy (IPSRT) developed out of particular ideas about 
what behavioural features contribute to relapse in bipolar disorder (II, (Swartz and Frank, 
2001)). The reestablishment of routine and regular activity for those behaviours that recur 
at least once per week is a primary goal in treatment. IPSRT provides a simple 
framework for practical advice and feedback. It has also informed the development of a 
phone based app for sensing activity and providing feedback to shape social activity 
(Matthews et al., 2014). 
 
The further role of structured psychotherapy will be considered in relation to relapse 
prevention. All such therapy recognizes as axiomatic the value of a highly collaborative 
therapeutic relationship with the patient. The commitment by a clinician to see a patient 
long term can contribute to an optimal management plan.  
 The general point emerges that outcomes for patients can be improved simply by 
enhancing ordinary clinical care, most obviously by adopting a consistent approach to 
psychoeducation or knowledge sharing.  Translating this observation into enhanced care 
for more patients should be an important objective for treatment.   
  
Functional impairments  
Clinicians must anticipate the need to give advice about expectations and capacity to 
work. Major life decisions may not be auspicious when made in a depressive or manic 
state. Furthermore, patients may experience considerable difficulty performing at the 
level for which their education may have prepared them (II, (MacQueen et al., 2001)). 
This may be a result of common sub-syndromal symptoms of depression or anxiety (I, 
(Denicoff et al., 2000)) or other barriers to psychological well-being (II, (Scott, 1996)). 
Factors specific to bipolar disorder such as experience when high, or personality style, 
may also conspire to widen the gap between aspiration and achievement. Finally, there is 
evidence that objective impairments of neuropsychological function are both significant 
and enduring (I, (Bourne et al., 2013)). These objective problems in sustaining attention, 
memory and executive function appear to be made worse by repeated episodes (Clark et 
al., 2002; Martinez-Aran et al., 2004) and are more severe in bipolar I patients (Bourne et 
al., 2015). In other words they may be a quasi-toxic consequence of the intensity of the 
illness course. Polypharmacy may also compound the problem (Clark et al., 2002; 
Frangou et al., 2005). 
 
The National Service Framework for Mental Health recognised the vital role of informal 
carers in the delivery of mental health care (Department of Health, 1999)). However, it 
treated the needs of adults of working age as generic and was probably influenced by 
evidence from research in schizophrenia (I, (Fadden et al., 1987)) and the dementias (I, 
(Clyburn et al., 2000)). The literature concerning bipolar disorder is sparse, but the 
perceptions and beliefs of carers about it, as for other diseases, may have important 
effects on levels of burden that are experienced (II, (Perlick et al., 1999)). There is scope 
to develop improved psychosocial interventions tailored to bipolar patients and their 
families.  A particular uncertainty, neglected hitherto, is the impact of manic states upon 
carers, and indeed their children. A preliminary investigation of the families of 86 stable 
patients showed that caregivers still showed a moderate level of subjective burden. The 
highest levels of distress related to the patient's hyperactivity, irritability, sadness and 
withdrawal. The illness had also affected the carers’ emotional health and life in general. 
Poorer social and occupational functioning, an episode in the last 2 years, history of rapid 
cycling and the caregiver being responsible for medication intake explained a quarter of 
the variance of the subjective burden (Reinares et al., 2006). 
 
It seems reasonable to note the emphasis on recovery with return of function as the 
modern aspiration for bipolar patients. Cognitive impairment is a barrier to good 
outcomes and there is preliminary evidence that cognitive remediation can play a part in 
improving function (Torrent et al., 2013).  
 
Physical health, alcohol and drug use 
 In this country, a retrospective cohort study compared 46,136 patients with ‘severe 
mental illness’ (SMI) with 300,426 without SMI (using the GP Research Database). 
Hazard ratios (HRs) for coronary heart disease (CHD) mortality in people with SMI 
compared with controls were 3.22 (95% confidence interval (CI), 1.99-5.21) for people 
18-49 years old and 1.86 (95% CI, 1.63-2.12) for those 50-75 years old. For stroke 
deaths, the respective HRs were 2.53 (95% CI, 0.99-6.47) and 1.89 (95% CI, 1.50-2.38). 
Event rates in these age groups are quite low, but increased HRs for CHD mortality 
occurred irrespective of sex, SMI diagnosis, or prescription of medication during follow-
up (Osborn et al., 2007). 
 
The risk across the life span has been documented in a series of studies for bipolar 
disorder specifically. In most countries the estimate of years lost in bipolar patients is 
between 10 and 20 years (Chesney et al., 2014). Put another way, just under 25% of the 
male population in Sweden die before the age of 70 years. The corresponding age for 
bipolar patients is just over 50 (Laursen and Nordentoft, 2011). Cardiovascular causes 
account for almost 40% of the deaths, which is nearly twice the number of suicides and 
accidental deaths; the risk is elevated across the life span. Moreover, the survival in the 5 
years from diagnosis of a cardiovascular event is substantially reduced in bipolar patients 
(Westman et al., 2015), which may mean either that patients present later in their illness 
course or receive inferior treatment (or both). 
 
The metabolic syndrome/obesity and type II diabetes are important in the mediating 
pathologies to cardiovascular disease. In a meta-analysis of the data from bipolar patients, 
rates of the metabolic syndrome were elevated about two fold compared with controls 
(Vancampfort et al., 2013). Treatment with dopamine antagonist drugs was associated 
with a rate of 43%, compared with 32% in those not so treated. However, the variation 
from country to country suggested a major contribution from dietary habits as well. In 
impressive population data from Taiwan, the times to initiation of treatment for both 
hyperlipidaemia and diabetes were significantly delayed for patients with bipolar disorder 
compared with the general population (Bai et al., 2013)). 
 
Thus, effective medical management of physical illness in patients with severe bipolar 
disorder is a major challenge.  The higher risk of cardiovascular disease in bipolar 
patients is not solely due to medication, and life style factors like smoking, diet and lack 
of exercise are also important.  Consequently, a bipolar diagnosis should imply annual 
screening for metabolic risk factors even if a dopamine antagonist is not prescribed.  
 
The metabolic syndrome is a composite of biochemical, blood pressure and weight 
indices. It is associated with older age, higher body mass index, and higher values for 
each individual criterion of the metabolic syndrome. The absolute waist circumference 
(>102 centimetres (40 in) in men and >88 centimetres (35 in) in women) and the waist-
hip ratio (>0.9 for men and >0.85 for women) are both used as measures of central 
obesity. In a small study, the presence of central obesity is the most sensitive indicator 
(92.0%) and fasting glucose 7.0 mmol/l or over was most specific (95.2%) in correctly 
identifying the presence of metabolic syndrome (Straker et al., 2005).  The treatment of 
blood pressure over 120/80 mmHg, and the use of statins in bipolar patients should 
follow existing medical practice.  
 
Weight gain, in part driven by medication, is a particular problem. A comprehensive 
guideline, much of which will be relevant to bipolar patients as well as patients with 
psychosis, is provided by ‘The BAP guideline on the management of weight gain and 
metabolic disturbances associated with psychosis and antipsychotic drug treatment’ 
currently in preparation for this journal. 
 
The consumption of alcohol and drugs will contribute to both physical and psychiatric 
morbidity and mortality. The assessment of these contributory factors and lifestyle advice 
are key to a more synergistic approach to treatment in bipolar disorder. Public Health 
England suggest that up to 14 units of alcohol per week for men and women represents 
lower risk drinking levels (excess mortality <1%). There is a monotonic increase in the 
risk of alcohol related death with higher levels of consumption. Excess mortality exceeds 
10% at a consumption around 35 units per week. It is recommended that drinking is 
spread over the week but with 2 or more alcohol free days. This represents a tightening of 
advice for men particularly, based on new data showing an increased excess of cancers in 
drinkers 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/489797/C
MO_Alcohol_Report.pdf ).  
  
Advice on the use of tobacco is also essential because in data from the US, bipolar 
disorder has the highest rate of current and lifetime use and the lowest quit rate of any 
other psychiatric disorder (I, (Lasser et al., 2000)). Treatment with effective nicotine 
substitutes will often be indicated (I, https://www.nice.org.uk/guidance/ph45 ). 
 
Audit of current practice: Prescribing Observatory for Mental Health (POMH-UK) 
The POMH-UK is based at the Royal College of Psychiatrists’ Centre for Quality 
Improvement and runs audit-based quality improvement programmes (QIPs).  The vast 
majority of UK mental health trusts participate in these traditional audit, intervention, re-
audit cycles.  For some QIPs it is possible to abstract current prescribing practice for 
people with bipolar disorder specifically and for other QIPs data relating to those with a 
diagnosis of an affective disorder.   
 
Treatment with dopamine antagonist agents should always trigger screening for four 
cardio-metabolic risk factors (hypertension, central obesity, raised blood glucose, and 
dyslipidaemia). In a national POMH audit conducted in 2012 (Prescribing Observatory 
for Mental Health, 2013), 22% of patients with an affective disorder who were prescribed 
antipsychotic medication had been screened for all 4 of these measures in the previous 
year, 54% for up to 3 measures, and 24% had received no screening. The respective 
figures for those with a diagnosis of a schizophrenia or related disorder were 36%, 49% 
and 15%. Thus, despite the major cardiovascular health risks for bipolar patients, these 
audit findings suggest that, when receiving antipsychotic medication, they are less likely 
to have physical health screening and monitoring than patients on such treatment with a 
diagnosis of schizophrenia.   
 When prescribing lithium, the practice standards (derived from NICE guidance) require 
that a patient be informed at the start of treatment about the potential adverse reactions, 
how they could recognise toxicity and how they should avoid toxicity. Audit data at 
baseline revealed that the proportion of patients provided with this information at the start 
of lithium treatment ranged between 42 and 62% (Prescribing Observatory for Mental 
Health, 2013). At a subsequent audit, conducted after provision of a bespoke, patient-held 
lithium information pack, the respective figures rose to between 54 and 68% (Paton et al., 
2013).  
 
A further finding was that approximately one in five patients who started lithium had no 
documented baseline test of renal function or thyroid function and this proportion 
remained relatively consistent over 5 years (2008-2013). However, there is some 
evidence that monitoring of serum lithium, renal and thyroid function improved over the 
same period; at baseline, there had been no documented monitoring of these parameters 
in the previous year for 10%, 19% and 18% respectively, but by the fourth audit, these 
proportions had fallen to 5%, 7% and 10%.  Serum lithium concentrations within the 
usual target range (0.4-1 mmol/L) are found in almost 100% of patients in some NHS 
Trusts, but the proportion is as low as 50% in others. 
 
Psychotropic drug prescribing for bipolar patients in the UK was fairly consistent over 
time. For patients taking lithium, around 20% took lithium alone, 45-50% took a second 
drug, about 30% a third, and 5% a fourth. This underlines current levels of 
polypharmacy. The added medicines are dopamine antagonists/partial agonists (55-60%), 
antidepressants (35-40%), valproate (13%), lamotrigine (5%), and depot or long acting 
drug (5%). For valproate, age/child-bearing potential did not seem to influence 
prescribing.  
 
Given these data, antidepressants appear to be relatively over-prescribed and lamotrigine 
relatively under-prescribed given the evidence of benefit (q.v.). However, when 
prescribed, lamotrigine use seems to follow the indications presented in guidelines 
(Grande et al., 2012).  
 
A template for audit of bipolar disorder is suggested in Table 4. 
 
Table 4 NEAR HERE 
 
 
TREATMENT OF DIFFERENT PHASES OF BIPOLAR DISORDER 
 
Terminology and treatment strategy 
 
 Bipolar disorder usually presents for treatment in an acute illness episode 
(mania, depression or mixed state) (I). The objective of short-term treatment is to 
reduce the severity and shorten the duration of the acute episode and achieve 
remission of symptoms (S). 
 Long-term treatment is indefinite for the prevention of new episodes and to 
achieve adequate inter-episode control of residual or chronic mood symptom (S).  
 Because of the high risk of relapse and the apparent progression to more frequent 
episodes, long-term treatment with appropriate medicines is advocated from as 
early in the illness course as is acceptable to a patient and their family (S). 
 Between episodes, mood instability or chronic depressive symptoms are common 
(I) and generally underestimated. 
 
Key uncertainty  
 Current strategies emphasize the treatment and prevention of syndromal relapse. 
Disabling aspects of long-term outcome such as chronic depressive symptoms, 
mood instability, co-morbid anxiety, enduring neurocognitive impairment or 
oxidative status may be important future therapeutic targets. 
 
It is usual to think of bipolar disorder as a sequence of acute illness episodes (mania, 
depression or mixed states) interspersed with relative euthymia.  This view of the illness 
conditions how treatment strategies and actual treatment phases are distinguished.  Short-
term treatments will refer to episodes and will often imply the intention to discontinue a 
medicine on recovery. Long-term treatment is indefinite and for the prevention of new 
episodes.  Although it is conventional in discussing unipolar disorder to distinguish 
relapse (the early return of symptoms treated in an acute episode) from recurrence (the 
return of symptoms after remission), this is a distinction that is rarely helpful in bipolar 
disorder with relatively frequent episodes. We will refer to long-term treatment for 
prevention of relapse. 
 
Currently neglected in the bipolar literature are the times between episodes. These 
represent most of the patient’s life and may be characterized by a variable sub-syndromal 
level of mood symptoms. Euthymia, the absence of symptoms and the presence of 
positive stable mood is actually quite unusual. Chronic symptoms in bipolar disorder are 
commonly depressive (II, (Judd et al., 2002; Judd et al., 2003; Kupka et al., 2007)) and 
significant levels of residual symptoms are predictive of relapse (Judd et al., 2008).  As 
already noticed, there are also cognitive distortions similar to those seen in depressive 
disorder (II, (Scott, 1996)), sometimes disabling anxiety (Albert et al., 2008) and 
neuropsychological deficits that are still largely ignored (Bourne et al., 2013). These 
negative aspects of long-term outcome are often accepted as the natural history of the 
disease. In addition, there is evidence for increased oxidative stress, measured as enzyme 
activity in brain post mortem (Andreazza et al., 2013), in peripheral tissues in life 
(Andreazza et al., 2008) or as increased concentrations of oxidized circulating glutathione 
(Rosa et al., 2014).  Inflammatory markers are also disturbed in bipolar patients 
(Modabbernia et al., 2013). Along with measures of social adjustment, these alternative 
measures of outcome represent key areas of focus for current uncertainty. 
 
 
1. Acute Manic Episodes and DSM-IV mixed states 
 Treatment choice should be dictated by the clinical context and, whenever 
possible, by patient preference and experience (S). However, systematic 
comparison of the performance of drugs for mania suggests that haloperidol, 
olanzapine, risperidone and quetiapine have the highest efficacy. 
 Drugs and dosages should be chosen that do not produce Extra-Pyramidal motor 
Side effects (S), which is of particular significance in bipolar patients because of 
their apparently greater risk of adverse motor reactions compared with 
schizophrenia (I for haloperidol). 
 When combined with lithium or valproate, a number of dopamine 
antagonists/partial agonists have been shown to be superior to lithium or 
valproate alone (I). Combination treatment can be considered especially when 
patients show break-through mania with the first agent. 
 GABA modulators (benzodiazepines) are useful adjunctive agents and can induce 
sedation or sleep (II). 
 ECT is an important treatment option in cases of delirious mania, since this may 
be a medical emergency, and in treatment of resistant mixed states 
 Discontinuation of short-term treatments for mania can be considered after full 
remission of symptoms. The required duration will often be of the order of 12 
weeks although higher doses may be reduced earlier (IV). 
Key uncertainty 
 Switch to depression after mania may occur in any illness course: it is not 
established which treatments, if any, make this more likely. 
 
Dopamine antagonists/partial agonists (Antipsychotic drugs) 
Mania can develop extremely quickly and incur risks both for the patient and for others.  
In its more severe form, mania is almost invariably treated with dopamine receptor 
antagonists/partial agonists and patients with psychotic mania were among the first 
patients treated successfully with chlorpromazine.  Dopamine receptor antagonists/partial 
agonists are antimanic not simply sedative. However, despite their widespread use by an 
earlier generation of psychiatrists, placebo controlled data to show that the older 
dopamine antagonists (“first generation” antipsychotics) were effective in mania were 
very limited before the turn of the century (e.g. II, (Johnstone et al., 1988)). This changed 
when placebo controlled studies of new drugs included haloperidol as a comparator.   
 
While the neurobiology of mania is still poorly understood, mania may be a 
hyperdopaminergic state appropriately treated by blockade of dopamine D2/3 receptors 
with antagonists or partial agonists.  This is a common effect of the anti-manic drugs 
described below. The detailed additional pharmacology is described for some of the 
drugs in the section on treating depression, because it may be more relevant for that 
indication. 
 
A series of RCTs have been completed showing the efficacy for mania of aripiprazole, 
asenapine, cariprazine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone and 
ziprasidone in comparison with placebo (Yildiz et al., 2011; Yildiz et al., 2015).  
Olanzapine, aripiprazole and ziprasidone are also available in parenteral formulations for 
acute use. Ziprasidone and cariprazine are not available in the UK.  
 
The newer antipsychotic drugs were developed with a primary objective to reduce the 
incidence of extra-pyramidal symptoms (EPS). Therefore their efficacy showed that an 
anti-manic action could be achieved in the absence of EPS (II, (Keck et al., 2000)).  This 
is an important clinical message, which should influence prescribing practice, for all 
dopamine antagonists.  
 
The marketing of the newer drugs as ‘atypical’ implied a qualitative break from the past 
(the ‘typical’ antipsychotics) in regard to EPS. This was misleading.  The reduced 
tendency to produce EPS depends on dose and pharmacology. The use of muscarinic 
antagonists (antiparkinsonian medication) provides a proxy for clinically significant EPS. 
In head-to-head studies (Rummel-Kluge et al., 2012), risperidone was associated with 
more use of such medication than clozapine, olanzapine, quetiapine, and ziprasidone. 
Quetiapine showed significantly less such use than olanzapine and risperidone. In 
addition, patients with bipolar disorder may be more at risk for EPS than patients with 
schizophrenia, for example when treated with high potency dopamine antagonists like 
haloperidol (Cavazzoni et al., 2006). Accordingly, successful treatment of mania without 
EPS is an important practical clinical objective that can be facilitated by differentiation 
between drugs that are anti-manic. 
 
The relative efficacy and acceptability of the treatments for mania has been analysed 
using network meta-analysis or NMN (Cipriani et al., 2011; Yildiz et al., 2015). All the 
dopamine antagonists (and the partial agonist, aripiprazole), showed superiority to 
placebo.  NMN demonstrated an order of relative superiority that ranked risperidone, 
olanzapine, quetiapine and haloperidol at the top; haloperidol was less well ranked for 
acceptability (drop outs from trials). The network was highly coherent and so strongly 
supports the validity of the overall recommendation to use dopamine antagonist/partial 
agonists in mania. The individual rankings of drugs are of interest but show considerable 
overlap in confidence intervals. 
 
Clozapine may also be considered by extrapolation from its likely superiority in treating 
psychosis (Leucht et al., 2013) and limited observational data in treatment resistant mania 
(Green et al., 2000; Li et al., 2015). 
 
Other factors that influence the choice of drug include properties such as sedation, which 
may be desirable in the short term but not in the long term, and the choice of formulation. 
Finally, in the UK only aripiprazole is licensed for up to 12 weeks’ treatment of moderate 
to severe manic episodes in bipolar I disorder in young people (13 years and older). 
 
The availability of parenteral formulations is valuable in emergencies and should form 
part of any local protocol for treating highly agitated patients (I, (Wilson et al., 2012)). In 
the past, often in an effort to achieve sedation, patients were habitually treated with high 
doses of, for example, haloperidol or droperidol (the latter now withdrawn in the UK), 
which could produce marked extrapyramidal symptoms unless combined with a 
muscarinic antagonist. When possible, such extrapyramidal adverse reactions should be 
avoided, even when managing an emergency. 
 
If sedation is the aim, benzodiazepines such as diazepam, lorazepam and clonazepam are 
more appropriate and can usually produce adequate sedation. When prescribed regularly 
at night they may also facilitate the return of a normal sleep wake cycle (II (Post et al., 
1996)). 
 
Other medicines for acute mania: lithium, carbamazepine and valproate  
Acute treatment trials support the use of lithium, carbamazepine and valproate in mania 
(Yildiz et al., 2011; Yildiz et al., 2015). Network meta-analysis ranks them below the 
more efficacious dopamine antagonists (Cipriani et al., 2011), but their use may often be 
considered if planning their long-term continuation. Expert guidelines in the USA have in 
the past made lithium and valproate (“mood stabilizers”), their first line preference for 
mania for this reason (American Psychiatric Association, 2002).  
 
The low therapeutic index of lithium means that lithium is usually commenced at a low 
dose and increased incrementally approximately every 5 to 7 days depending on results 
of serum lithium levels. Thus, one cannot usually start a patient on a therapeutic dose of 
lithium on the first day of treatment whereas this can often be achieved with a dopamine 
antagonist or partial agonist.  The much improved evidence base for the use of the 
dopamine antagonists and partial agonists has resulted in a convergence of practice and 
experiment in their acceptance as first line for mania. 
 
Valproate is the term that is often used to describe different formulations of valproic acid, 
the active chemical entity. Sodium valproate has been widely used in epilepsy and is also 
available in a sustained release formulation. Valproate semisodium (also known as 
divalproex) is a non-covalent dimer molecule (comprised of sodium valproate and 
valproic acid) which has been studied in bipolar disorder and is licensed in the UK as 
®Depakote (see Annex for information on dosing of different formulations). 
 
Valproate semisodium is effective in severe mania (II, (Macritchie et al., 2003)), when 
the dose should be titrated upwards quickly to get control: 750mg on day one and 
20mg/kg+ on day two. Previous US Guidelines gave unusual weight to the efficacy data 
for valproate and the conviction that lithium and valproate are “mood stabilizers” (see 
below).   
 
Exposure to valproate in utero is associated with developmental disorders and foetal 
malformations in women. Warnings against its use in women of child bearing potential, 
and the need for their informed consent if proposing to do so have been strengthened 
recently (https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-
abnormal-pregnancy-outcomes). 
 
The combination of a dopamine antagonist drug with lithium or valproate in acute 
mania 
In practice, patients may already be taking lithium or valproate when mania occurs as a 
breakthrough during long-term treatment.  Under these conditions it would be common to 
optimise the maintenance treatment and/or add a dopamine antagonist/partial agonist 
drug.  Optimisation is favoured if symptoms are not severe, the history suggests that 
lithium or valproate has been effective until the current ‘breakthrough’, the current 
treatment is well tolerated and in the case of lithium the most recent plasma level 
suggests that a dose increase will not push the level above the upper limit of the normal 
therapeutic range.  Otherwise, combination treatment with a dopamine antagonist/partial 
agonist will be favoured. Most patients included in trials which have compared 
combination/augmentation therapy versus monotherapy with lithium or valproate had 
prior treatment with lithium or valproate, whereas most participants in trials comparing 
combination/augmentation therapy versus dopamine antagonist as monotherapy had not 
been on medications or were washed out from their previous medication before 
randomization (Ogawa et al., 2014).  The clearest effect was demonstrated when the 
antipsychotic is added to lithium or valproate not the reverse. Also, in Swedish database 
studies, the impact of long-term combination treatment on violence was only seen when 
antipsychotics were added to mood stabilizers and not vice versa (Fazel et al., 2014). 
Thus, the asymmetry may be a consistent finding and reflect the greater acute efficacy of 
dopaminergic drugs. 
 
The issue of long-term treatment with lithium and valproate will be addressed below. 
While it may seem logical to initiate one or other option in acute mania as a prelude to 
long-term continuation (in combination with a dopamine antagonist), there are no reasons 
to make this mandatory. Lithium in particular is sometimes difficult to use in exhausted, 
dehydrated patients. Moreover, efforts to prescribe lithium for patients with poor 
adherence may be misplaced. Patients very often stop taking lithium; the median time to 
discontinue was only 6 months in Denmark (Kessing et al., 2007).  Discontinuation is 
associated with admission to hospital (I, (Johnson and McFarland, 1996)). This 
association will be due, in large part, to relapse of mania, which can be provoked by 
abrupt lithium discontinuation. Unless patients are adherent to lithium therapy for a 
minimum of two years, these withdrawal effects will nullify any potential prophylactic 
effect (Goodwin, 1994). 
 
Carbamazepine is not the optimal partner for combination therapy. Carbamazepine 
induces the metabolism of many other drugs and combinations are better avoided 
(Monaco and Cicolin, 1999). Alternatives, licensed for use in epilepsy and less likely to 
interact with other drugs, include oxcarbamazepine and eslicarbazepine acetate (rapidly 
converted to eslicarbazepine after oral administration). Eslicarbazepine acetate failed in 
trials on mania on primary but not all secondary outcomes in trials limited by high 
placebo response rates (Grunze et al., 2015). Thus, the use of alternatives to 
carbamazepine represents a plausible extrapolation, not well supported by direct 
evidence. 
 
GABA modulators (benzodiazepines) 
Diazepam, lorazepam, clonazepam and related agents are useful in the management of 
acutely agitated manic states (Allen et al., 2001). They are adjunctive, so are indicated 
when sedation or tranquillisation is a priority and when there is a pressing need to induce 
sleep. Their safety in relatively high sedative doses and the absence of important 
pharmacokinetic interactions with other agents are advantages.  
 
The use of adjunctive GABA modulators can help to avoid excessive doses of 
antipsychotic drugs with the attendant risk of cardiovascular and other adverse reactions, 
including the neuroleptic malignant syndrome. 
 
The switch into depression following mania  
It is often stated that treatment with relatively selective and potent dopamine antagonists, 
like haloperidol, is more likely than treatment with lithium or valproate to result in a 
switch from mania to depression.  This is also a reason that is sometimes given for 
preferring a drug with dopaminergic/serotonergic effects like olanzapine or risperidone.  
Evidence is very limited but one large, naturalistic study suggested switch rates of about 
5% in the 12 weeks following initiation of treatment for mania (Vieta et al., 2009). 
Patients with previous depressive episodes, substance abuse and illness severity were 
more at risk.  The study was deliberately enriched for olanzapine (together with an 
assortment of other ‘atypical’ and ‘typical’ antipsychotic drugs, not specified). The 
choice of atypical drugs (usually implying a mixed dopaminergic/serotonergic 
pharmacology) was associated with 10% fewer depressive relapses in confirmation of 
clinical impression. Controlled data for perphenazine (an older drug) supports the 
potential negative impact of some dopamine antagonists (Zarate and Tohen, 2004); 
however, this was a small study and perphenazine’s pharmacology is not very different 
from the newer dopaminergic/serotonergic antagonists 
(http://www.guidetopharmacology.org/ ). The data from the lamotrigine/lithium/placebo 
relapse prevention trials are a reminder that the risk of relapse of the index episode will 
usually be higher than the risk of switching (Goodwin et al., 2004). 
 
At present, it would be unwise to base an acute treatment strategy on the assumed risk of 
switch to depression. However, high doses of dopamine antagonists, especially those with 
high affinity for dopamine receptors may cause akathisia and dysphoria and should be 
avoided (Mizrahi et al., 2007). 
 
Discontinuation of short-term treatments 
Doses of drugs used in short-term treatment of mania, particularly dopamine 
antagonists/partial agonists, should be reduced only after complete remission of 
symptoms, and preferably after 8 or more weeks of euthymia. Benefits of continuation of 
olanzapine and risperidone were still seen six months (but not 12 months) after illness 
onset (Yatham et al., 2015a). As a precaution, doses should not be reduced abruptly but 
tapered over several weeks (IV). 
 
Lithium or valproate, if used in treatment of an acute manic episode, are potentially a 
rational choice for long-term continuation. However, if either is to be discontinued after 
full remission of an acute manic episode, the same consideration applies. Lithium 
discontinuation should occur over a minimum of four, preferably 8 weeks, given the risk 
of premature relapse (Suppes et al., 1991). Tapering is also preferable to sudden 
discontinuation for valproate (IV) (Franks et al., 2008). 
 
Adjunctive drugs used during short-term treatment of mania, particularly GABA 
modulators, should be reduced gradually once the symptoms for which they were 
prescribed (e.g. agitation, insomnia) have responded and in addition the underlying manic 
illness has responded to the primary anti-manic treatment.  
 
All patients who have recovered from a manic episode, including their first manic 
episode, should consider subsequent maintenance treatment. The patient and clinician 
may decide to continue the drug that proved effective in the treatment of acute mania; 
this will often be a dopamine antagonist/partial agonist.  However, consideration should 
also be given to switching to lithium (see below) (IV). 
 
Short-term treatments of mixed states 
Most treatment recommendations for mixed states (DSM-IV-TR) have resulted from sub-
group or secondary analysis of data from trials in mania.  Pooled data from acute efficacy 
trials of dopamine antagonists/partial agonists have not suggested important differences 
in sub-group effects (Baldessarini et al., 2003).  With the accumulation of new data fom 
acute (3-6 week) studies of dopamine antagonists (asenapine, olanzapine, paliperidone-
ER, risperidone, and ziprasidone) and aripiprazole, either as monotherapy or as 
adjunctive therapy, versus placebo, meta-analysis has confirmed efficacy in treating acute 
mixed episodes with predominant manic symptoms (Muralidharan et al., 2013). Their 
efficacy in treating depressed episodes with mixed features remains unclear. 
 
The demise of the mixed state diagnosis in favour of the extended specifier description 
will have implications for future trials, but as yet little has emerged that is of relevance to 
choice of treatment.  
 
There is no indication to either start or continue treatment with an antidepressant in a 
mixed state (IV). 
 
Electroconvulsive therapy 
Electroconvulsive therapy (ECT) may be considered for manic patients who are severely 
ill, whose mania is treatment-resistant (including mixed states (Valenti et al., 2008)), who 
express a preference for ECT and patients with severe mania during pregnancy. Formal 
evidence for efficacy in mania is limited; patients with severe mania are difficult to enter 
into trials. However, audit findings of clinical practice support high rates of response and 
remission (Mukherjee et al., 1994). Indeed an earlier study suggested a 60% remission 
rate in manic patients who had previously responded poorly to lithium or dopamine 
antagonists/partial agonists (Black et al., 1987b). This observational data is strong and 
consistent enough to merit moderate ranking in the GRADE system. 
 
It can be argued that ECT should be considered especially in cases of delirious mania, 
since this may be a medical emergency when accompanied by fever, dehydration, and 
autonomic dysfunction and in treatment of resistant mixed states (Medda et al., 2015).  
 
In view of the polypharmacy common in bipolar disorder, vigilance is required because 
fit thresholds may be altered and the potential for either too brief or prolonged seizures 
during ECT increased. 
 
It is more usual for ECT to be considered in depression (see below). 
 
 
Comparison with NICE guidelines 
 
There are no substantial differences between the conclusions of the NICE committee and 
ourselves regarding the treatment of an acute manic episode. 
 
 
2.  Short-term treatment of Depressive episodes 
 
 Quetiapine has the most convincing short-term efficacy and relapse prevention 
profile for bipolar depression (I). Olanzapine (in combination with fluoxetine and 
to a lesser extent as monotherapy) and lurasidone also have data supporting 
acute efficacy. 
 Antidepressant drugs approved for unipolar depression may be effective for 
treating depression in bipolar disorder but the evidence base is very poor. The 
case is based primarily on extrapolation. They require co-prescription of another 
agent that will reduce the risk of mania (lithium, valproate or dopamine 
antagonist/partial agonist drug) in bipolar I disorder (I). 
 Lamotrigine has evidence for acute efficacy and relapse prevention (I). 
 The risk of a switch to mania is greater for tricyclic antidepressants or other dual 
action medications, such as venlafaxine, than with SSRIs (II). 
 While they are unlikely to provoke a manic switch, lithium, valproate, and 
carbamazepine have poor evidence for acute efficacy in bipolar depression. 
 ECT has efficacy in treatment-resistant bipolar depression (II): other options 
have not been adequately studied.  
 Discontinuation of an antidepressant should follow BAP recommendations for 
unipolar depression, but with a more rapid taper in rapid cycling patients (IV). 
Key uncertainties 
 There is a paucity of evidence to decide between different agents in the treatment 
of bipolar depression.  
 Refractory depression is not uncommonly associated with a bipolar illness course.  
 Folate may impair the response to lamotrigine. 
 Most data are for a bipolar I illness course: it is often uncertain whether the 
treatment of bipolar II and particularly the other specified bipolar disorder cases 
with depression should be different from the treatment of unipolar cases.   
 There may be a risk in bipolar II disorder, that antidepressants induce hypomania, 
mixed states or rapid cycling.  It is uncertain whether this is mitigated by 
concurrent anti-manic medication.  
 The role of psychological treatments in bipolar depression remains uncertain, in 
the absence of replicated good quality evidence. Negative trials of CBT in bipolar 
disorder suggest caution in extrapolation of the approach from experience in 
unipolar depression. 
 
Dopamine antagonist drugs (antipsychotic drugs) in bipolar depression 
The use of dopamine antagonist drugs in bipolar depression has assumed increasing 
importance as doubt has grown over the role of conventional antidepressants. Efficacy 
can only be supported for specific agents, not for the class. This is because the relevant 
pharmacology is probably not antagonism at dopamine receptors per se. The affinities at 
other receptors are both multiple and varied (Michl et al., 2014). What among these 
properties confers antidepressant efficacy is not known. This is partly because not all 
drugs have been studied equally for depression, so the data on which to map efficacy to 
drug action are very incomplete. 
 
Most of the controlled data comes from studies of major depressive episodes in a bipolar 
I illness course. Where there is sufficient evidence from secondary analysis of bipolar II 
sub-groups it will be noted in the following. Relapse prevention studies offer supporting 
evidence for acute efficacy. Such studies compare the effect of double blind continuation 
of an active drug with its discontinuation to placebo. The active drug is used to treat the 
index episode. Where the index episode is depression, the data will support efficacy in 
depression. Such designs will be relatively uninformative about preventing relapse to 
mania (and vice versa when the index episode is mania). All such studies are associated 
with high dropout rates, so that interpretation of drug/placebo differences over the longer 
term (the prevention of new episodes) will be problematic. 
 
Quetiapine  
In common with a number of other drugs for psychosis, quetiapine has moderate affinity 
for dopamine D2 and serotonin 5-HT2A receptors. At doses of 300 and 600 mg/day it 
produced large and early attenuation of depressive symptoms in bipolar patients 
compared with placebo (Calabrese et al., 2005; Thase et al., 2006). Pooled analysis of 
these two similar trials, together randomizing nearly 1000 patients, showed effects in 
bipolar I and bipolar II participants (with slightly lower response rates to active treatment 
in the latter subgroup) (Weisler et al., 2008). The only concern about the relatively large 
effect sizes in these trials is the problem of unblinding, which must occur for quetiapine, 
owing to its sedating subjective effects. This justifies downgrading the trials in the 
GRADE system. 
 
In relapse prevention studies of patients responding to quetiapine and randomized to 
continued quetiapine or switch to placebo, continuing quetiapine is associated with fewer 
episodes of mania, mixed mania and depression after recovery from either mania or 
depression (Suppes et al., 2013). This further supports the evidence for acute efficacy 
and, arguably, for relapse prevention (see below).  
 
Current uncertainties relate to the dose: even 300mg produces substantial rates of 
somnolence and sedation, with associated dropout from treatment and the longer term 
risks of metabolic disturbance. After only 8 weeks there is evidence of weight gain and 
significant increases in triglycerides and blood glucose. While not of great importance in 
short-term treatment, these changes are an important signal to monitor and treat such 
problems in the medium to long term. There are important differences in metabolic 
impact between different dopamine antagonist drugs, and quetiapine appears to lie 
towards the more problematic end of the spectrum (Leucht et al., 2013).  
 
Quetiapine may have unusual properties relative to other dopamine antagonists; one 
suggestion is that an active metabolite, nor-quetiapine, binds with moderate affinity to the 
noradrenaline transporter (Goldstein et al., 2007). This may contribute to its 
antidepressant action (Cross et al., 2015).  
 
If norquetiapine is the active antidepressant agent, implications follow from the 
polypharmacy common in bipolar disorder. The nor-alkylation (N-desalkylation) is 
catalysed primarily by CYP3A4. This enzyme may not only be inhibited, but also 
induced by other drugs (http://medicine.iupui.edu/flockhart/table.htm ). Relevant agents 
that block N-desalkylation include fluvoxamine and norfluoxetine, and inducers include 
carbamazepine, modafinil, and St John’s wort. Thus, fluvoxamine increases quetiapine 
concentrations by 159%, while carbamazepine can reduce them by 86% (Castberg et al., 
2007); effects on norquetiapine concentrations have not been reported but might be the 
reverse depending on its route of metabolism. 
 
Quetiapine has also been investigated and found effective in unipolar depression and 
generalized anxiety (Zhornitsky et al., 2011).  Hence it would be misleading to think of it 
as a selective drug for bipolar depression: by the same token its efficacy in bipolar 
depression is not evidence for a biological difference between bipolar and unipolar 
depression although the effect size was larger in the bipolar trials. 
 
Olanzapine 
Olanzapine has affinity for dopamine D2, serotonin 5-HT2A, muscarinic and histamine 
receptors. Interest in the use of dopamine antagonists or partial agonists as monotherapy 
began when a large RCT showed that olanzapine had a weak antidepressant effect in 
bipolar I depression compared with placebo (Tohen et al., 2003). A second study has 
been pooled with the original data and also supports modest efficacy for olanzapine (I, 
(Tohen et al., 2013)). Its combination with fluoxetine in the original study showed even 
better separation from placebo. A relapse prevention study against placebo also supported 
efficacy against depressive relapse (Tohen et al., 2006). 
 
Olanzapine is accordingly an option for the treatment of bipolar depression: its 
combination with fluoxetine will be discussed below. Similar considerations to those for 
quetiapine (sedation, unblinding) mean RCT evidence may have been subject to bias so 
downgrading its quality rating. 
 
Lurasidone 
Lurasidone is an antagonist at D2, 5-HT2A, and 5-HT7 receptors, and a partial agonist at 
5-HT1A receptors. It has lower binding affinity for α2C and 5-HT2C receptors. It has 
been demonstrated to show efficacy in two short-term studies in bipolar depression: one 
as monotherapy and the other as add-on to lithium or valproate (Loebel et al., 2014a; 
Loebel et al., 2014b). Lurasidone has a low subjective adverse reactions burden and 
produced minimal changes in weight, blood lipids, or glycaemic control. The commonest 
reported adverse reactions are akathisia and somnolence. At the time of publication it did 
not have a license for use in bipolar depression in Europe, but has an indication for 
schizophrenia. In the US it has a license for the acute treatment of bipolar depression as 
well as schizophrenia. 
 
Aripiprazole 
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors. Data on aripiprazole are of 
interest. In two 8-week monotherapy studies in bipolar depression, it failed to separate 
from placebo at the pre-specified 8-week endpoint although separation at earlier times 
was evident (Thase et al., 2008a). It has been conventional to accept this negative finding 
as definitive, along with the failure to demonstrate efficacy on the depressive pole in the 
existing relapse prevention study (Keck et al., 2007). However, the monotherapy studies 
in bipolar depression may have failed because of shortcomings in the trial design and the 
relapse prevention study was clearly under-powered to detect effects on depressive 
relapse. 
 
By contrast, in treatment-resistant unipolar patients two trials of adjunctive aripiprazole 
suggested antidepressant efficacy (Thase et al., 2008b). There is no comparable 
controlled evidence for refractory bipolar depression, but a small, uncontrolled case 
series claimed benefit from adding aripiprazole to a variety of other treatments (Ketter et 
al., 2006). 
 
Any use of aripiprazole for bipolar depression is clearly an extrapolation from the 
unipolar data, but its dopamine partial agonist activity gives it modest plausibility as a 
treatment option with a different mode of action.  
 
Cariprazine 
Cariprazine is a highly selective dopamine D3 and D2 receptor partial agonist with 
preferential binding to D3 receptors. Its mechanism of action is therefore novel and of 
potential interest for the treatment of bipolar depression. Evidence for efficacy in bipolar 
depression has been published (Durgam et al., 2015a; Durgam et al., 2015b). 
 
Antidepressants  
Antidepressants are commonly prescribed for people with bipolar depression (35-40% 
prevalence in the POMH-UK audit). Their use is nevertheless controversial (Pacchiarotti 
et al., 2013). The usual criticisms are either that antidepressants lack efficacy in bipolar 
depression or they destabilize mood and cause switch to mania. This is undeniably 
contradictory since it seems to imply either too little or too much effect. Unfortunately, 
there is a real dearth of placebo controlled trials on which to make an evidence based 
recommendation. Meta-analysis a decade ago compared the few drugs tested, as a group, 
versus placebo (imipramine, fluoxetine and tranylcypromine). Most randomized data 
were obtained in patients also receiving lithium or valproate and, in aggregate, 
comparison with placebo supported efficacy for antidepressants in general (Gijsman et 
al., 2004). The STEP-BD trial weakened that conclusion (Sidor and Macqueen, 2011), 
but did not contradict it. The exception was fluoxetine in combination with olanzapine, 
which has shown individual efficacy versus placebo and, modestly, lamotrigine (Brown 
et al., 2006; Tohen et al., 2003).  
 
Recently there has been a double blind comparison of venlafaxine with lithium in bipolar 
II depression suggesting an important advantage to venlafaxine in continuation treatment 
(Amsterdam et al., 2015). This adds to other small studies in bipolar II patients 
suggesting an advantage for fluoxetine compared with lithium and provides the very 
limited evidence favouring the use of antidepressants in bipolar II disorder (McInerney 
and Kennedy, 2014). Expert opinion has also proposed SSRIs to stabilize mood in 
significant numbers of bipolar II patients (Parker et al., 2006). It is recommended that if 
an antidepressant is prescribed as monotherapy in bipolar II disorder, any increase in dose 
is gradual and that there be vigilance for, and early management of, any adverse reactions 
such as hypomania, mixed states or agitation (IV). 
 
In contrast to the dearth of evidence in bipolar patients, there has been a very large 
number of trials examining the efficacy of antidepressants in unipolar major depression 
(I, (Anderson, 2001; Undurraga and Baldessarini, 2012)); these studies systematically 
excluded patients with a bipolar illness course. The drugs tested enhanced noradrenaline 
and/or serotonin function by inhibiting monoamine re-uptake or metabolism. Hence their 
actions are likely to be rather homogeneous. The unipolar data support this: network 
meta-analysis shows major overlap of efficacy for SSRIs with venlafaxine, duloxetine 
and mirtazapine. Reboxetine, a selective noradrenergic re-uptake inhibitor, was the only 
clear outlier (Cipriani et al., 2009). Accordingly, the general finding of antidepressant 
efficacy in bipolar depression may be supported by the experience of treating unipolar 
depression. It means that the use of these drugs as a class in bipolar patients is essentially 
an extrapolation.   
 
The anergic pattern of illness often seen in bipolar patients may favour the use of 
activating antidepressants such as monoamine oxidase inhibitors (MAOIs) (IV). It is 
usual to caution that while efficacy may be extrapolated for classes of drugs, adverse 
reactions may be less predictable. However, the extensive experience of using 
antidepressants in unipolar disorder means that this is not an important limitation, except 
potentially with the risk for switch to mania. If antidepressants can cause a switch to 
mania or the emergence of a mixed state, it seems further to imply efficacy, even if it is 
an argument against using antidepressants except with considerable vigilance. 
 
Another approach to comparing unipolar and bipolar depression has been to audit the 
response to the same treatments in hospitalised patients (II, (Bottlender et al., 2001; 
Moller et al., 2001)): the severity of illness and times to response with tricyclic 
antidepressants appeared to be identical for bipolar and unipolar groups.  Less positively, 
audit data from a very large Taiwanese database suggested that a poor response (usually 
to SSRIs) in first episodes of depression was predictive of a subsequent bipolar diagnosis 
(Li et al., 2012). This may imply that compared with unipolar patients, bipolar patients 
are simply more difficult to treat, but an equally plausible interpretation would be that 
antidepressants are less effective in the bipolar group (Goodwin, 2012). The issue is 
inevitably confounded in an observational study. 
 
The view that we cannot safely extrapolate efficacy from unipolar to bipolar depression 
is widely held. There are several negative studies cited to support it. The STEP-BD study 
compared paroxetine and bupropion with placebo and the results were certainly negative 
(Sachs et al., 2007). However, whether this result represents a failure of the trial or of the 
active treatments is a moot point. The EMBOLDEN-II study compared two doses of 
quetiapine with placebo and included paroxetine as a comparator (McElroy et al., 2010). 
Paroxetine did not separate from placebo. However, half the patients in the study were 
treated with quetiapine, which arguably carries an appreciably higher risk of unblinding 
than paroxetine and this may have reduced the chances of finding a positive effect. 
Finally, agomelatine failed in a placebo controlled trial in which very high placebo 
response rates will have reduced assay sensitivity (Yatham et al., 2015b). Such negative 
studies provide a poor basis for the conclusion that antidepressants do not work at all in 
bipolar patients. Comparable studies can also fail in unipolar populations for a variety of 
technical reasons (Schalkwijk et al., 2014) and the studies themselves were powered to 
detect conventional positive effects, not to determine equivalence with placebo (non-
inferiority).  
 
The argument that antidepressants work in unipolar but not in bipolar depression also 
implies that there must be an important neurobiological difference between the two 
conditions. This is not expressed phenomenologically except in the sense that severity 
appears to increase across the bipolar spectrum (Moreno et al., 2012); one exception 
could be where depression emerges immediately out of a manic episode and the episode 
itself is effectively bipolar or mixed, but this is atypical. Neurobiological differences 
appear likely to be quantitative rather than qualitative (Redlich et al., 2015), although 
potentially of great interest. Indeed, if there are differences in the responsiveness to 
antidepressants between bipolar and unipolar groups, it provides a starting point for 
further dissection of how antidepressants work. For example, one hypothesis is that 
antidepressant action involves correction of negative emotional bias (Harmer et al., 
2009); if bipolar subjects have less negative emotional bias, it might correlate with the 
reduced effectiveness of conventional antidepressants.  
 
Anticonvulsants in depression 
There is no basis for supposing antidepressant effects to be a class effect of 
anticonvulsant action. However, lamotrigine is of particular interest since it may offer 
important clues to common or unique mechanisms of action relevant to the development 
of new treatments. 
 
Lamotrigine  
Lamotrigine inhibits voltage-sensitive sodium channels in the brain, which may limit cell 
firing. It also blocks L-, N-, and P-type calcium channels and is a weak 5-HT3 receptor 
antagonist. It is a weak inhibitor of dihydrofolate reductase (DHFR). 
 
The efficacy of lamotrigine has been uncertain for acute bipolar depression. The original 
published study of lamotrigine suggested benefits in bipolar depression compared with 
placebo (Calabrese et al., 1999) and a second study was also supportive (III, (Frye et al., 
2000)).  However, four previously unpublished trials conducted by GSK individually 
failed to show a separation from placebo. These negative findings appeared paradoxical 
when relapse prevention studies were positive (see below (Goodwin et al., 2004)). How 
can a drug prevent relapse to depression if it does not have efficacy in the acute episode? 
 
A pooled analysis of the original patient data from all five trials was, in fact, able to show 
a modest benefit for lamotrigine in bipolar I and II patients with acute depression (I, 
(Geddes et al., 2009)). Further analysis of the patients with HAM-D scores of 24 and 
above at baseline showed, as predicted, a more substantial effect. By contrast, patients 
with scores below 24 at entry simply showed too high a placebo response to allow 
detection of an effect of the active treatment in any of the individual studies. These 
findings give limited support for the use of lamotrigine as a monotherapy treatment for 
bipolar depression. 
 
The addition of lamotrigine to lithium proved effective in bipolar depression in an 
independent European study (van der Loos et al., 2009; van der Loos et al., 2011). This 
combination would have the additional theoretical benefit of combining two drugs with 
positive long-term data and complementary polarity indices (Popovic et al., 2012; 
Popovic et al., 2014). Similarly, in the CEQUEL trial of depressed bipolar patients 
already taking quetiapine, addition of lamotrigine showed both an early effect on 
depressive symptoms compared with placebo and important benefits for remission, 
sustained to 1 year of follow (Geddes et al., 2015). Finally, an under-powered, open label 
comparison in treatment-resistant bipolar depression also suggested benefits as an add-on 
compared with risperidone and inositol (Nierenberg et al., 2006). 
 
The CEQUEL trial included a folate 500 microgm/placebo comparison as a factorial 
addition. It was expected that folate might augment treatment effects, but in fact the 
converse was the case. Folate impaired the response to lamotrigine. This effect is noted 
here because folate is believed to be neutral or beneficial for mood, and widely used in 
pregnancy, of course. Negative effects on mood might be an important adverse reaction 
to patients taking lamotrigine. The known interaction of lamotrigine with the enzyme 
DHFR, makes it more likely that the effect is real (and would implicate this pathway in 
its mechanism of action). 
 
In summary, lamotrigine has established acute efficacy both as a monotherapy and in 
combination with lithium and quetiapine. The acute findings are supported by relapse 
prevention studies (see below). While the need to titrate the dose might seem likely to 
delay its onset of action, this was not evident in the acute trial data. Nevertheless, the 
slow titration may be a consideration in monotherapy when speed of action is a priority. 
Its low burden of adverse reactions mean unblinding in RCTs was unlikely and risk of 
bias low. 
 
The presence of a recent rapidly unstable mood or a mixed state may be a particular 
reason to consider lamotrigine (IV).  
 
Lamotrigine is uncommonly a single first-line agent in bipolar I but it can be considered 
in bipolar II on the basis of limited positive evidence, including benefit in rapid cycling 
patients (Bowden et al., 1999). 
 
Valproate 
In a recent review and meta-analysis, four small studies support an effect of valproate in 
bipolar depression (Smith et al., 2010). This accords with relapse prevention data for 
depression (see below).  A larger, more convincing study is required to establish acute 
efficacy. 
 
Lithium in depression 
Treatment guidelines (Sachs et al., 2000) have repeatedly suggested an overwhelming 
expert preference for the use of lithium as first line treatment rather than antidepressants. 
However, the actual evidence for acute efficacy of lithium in bipolar depression, either as 
a sole agent or in combination with others, is disappointing (II, ((Bhagwagar and 
Goodwin, 2002; Young et al., 2010)). Relapse prevention and anti-suicide effects are 
tangible benefits however (see below). 
 
Dopamine agonists 
The reported efficacy of cariprazine in controlled studies and the evidence for 
aripiprazole's efficacy in resistant depression suggests that dopamine agonism or partial 
agonism might be a potential mechanism of antidepressant action. The full agonist 
pramipexole has also been reported to show efficacy in small studies in treatment-
resistant unipolar and bipolar depression (Dell'Osso and Ketter, 2013; Zarate et al., 
2004). Adverse neurological reactions to dopamine agonists, well established in the 
treatment of Parkinson’s disease, include oro-facial and other dyskinesias and compulsive 
behaviours.  
 
Modafinil 
Modafinil has some antagonist affinity for the dopamine reuptake site and perhaps as a 
partial agonist at the dopamine D2 receptor. It elevates histamine concentrations in the 
brain. Its indication is as a wakefulness-promoting agent in narcolepsy, with additional 
clinical use in shift work sleep disorder and excessive daytime sleepiness associated with 
obstructive sleep apnea. It has also been studied as the R-enantiomer (armodafinil). In 
bipolar depression (and unipolar disorder) there is very limited evidence for efficacy 
(Goss et al., 2013). 
 
Ketamine 
There is considerable interest in the potential for ketamine, a NMDA (N-methyl-D-
aspartate) receptor antagonist, to be an important addition to treatment options in major 
depression (Abdallah et al., 2015). This is particularly the case in relatively Treatment-
resistant cases. However, there is only limited evidence in bipolar depression for efficacy 
of a single intravenous dose of ketamine (as add-on therapy to mood stabilizers), not for 
remission. Ketamine's psychotomimetic effects tend to compromise study blinding and 
no studies so far have tried to control for this. The use of ketamine and other bipolar 
modulators has been the subject of a Cochrane review. 
(http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011611.pub2/epdf/standard ). 
There are considerable uncertainties about how any acute benefit from ketamine, which is 
often clinically evident, can best be sustained. The obvious approach is to give repeat 
doses and to titrate response on an individual basis. The main concerns relate to the safety 
of repeat administration, which has not been systematically established. Ketamine is not 
widely available outside research centres in the UK. 
 
Electro-convulsive therapy (ECT) and Vagal Nerve Stimulation (VNS) 
ECT is effective in severe depression: the relevant trials will have included bipolar cases, 
although trials exclusively in bipolar disorder did not exist before one important review 
(I, (The UK ECT Review Group, 2003)) and remain rare. However, in a recent study, 
ECT proved superior to an evidence-based drug treatment algorithm in a RCT in 
treatment-resistant bipolar patients (Schoeyen et al., 2015), although full remission was 
not much improved by ECT. 
 
ECT’s efficacy against both poles of bipolar disorder predicts it would be a reasonable 
choice for patients with mixed features (bipolar or unipolar). As noted above, an 
observational cohort study that described high rates of response and remission to ECT in 
bipolar patients with a DSM-IV-TR defined mixed state (Medda et al., 2015) has 
supported this conjecture. 
 
Beliefs about ECT in the general population appear to remain influenced by unfavourable 
media portrayal (Lebensohn, 1999) and this has not diminished (IV). While clinicians 
have a responsibility not to pander to ignorance and prejudice, it may be helpful to allay 
fears that ECT is often used against the will of individual patients (S). In fact it is unusual 
for ECT to be used without a patient's consent, and under mental health legislation, even 
in services with a high utilization rate; even then, outcomes appear reassuring (Wheeldon 
et al., 1999).  
 
VNS has limited support for use in treatment-resistant depression: there is no specific 
role identified in bipolar disorder (Shah et al., 2014). 
 
The risk of a switch to mania during treatment of a depressive episode 
One short-term outcome of treatment for depression is a switch to mania. This may occur 
as a consequence of illness course or because some treatments have a greater potential to 
cause switching than others. Of course, clinically there is an obvious gradient between 
patients with highly variable mood and those with a much more episodic pattern. There 
have been few efforts to differentiate the treatment responses along this gradient, except 
by reference to ‘rapid cycling’, which is an imprecise course specifier.  
 
In a meta-analysis of patients without a previous history of mania, treatment with tricyclic 
antidepressants was twice as likely to result in a manic event as treatment with SSRIs or 
placebo (Peet, 1994)). In short-term bipolar treatment trials with antidepressants, switch 
rates were low but there was again a higher rate of switch for tricyclic antidepressants 
compared with other antidepressants (SSRIs in particular) (Gijsman et al., 2004). 
Fluoxetine plus olanzapine was effective in reducing depressive symptoms without 
provoking manic relapse (Tohen et al., 2003). However, a broader meta-analysis of the 
available data reached the pessimistic conclusion that drugs for unipolar depression may 
produce switching even in the presence of mood stabilizers, although the study could not 
exclude confounding effects as an alternative explanation (Tondo et al., 2010). 
 
Venlafaxine may also increase the risk of switching patients, perhaps because of its 
action on serotonin and noradrenaline re-uptake. In the Stanley network study, patients 
treated with venlafaxine switched to mood elevation (defined as a YMRS rating over 13) 
in 31% of case, compared with sertraline (15%) and bupropion (14%): response rates 
were similar at around 50%, but there was no placebo control (Post et al., 2006).  These 
rates are high which seems likely have been due to the inclusion of rapid cycling patients. 
 
High quality naturalistic data has much to offer this question. Recent linkage of clinical 
data with prescribing data in Sweden suggested that monotherapy with drugs for unipolar 
depression is indeed associated with manic relapse in bipolar I patients, compared with 
combination with a mood stabilizer (Viktorin et al., 2014). There was no increase in the 
rate of manic relapse in patients taking lithium, valproate or carbamazepine. This 
employed a powerful within individual, longitudinal design to determine relative risk 
although patient numbers in the monotherapy group were small. 
 
The naturalistic data, and clinical common sense suggest that a drug for mania in 
combination with the drug for depression may reduce the risk of a manic switch in 
depressed patients with a high risk of mania.  The drug for mania could be lithium, 
valproate or a dopamine antagonist/partial agonist. The International Society for Bipolar 
Disorders (ISBD) consensus on the use of antidepressants in bipolar patients highlighted 
the clinical consensus discouraging their use in patients with rapid cycling, depressive 
episodes with mixed features and as monotherapy (Pacchiarotti et al., 2013). 
 
Discontinuation of long-term treatment for depression 
There is uncertainty about the value of long-term treatment with antidepressants, so it is 
frequently implied that early discontinuation is desirable ((Montgomery et al., 2000)). 
This has been echoed more dogmatically in recent NICE guidance. Absence of evidence 
is not evidence of absence, in this case, of short-term benefit (see also below). Indeed, the 
International Society for Bipolar Disorders Task Force report recommended to continue 
antidepressants over the long term in those who had had a relapse in depression after 
stopping antidepressants (Pacchiarotti et al., 2013). 
 
Both the antimanic and the antidepressant medicines should be terminated together if the 
intention is that treatment should be simply for an acute episode.  Discontinuation of an 
antidepressant should follow recommendations in related BAP guidelines and taper over 
4 weeks if possible (Cleare et al., 2015).  In particular, the possibility of adverse 
withdrawal effects should be discussed and reassurance offered. 
 
Paradoxical manic episodes have been described during withdrawal of antidepressant 
drugs in patients with bipolar and unipolar depression (Narayan and Haddad, 2011). 
  
In patients who do switch to mania during treatment, the antidepressant should be tapered 
and discontinued (consensus opinion). 
 
Table 6. NEAR HERE 
 
Conclusions: the comparative efficacy and acceptability of different drugs for bipolar 
depression 
NICE2014 used network meta-analysis to shape its recommendations. The analysis plan 
required a minimum sample size and handled each treatment separately. Most of the 
comparisons between treatments were indirect (via placebo). The conclusion was that six 
interventions were statistically superior to placebo (valproate>the combination of 
fluoxetine and olanzapine>lurasidone>quetiapine> olanzapine alone=lamotrigine). Other 
interventions that were included in the network but were not statistically superior to 
placebo were imipramine, lithium, moclobemide, paroxetine, and ziprasidone. 
 
An independent approach to the same data combined the SSRIs and the tricyclic 
antidepressants for comparison with the better-studied treatments (Taylor et al., 2014). 
The exact order of the resulting ranks was different but not radically so. The question 
posed by this analysis is whether it can/should usefully inform clinical practice, since it 
depends so heavily on small studies and indirect comparisons. In discussion, our 
consensus group noted a number of contradictions. For example, SSRIs (which included 
paroxetine) ranked higher than quetiapine even though paroxetine was inferior to 
quetiapine in the only head-to-head trial (McElroy et al., 2010). In addition, venlafaxine 
was excluded from the analysis, because studies were not double blind, but appeared to 
have a relatively large effect (Vazquez et al., 2013).  It was agreed that the limitations of 
the data prevented uncritical acceptance of final rankings, and new data might well 
change the outcome in the coming years. Nevertheless they provided a useful summary of 
where the field currently is, in all its weakness.  
 
The most controversial issue was NICE2014’s endorsement of the use of fluoxetine, an 
antidepressant, with olanzapine. While this was a specific recommendation, there seems 
little reason not to regard fluoxetine as a representative SSRI. Therefore, to rank it first 
line is to rank SSRIs in general first line by extrapolation. In bipolar I patients 
antidepressants should then be prescribed only as an adjunct to anti-manic medications 
(not necessarily olanzapine, of course).  Opinion was divided between those inclined to 
accept this extrapolation and those who feel strongly that the limited bipolar depression 
data is inconclusive as it stands. Currently it is not possible to resolve these opposing 
views. However, given that there are limited options to treat bipolar depression, the group 
concluded that it was reasonable to consider a trial of an antidepressant in a patient with 
bipolar depression if other treatments with a stronger evidence base were ineffective or 
not tolerated.  The group noted that the ISBD international task force, in trying to balance 
the same opposite opinions, did not broadly endorse antidepressant use, but 
acknowledged the experience that individual bipolar patients may benefit nevertheless. 
The frequent current use of antidepressants appears not to be proportionate to the 
established benefit in bipolar I patients. Their role in bipolar II patients is equally 
controversial. 
 
The group noted that quetiapine has an unusual weight of evidence to support its use in 
adults with bipolar depression and may have a unique combination of pharmacological 
actions which account for this. It therefore merits first line status. Olanzapine, and 
lurasidone, may also be considered as options, though neither is currently licensed in 
Europe to treat bipolar depression. Lurasidone appears to have a more favourable 
metabolic profile than either quetiapine or olanzapine (Leucht et al., 2013). 
 
There is little evidence to guide next step treatment if the first choice fails. Before 
resorting to strategies derived from unipolar patients with treatment resistant depression, 
the options shown to be effective in bipolar depression should be exhausted first, perhaps 
in combination. 
 
The use of aripiprazole can only be by extrapolation, given the failed trials in bipolar 
depression, but cariprazine, also a dopamine partial agonist, has now shown efficacy in 
two studies (Durgam et al., 2015a; Durgam et al., 2015b). This seems to support the 
pharmacological argument that dopamine agonism (or partial agonism) contributes to 
antidepressant action.  
 
Dopamine antagonists should not be regarded as potential options for the treatment of 
bipolar depression in the absence of appropriate trials. 
 
Finally, lamotrigine has supportive data for an acute effect, notably from two independent 
adjunctive studies, which together with longer term data, should make it a more widely 
used option. It appears currently to be under-used outside expert centres. 
 
Unlike NICE2014, the group did not see evidence to support psychotherapy alone for the 
treatment of depression. NICE2014 made a distinction between primary and secondary 
care implying that there are mild cases of bipolar disorder that can be managed with 
psychological treatment alone. It may apply to young people with possible diagnoses of 
bipolarity, mild symptoms (and a good prognosis). However, the prominent endorsement 
of psychological treatments for bipolar disorder, without qualification, as ‘Key priorities 
for implementation’ goes well beyond the evidence. The partial way in which the data 
appears to have been reviewed by NICE2014 to justify their conclusions has also been 
highlighted (Jauhar et al., 2016). 
 
3. Long-term treatment 
 
 Lithium remains the most effective treatment preventing relapse and admission to 
hospital in bipolar I disorder (I). Lithium should be considered for all patients 
with bipolar I disorder willing to take it reliably (S). 
 Lithium prevents relapse to mania and, less effectively, depression (I).  The 
highest dose that produces minimal adverse reactions and effects should be 
employed. Concentrations below 0.6 mmol/l are potentially too low to be fully 
effective and adverse reactions and effects become important above 0.8 mmol/l. 
Lithium may be effective in a minority of patients as monotherapy (I). 
 Lithium reduces the risk of suicide (I). 
 Valproate as monotherapy has limited trial data, is somewhat less effective than 
lithium in the prevention of relapse and should not usually be considered for 
women of child bearing potential (I).  
 Carbamazepine as monotherapy is less effective than lithium, has little if any 
effect on relapse to depression and is liable to interfere with the metabolism of 
other drugs (I). 
 Lamotrigine is effective against depression in long-term treatment (I) and should 
be considered where depression is the major burden of the illness (IV). 
 Dopamine receptor antagonists and partial agonists reduce the risk or relapse 
and admission in long-term treatment (I). Relative effects on the manic and 
depressive poles of the illness appear to depend on the complex pharmacology of 
the drugs but may be predicted by acute treatment effects. 
 Antidepressants to which patients have shown an acute treatment response may, 
appropriately, be continued long term when the risk of a severe depressive 
relapse is high (III). In bipolar I disorder, they should be used in combination 
with a medicine that has long-term antimanic efficacy (II). 
 Discontinuation of long-term treatment is not indicated when there is good 
clinical control of the illness. When it is necessary, it should be tapered (IV). In 
the case of lithium there is a specific risk of manic relapse if it is discontinued 
within a two-week interval (I). Poor adherence is a contra-indication to lithium 
because of the risk of new illness episodes on discontinuation (I). 
 
Key uncertainties 
 There is uncertainty in relation to the effects of short-term treatment on day-to-
day or week-to-week mood stability. 
 Successful long-term management often appears to require combination treatment 
(III).  Combination of lithium with valproate, or quetiapine with lithium or 
valproate is superior to monotherapy. At present there is little to guide practice 
other than safety concerns and pragmatic outcomes in individual cases.  
 The long-term value of antidepressants is not sufficiently established. 
 Extrapolation of long-term strategies for bipolar I disorder to bipolar II or the 
bipolar spectrum remains speculative. 
  
Bipolar disorder tends to be a long-term, indeed, life-long challenge. At present the 
preferred strategy to prevent relapse is for continuous rather than intermittent treatment 
with oral medicines, to prevent new mood episodes. That means a negotiated decision to 
take one or more medicines for the long term – in effect, indefinitely.  Such a decision is 
best made when patients are in remission, and ideally, the evidence for the efficacy and 
safety of any treatment should have been established over long periods of time. In 
practice, controlled data may cover much shorter periods of time, and for that reason 
NICE have been resistant to considering the data from such trials. As already explained, 
we take a more nuanced view, especially where practice can be supported by naturalistic 
data and clinical experience. 
 
There is now good naturalistic data from Denmark that, for patients treated with lithium, 
starting early in the illness course is more often associated with a very good outcome than 
those starting later (Kessing et al., 2014). There is no RCT data to support the validity of 
this finding but its plausibility supports the intention to initiate treatment early in the 
bipolar illness course. However, the study illustrates the population challenge because 
under 20% of patients started on lithium early remained without relapse at 10 years 
follow up. Early relapse (within two years) was the rule. 
 
The central problem is that, whatever the intention, adherence to long-term treatment 
appears to be poor (Kessing et al., 2007). To underline this point, about 40% of bipolar 
patients who commit suicide are not receiving long-term lithium or valproate (Clements 
et al., 2013). For this reason, early psychoeducation should receive high priority in 
clinical management. With rational psychopharmacology, it appears to work in practice 
to improve outcome (Kessing et al., 2013). 
 
Medicines with putative efficacy against depressive and (hypo)manic  relapse are 
sometimes described as mood stabilizers.  We do not favour this terminology because it 
implies equal efficacy in the prevention of depression and mania (which is not seen with 
most drugs) and does not refer to a mechanism of action.  In fact, the long-term use of a 
variety of agents alone or in combination may contribute to mood stability. 
 
The management plan must incorporate additional flexible treatment when an acute 
stressor is imminent or present, early symptoms of relapse (especially insomnia) occur, or 
anxiety becomes prominent. Higher doses of long-term treatments or, perhaps more 
simply, short-term add-ons (e.g. GABA modulators) will be necessary. The focus will 
often be sleep disturbance, so the patient may keep a benzodiazepine or other hypnotic in 
small supply.  
 
Dopamine antagonists/partial agonists may also be kept on hand with the doctor’s 
agreement, and, if taken at the onset of a manic episode, may reduce its severity. It may 
also be agreed that the patient can increase the doses of their other medicines under 
specific circumstances. This approach serves two purposes: the individual is more likely 
to comply with the treatment regimen if they feel they have greater control, and they can 
also take immediate action, when it may otherwise take too long to get an appointment 
with their psychiatrist. 
 
Finally, if a patient has accepted treatment for several years and remains well, they 
should still be strongly advised to continue indefinitely, because the risks of relapse 
remain high. This can be concluded from the findings in several small studies of lithium 
responders. Even when lithium withdrawal was supervised and intended to be slow, 
relapse was much more common in the withdrawn group (Biel et al., 2007; Yazici et al., 
2004). That said, patients may, of course, decide to discontinue long-term treatment.  
This may be most propitious when they have made a full recovery from their last episode, 
have had no bipolar episodes in the preceding four years, have no history of severe 
consequences from mania or bipolar depression and no previous history of cycling with 
many bipolar episodes. Naturalistic data certainly suggest that patients with residual 
symptoms have significantly worse outcomes, so drug discontinuation in a poor 
prognosis group would not be rational (Judd et al., 2008; Angst et al., 2003).  Whatever 
the circumstances, short-term support and a management plan to recognise and treat early 
warning signs of mania or depression will be necessary.  
 
Long-term treatment with Lithium  
Lithium occupies a particularly important place in the management of bipolar I disorder. 
Thus, the strongest evidence among medicines that are often referred to as mood 
stabilisers for bipolar I disorder is still for lithium. Lithium certainly prevents relapse to 
mania and depression. 
Adequate numbers of patients have been randomized into placebo-controlled short-term 
or ‘maintenance’ trials of lithium treatment dating from soon after its introduction (I, 
(Burgess et al., 2001)), and more recently when lithium has been a reference compound 
for other treatments (Severus et al., 2014). The relative risk of relapse on lithium over a 
year or more was 0.6 compared with placebo. So of 753 patients on lithium 258 (34%) 
relapsed; of 827 on placebo, 467 (56%) relapsed. That means in general that one would 
need to treat about 5 patients for about a year with lithium to avoid one relapse.  
Considering relapse to either pole of the illness individually, there was a greater relative 
reduction in the risk of manic relapses (0.5) compared with depressive relapses for 
lithium (0.7-.8).  In fact, on current evidence, lithium is only modestly effective in 
protecting against depressive relapse (Severus et al., 2014).   
 
The largest study of lithium to date was a double-blind comparison of switching to 
lithium or placebo in patients who responded acutely to quetiapine (Weisler, 2014).  A 
post hoc analysis suggested that a lithium level of 0.6 mmol/L or higher was more 
effective than lower doses for Li monotherapy maintenance in the prevention of relapse 
(Nolen and Weisler, 2013). There has been uncertainty over the years about whether 
single daily dosing is safer than more frequent dosing regimes. Twice daily, versus once 
daily dosing of lithium gives sustained higher minimum concentrations and this has been 
linked to more pathological renal changes on biopsy (and a higher risk of polyuria (Carter 
et al., 2013)). Given the advantage for adherence of once daily dosing, we recommend 
once daily night time dosing for lithium (IV).   
 
Lithium concentrations in blood should be regularly monitored. How regularly is open to 
debate. This is problematic because failure to follow guidance may have legal 
implications for doctors. NICE2014 recommended measurement every 3 months for the 
first year of treatment and every 6 months thereafter (with a number of exceptions). 
Doctors should probably try to adhere to this recommendation. In reality, however, an 
annual check of all relevant blood indices is probably adequate in stable, physically 
healthy patients (McKnight et al., 2012).  It is unclear whether the common failure to do 
any monitoring at all in some services is affected by what frequency is actually 
recommended.  
 
Vigilance and increase monitoring is required when patients become physically ill or 
when they add medications with the potential to modify the clearance of lithium (non-
steroidal anti-inflammatory drugs, for example).  
 
Long-term treatment with anticonvulsants 
There is no basis as yet for equating anticonvulsant action with ‘mood stabilization’, as 
has sometimes been claimed (Post et al., 1998). Anticonvulsants have a heterogeneous 
pharmacology and there is no evidence to suggest a class effect, such that anticonvulsants 
stabilize mood. Thus, valproate, carbamazepine, lamotrigine, gabapentin and topiramate 
are all anticonvulsants with different modes of action. In the case of the latter two 
compounds, there is almost no reliable evidence at all favouring their use either in acute 
mood episodes or to prevent relapse. Specifically, for gabapentin and topiramate 
controlled studies in acute mania were negative (gabapentin I, (Pande et al., 2000); 
topiramate I, (Kushner et al., 2006)). There remains some interest in using topiramate for 
weight reduction in obese bipolar patients (Chengappa et al., 2006).  
 
Valproate 
Valproate is often referred to, with lithium, as a mood stabilizer. Data on valproate are 
much more limited than that for lithium, however. The comparison with placebo is driven 
by a single RCT of valproate (as valproate semisodium, ®Depakote), which showed rates 
for all relapse of 24% against placebo at 38%.  This suggests an absolute risk reduction of 
about 15%, numerically comparable with lithium (22%) but statistically non-significant. 
In fact the effect for depressive relapse was higher than for mania in this study (Cipriani 
et al., 2013c).  The BALANCE trial specifically compared valproate, lithium and the 
combination in a randomized, non-blind maintenance study with a run in on the 
combination treatment to minimize drop-outs after randomization. Lithium alone and in 
combination with valproate was superior to valproate alone (Geddes et al., 2010). 
Nevertheless, observational data supports an effect for valproate not much less than 
lithium’s in practice  
 
Carbamazepine  
Carbamazepine was the first agent after lithium to be advocated for long-term treatment 
of bipolar disorder (II, review by (Okuma and Kishimoto, 1998)). It has been re-
examined in two other trials, which showed a substantial benefit with lithium compared 
with carbamazepine in preventing relapse (I, (Greil et al., 1997; Hartong et al., 2003)). 
  
Lamotrigine  
Two maintenance trials of lamotrigine as monotherapy supported an effect against 
depression, not mania (I, (Goodwin et al., 2004)). The samples were enriched for 
lamotrigine responders, and compared lamotrigine, lithium and placebo. In one, the index 
episode was mania and, in the other, depression.  The results from both trials are mutually 
supportive in showing an advantage for lamotrigine in the prophylaxis of depression. 
There was a comparable advantage to lithium for prophylaxis of mania.  There was no 
excess of depressive episodes in lithium treated patients nor manic episodes in 
lamotrigine treated patients compared with placebo.  Indeed for both agents there was a 
trend towards effects against the opposite pole of the illness.  Thus, neither provoked 
mood instability to the opposite polarity.  CEQUEL also demonstrated benefit over 12 
months for combination treatment with lamotrigine (Geddes et al., 2015).  
 
 
Long-term treatment with Dopamine antagonists/partial agonists 
Dopamine antagonists/partial agonists have long been used in bipolar outpatients as long-
term treatment. They have been prescribed for some patients in depot formulations, either 
as monotherapy or in combination with other agents. Before the development of the 
newer dopamine/serotonin antagonists and partial agonists, their use was poorly 
supported by formal evidence for patient benefit. There is a clinical impression that the 
newer agents offer advantages because they are less likely to produce dysphoria or 
provoke depressive relapse 
Most of the newer, so-called second-generation dopamine antagonists/partial agonists 
have been studied in relapse prevention trial designs. Such studies enrich the study 
sample for acute responders to the drug of interest, and the active drug may be withdrawn 
abruptly, which risks amplifying any drug/placebo difference with withdrawal effects. 
This can be inferred from an excess of early relapses seen for example in a study of this 
design with olanzapine (Tohen et al., 2006).  Therefore such studies, with occasional 
exception, primarily support short to medium-term use.  
 
Use in the longer term is mainly an extrapolation, albeit supported by strong naturalistic 
data.  Comparison of rates of hospital admission on and off treatment over four years, are 
strongly supportive of efficacy for lithium (Hazard Ratio (HR): 0.66, 95% CI: 0.62; 
0.70), valproate (HR: 0.72, 95% CI: 0.67; 0.79), lamotrigine (HR: 0.79, 95% CI: 0.73; 
0.84), olanzapine (HR: 0.77, 95% CI: 0.71; 0.82), and quetiapine (HR: 0.82, 95% CI: 
0.75; 0.89)(Joas et al., 2016). Lithium, valproate, lamotrigine, carbamazepine, 
olanzapine, and quetiapine treatment periods were associated with reduced rates of manic 
episodes. Lithium, valproate, lamotrigine, quetiapine, and olanzapine were associated 
with reduced rates of depressive episodes. Lithium only was associated with reduced 
rates of mixed episodes.  
 
Olanzapine  
Olanzapine has been studied as a comparator to depot risperidone and showed a reduction 
in manic and depressive relapse (Vieta et al., 2012). There was no enrichment for 
olanzapine responders so, notwithstanding a dropout rate of 40-50% over 18 months, this 
trial offers good evidence for patient benefit as a maintenance treatment.  Olanzapine was 
also slightly superior to lithium as monotherapy after acute response to the combination 
of lithium with olanzapine but produced significant excess weight gain (Tohen et al., 
2005; Zarate and Tohen, 2004). This study suggests that olanzapine prevents early manic 
relapse after lithium withdrawal, although the lithium dose was tapered over 4 weeks to 
prevent very early withdrawal effects. 
 
Quetiapine 
Quetiapine has been shown to be effective as monotherapy, and in combination with 
lithium or valproate (Suppes et al., 2009), in the prevention of relapse to either pole of the 
illness. These findings are consistent for patients entering treatment from either pole of 
the illness. The doses employed in trials were high (300-600mg/day) and in the 
monotherapy trial the median dose was 546mg/day (Weisler et al., 2011). 
 
Lurasidone 
Lurasidone may prove useful in bipolar depression (see above). Its long term use is 
supported by a relapse prevention study in which 28 weeks of continued treatment with 
adjunctive lurasidone was associated with a trend significant risk reduction in time to 
recurrence of any mood event compared with placebo plus lithium or valproate, and a 
significant reduction in time to recurrence of a depressive episode. Patients entered the 
study and were stabilized from either pole of the illness (Calabrese et al., 2015). 
 
Aripiprazole, ziprasidone, paliperidone  
Aripiprazole was more effective than placebo after acute and continuation treatment of 
mania: acute withdrawal of the aripiprazole did not produce an excess of early relapse in 
this study (Keck et al., 2007). Ziprasidone has positive adjunctive data (Bowden et al., 
2010) and paliperidone only proved effective preventing mania (Berwaerts et al., 2012).  
 
Dopamine antagonists/partial agonists may be appropriate for the long-term management 
of bipolar patients especially where non-mood congruent psychotic features are 
prominent. 
 
Dopamine antagonists/partial agonists may be useful in difficult-to-treat cases of rapid 
cycling (III, e.g.(Lowe and Batchelor, 1986 ; Carvalho et al., 2014)). When added to 
usual treatment, principally with lithium or anticonvulsants, combination with clozapine 
was superior to usual treatment alone over one year in treatment–resistant bipolar patients 
including those with rapid cycling and mixed states (II, (Suppes et al., 1999)), but rapid 
cycling remains a major clinical challenge. Secondary analysis of the acute depression 
studies with quetiapine suggest efficacy in the short term for rapid cyclers (Vieta et al., 
2007), but the real problem is long-term stability.    
 
A small pilot study of vagal nerve stimulation is also compatible with some benefit in 
resistant rapid cycling patients, a very disabled group (Marangell et al., 2008). 
 
Long acting dopamine antagonists 
Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine 
decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, 
paliperidone palmitate, and aripiprazole monohydrate. Their primary indication is in the 
treatment of psychosis, but logically, LAIs could be used in bipolar patients where the 
treatment plan is continuation of treatment with dopamine antagonists, but adherence to 
oral medication is poor. Evidence to support their use in bipolar disorder is very limited 
(Bond et al., 2007; Gigante et al., 2012). The data for long-acting injectable risperidone is 
consistent in being positive for preventing mania, not depression (Quiroz et al., 2010; 
Vieta et al., 2012).  
 
When switching from an oral drug to an LAI form, it is good practice to start with the 
oral antipsychotic for the length of time required to establish the effective, best tolerated 
dose before switching to the LAI form (Llorca et al., 2013). 
 
 
Long-term treatment with antidepressants 
Whether or not antidepressants should be used long term in bipolar disorder remains 
uncertain.  One small maintenance study (II, (Prien et al., 1984)) has had an important 
influence because it suggested that the treatment of bipolar patients with imipramine 
alone resulted in an unacceptable number of manic relapses over a one to two year follow 
up period.  This effect was prevented by co-treatment with lithium.  It supports the 
recommendation that monotherapy with antidepressants is unwise in patients with bipolar 
I disorder.  
 
Long-term treatment of bipolar I patients with antidepressants is common in clinical 
practice. Given the significant burden of disease imposed by chronic depressive 
symptoms and recurrent depressive episodes, this may not be surprising.  The evidence 
supporting their use in the long-term prophylaxis of unipolar depression is strong (I, 
(Geddes et al., 2003)).  The equivalent evidence for bipolar patients is almost non-
existent. There is non-random evidence for successful short-term prophylaxis with 
antidepressants drugs in bipolar patients also receiving combination treatments such as 
lithium, valproate, carbamazepine and antipsychotics (Altshuler et al., 2001; Altshuler et 
al., 2003). But the patients in whom this is evident are about 10% of the total sample 
included. These and the few other relevant findings are far from compelling (Ghaemi et 
al., 2001; Pacchiarotti et al., 2013).  Clinicians will have to use clinical judgement in 
deciding whether an individual patient should continue with an antidepressant  
 
The uncontrolled and audit experience of using antidepressants is substantial, and, of 
course, applies to real clinical populations. As others have commented, some guidelines 
for the treatment of acute bipolar depression have gone too far in their proscription 
(Moller and Grunze, 2000).  
 
Bipolar II patients and, in particular, patients with bipolar spectrum depression have not 
been sufficiently investigated. Anecdotally, it is possible that effective treatment with 
antidepressants is possible without an additional anti-manic drug (Parker et al., 2006).  
This is an area that merits further investigation, as the diagnostic issues become more 
widely understood.  
 
The comparative efficacy and acceptability of different drugs for long-term treatment 
Network meta-analysis of long-term treatments suggests comparable efficacy for most of 
the drugs described above (Miura et al., 2014). However, the value of the quantitative 
comparisons was limited by the design weaknesses already described. Lithium, 
olanzapine, quetiapine, risperidone LAI and valproate prevented manic relapse. Only 
lamotrigine, lithium and quetiapine were convincingly shown to prevent depressive 
relapse. 
 
Long-term treatment: winning combinations  
For perhaps too long, monotherapy with lithium was believed to be the best treatment for 
bipolar disorder. It was speculated in previous editions of this guideline that effective 
prevention of progression to frequent relapse or chronicity may require combination 
treatment from quite early in the illness course. Increasingly, combinations of agents are 
being prescribed for the majority of patients who fail on monotherapy. They will derive 
from apparently effective combinations used to control acute symptoms. Indeed 
There is a strong evidence base to support the combination of a dopamine 
antagonist/partial agonist plus lithium or valproate to treat acute mania that has not 
responded adequately to lithium or valproate in monotherapy (Ogawa et al., 2014). 
However, there are only a limited number of studies that compare long-term 
monotherapy versus combination treatment.    
 
Two RCTs have shown that, when acute mania or depression responds to the 
combination of quetiapine with valproate or lithium, then continuing the combination, 
versus switching to lithium/ valproate monotherapy, is associated with a lower rate of 
relapse of both depression and mania (Vieta et al., 2008; Suppes et al., 2009).   For 
olanzapine (Tohen et al., 2004) and aripiprazole (Marcus et al., 2011), a single RCT has 
shown that, when the combination of either drug with lithium or valproate is effective in 
treating acute mania, then continuing the combination is associated with a lower risk of 
manic relapse than switching to lithium or valproate alone.  The BALANCE study 
showed that over 2 years valproate monotherapy was inferior to both lithium 
monotherapy and valproate/ lithium combination in terms of total relapses (Geddes et al., 
2010). However combination treatment, compared to monotherapy, carries a greater risk 
of medication side effects.   
 
Maintenance ECT 
Continuation and maintenance electroconvulsive therapy (ECT) is sometimes currently 
employed in patients who have failed pharmacotherapy but responded to an acute course 
of ECT. The evidence for this approach consists of case reports and retrospective chart 
reviews, with little focus on bipolar disorder per se (Frederikse et al., 2006; Petrides et 
al., 2011). There are supportive chart reviews for patients with bipolar disorder (Santos 
Pina et al., 2015). 
 
Suicide 
As a rule, suicide is associated with depression, and risk assessment should always be 
emphasized during acute episodes of depression in bipolar patients. Assessment of 
suicide risk should be as for other depression diagnoses and should follow widely 
accepted principles of good clinical practice (Hawton, 1987). Suicidality will often be 
related to illness severity and may guide the need for admission. Suicide in bipolar 
patients is a risk that persists across the lifespan. 
 
There have been reports of suicidal acts in association with antidepressant treatment in 
younger people. Whether these are caused by antidepressants has been the subject of 
considerable hype, but appears unlikely (Gibbons et al., 2015). One speculation was that 
this might be more likely in undiagnosed bipolar depression.  However, the onset of 
suicidality in bipolar patients was not associated with the use of antidepressants in the 
STEP-BD study, although the numbers were small (Bauer et al., 2006c). 
 
 
Adverse reactions to long-term treatment 
Weight gain is a major problem associated with the use of many of the medicines offered 
long term to bipolar patients (Torrent et al., 2008). The use of olanzapine and quetiapine 
is particularly associated with unfavourable metabolic indices, especially when the 
patient population is obese (Lieberman et al., 2005).  Efforts are necessary to alert 
patients to the need both to maintain normal levels of exercise and moderate calorie 
intake. While this has traditionally been a cosmetic concern, strongly felt by patients, it 
has important medical implications particularly related to the risk of future  
cardiovascular disease (see BAP guideline on the management of weight gain and 
metabolic disturbances associated with psychosis and antipsychotic drug treatment).  
 
A rise in serum prolactin caused by dopamine receptor antagonism, is a frequent and 
neglected problem (Pacchiarotti et al., 2015).  It may lead to secondary hypogonadism 
(Howes et al., 2007) and low bone mineral density (BMD), the most important risk factor 
for osteoporotic fractures. Lifetime risk of such fractures for women in the general 
population is already high at approximately 50%. Decreased BMD and increased fracture 
risk have been shown in patients with severe mental illness (Howard et al., 2007; Meyer 
and Koro, 2004; Lehman and Meyer, 2005).  Prolactin and gonadal function are hardly 
ever assessed in women on dopamine antagonists, BMD is not measured, and 
osteoporosis remains undiagnosed, let alone prevented or treated. All pre-menopausal 
women on amisulpride and most on risperidone (including at low doses) are at risk of 
amenorrhoea, low or undetectable oestradiol concentrations and many will also have low 
BMD. Hence, prevention and treatment of osteoporosis must become a target for 
improvement in physical health of potentially neglected populations of patients. 
 
Tardive dyskinesia (TD) remains a concern for patients treated long term with dopamine 
antagonists/partial agonists (Keck et al., 2000). Acute EPS are still regarded as a 
predictor of subsequent TD, and are probably more common in bipolar patients (Gao et 
al., 2008). Hence the lower EPS associated with the use of the lower potency dopamine 
/serotonin antagonists and the use of the drugs like haloperidol at lower doses should 
reduce the long term risk. Current data on TD are supportive if not conclusive of much 
reduced risks with the newer agents (O'Brien, 2015). 
 
 
Conclusions 
 
Like NICE2014, the group highlighted the superior evidence base for lithium and the 
need for its advantages to be emphasized in training and practice. 
 
In view of the long term problem of depressive symptoms in bipolar patients, the 
potential role of lamotrigine and its currently low rates of utilization in most NHS centres 
have been highlighted. In contrast, the common long-term use of antidepressants appears 
less easy to justify on the basis of the evidence. 
 
NICE2014 was more restrictive in it recommendations for long-term treatment with 
dopamine antagonists/partial agonists (Table 7). Naturalistic data supports a broad range 
of efficacy for these medicines. Moreover, in an individual patient, if a medicine leads to 
prompt remission from the most recent manic or depressive episode, this may be 
considered evidence favouring long-term use as monotherapy (IV).  Because effective in 
the short term, this may lead to their preferential use; active consideration of lithium as a 
better alternative should be promoted. 
 
However, the greatest challenge is the early adoption of a long-term treatment strategy 
acceptable to patient and family. The complex need for access to a responsive and 
intelligent clinical service, psychoeducation and relevant behavioural change, adherence 
to prescribed medicines and informed prescribing is difficult to meet within current 
services for too many patients. 
 
Table 7. NEAR HERE 
 
 
Specific Psychological interventions for relapse prevention in bipolar disorder  
o Psychoeducation is the preferred or ‘first line’ psychological intervention. 
 
o Uncritical endorsement of CBT as a generic method for relapse prevention 
in bipolar disorder is not justified. 
 
o In general, psychological interventions appear to demonstrate efficacy 
most convincingly with patients early in their illness course. 
 
Key uncertainties 
 
 Whether psychological interventions can be modified to be efficacious in patients 
with many previous episodes. 
 Efficacy and feasibility of on line psychological intervention 
 
Group and individual Psychoeducation 
 
As already indicated, we recommend psychoeducation as the preferred or first line 
psychological intervention.  
 
Cognitive behaviour therapy (CBT) 
While bipolar patients share many of the common cognitive distortions and attitudes 
described in unipolar patients (II, (Scott et al., 2000)), a cognitive model is not 
convincing as a complete theory of the illness.  Nevertheless, cognitive theories can 
fruitfully address some specific problems bipolar patients bring to treatment. Therapy 
derives pragmatically from clinical experience with bipolar patients (review by (Scott, 
1996)). A preliminary trial in 42 subjects suggested that CBT could speed recovery from 
depression and prevents the cascade of isolated manic symptoms into full-blown episodes 
(Scott et al., 2001). A formal trial of CBT for currently euthymic bipolar patients 
produced important reductions in rates of syndromal relapse, depression symptom 
reduction, less mania symptom fluctuation and higher social functioning over a one-year 
period compared with treatment as usual (Lam et al., 2003).  The study targeted patients 
who had taken mood stabilisers and were still suffering from frequent relapses.  
Compared with treatment as usual, such enhancement of clinical care appeared to be 
helpful. Treatment included components of education, motivation to take medicines 
reliably, self-monitoring, active relapse prevention measures and problem solving. Action 
plans and modification of behaviours often do not depend solely on the patient to 
recognize abnormal mood states. Disappointingly, the findings from the Lam study were 
not replicated in a larger, more pragmatic CBT study, which showed no benefit at all for 
a large sample of patients versus treatment as usual (Scott et al., 2006). A secondary 
analysis suggested that patients earlier in their illness course were slightly more likely to 
show benefit – as for psychoeducation (see below). Pilot data in an early onset group also 
weakly support this conclusion (Jones et al., 2015b). Negative findings for CBT include 
evidence for equivalence to a cheaper group psychoeducational approach (Parikh et al., 
2012) and a simpler supportive individual approach (Meyer and Hautzinger, 2012). 
 
Resources for complex psychotherapy are always likely to be limited and provision 
should be focused on those patients most likely to benefit. Patients with particularly 
severe personal and social disturbance early in their illness course should probably be 
given priority access. Uncritical endorsement of CBT as a generic method for relapse 
prevention in bipolar disorder is not justified. 
 
Interpersonal and social rhythm therapy (IPSRT) 
The principles of IPSRT derive from interpersonal therapy (IPT), which has never itself 
been studied in bipolar patients (Frank et al., 2000). It places a particular emphasis on 
preserving sleep and regular daily activities. A comparison of IPSRT with ‘intensive 
clinical management’ suggested benefit from this approach. Patients assigned to IPSRT 
in the acute treatment phase developed greater regularity of social rhythms at the end of 
acute treatment and survived longer without a new affective episode over 2 year follow 
up (Frank et al., 2005). IPSRT is of particular interest because it has obvious potential to 
be adapted for automatic monitoring and feedback of diurnal activity from mobile phone 
apps (Nicholas et al., 2015). If it works, a personalized approach to IPSRT-derived self 
management could be made widely available and integrated into clinical care. 
 
Family/Caregivers interventions 
Family interventions are effective in the short and long-term treatment of bipolar disorder 
(Miklowitz et al 2008; Reinares et al, 2008), although not all patients are candidates to 
those treatments. They are mostly based on psychoeducational and CBT paradigms with 
some extra emphasis on expressed emotions. Involvement of family members is clearly 
of most value in younger patients. The key components are psychoeducation about 
bipolar disorder, communication skills training and problem solving skills training. 
 
Cognitive and functional remediation 
Even those patients who achieve full clinical remission present, in many cases, with long-
term cognitive problems and social dislocation. Cognitive and functional remediation, as 
prescribed in group format (Vieta et al., 2014), may be helpful to improve global as well 
as interpersonal and occupational functioning (Torrent et al., 2013). 
 
Further work is required to determine whether there are real differences between 
therapies and whether simpler interventions are worthwhile. The provision of greatly 
increased levels of psychotherapy to vulnerable patients is not without its risks, most 
notably of sexual or financial exploitation by the therapist (Nutt and Sharpe, 2008). The 
disinhibition of bipolar patients in a manic state poses a particular hazard. 
 
Comparison with NICE guidelines: specific psychological treatments 
 
The primary focus of the BAP guideline is a balanced recommendation for the use of 
medicines in the context of a coherent and integrated psychoeducational framework. The 
consensus around the common elements of promising psychological interventions seems 
more convincing than specific therapies, and more immediately applicable through a 
broadly understood goal of psychoeducation for all patients. 
 
NICE2014 made more specific recommendations for psychological treatment of bipolar 
depressive episodes: 
 
‘a psychological intervention that has been developed specifically for bipolar disorder 
and has a published evidence-based manual describing how it should be delivered 
or a high-intensity psychological intervention (cognitive behavioural therapy, 
interpersonal therapy or behavioural couples therapy) in line with  
the NICE clinical guideline on depression.’ 
 
We are not convinced that extrapolation from unipolar depression is justified (IV). 
 
 4. Treatment of alcohol and substance use disorder 
 
The commonest co-morbidity of bipolar disorder is alcohol or substance use disorder.  
Patients appear more likely to present with dysphoric manic states and so bipolar disorder 
should be considered in the differential diagnosis of such presentations. The co-morbidity 
is often present at the first episode. 
 
It is now a clinical consensus that alcohol and substance use co-morbidity should not be 
seen as a secondary phenomenon that will remit with treatment of the bipolar disorder. 
The treatment of alcohol and substance use disorder should be planned in its own right. 
Contemporary approaches are summarized in another BAP guideline and will not be 
repeated at length here.  
 
Thus, we support NICE’s recommendation to ‘Discuss the use of alcohol, tobacco, 
prescription and non-prescription medication and illicit drugs with the person, and their 
carer if appropriate. Explain the possible interference of these substances with the 
therapeutic effects of prescribed medication and psychological interventions.’ 
 
It will be helpful to clarify the treatment target choosing from among assisted withdrawal, 
reduction, relapse prevention or maintenance of controlled drinking. In very heavy 
drinkers, even modest reductions in consumption will significantly reduce the potential 
physical harms. 
 
As described in full in the BAP guideline, naltrexone or nalmefene may help patients to 
reduce their alcohol consumption (III). Acamprosate should be offered if naltrexone has 
not been effective (IV). Disulfiram may be considered if the patient wants abstinence and 
acamprosate and naltrexone have failed. The patient must be able to understand the risks 
of taking disulfiram and have their mood monitored (IV).  
 
It may be helpful also to specify caffeine use and treat its reduction as a valid target in 
sensitive patients. 
 
There is a paucity of studies on which to shape a specific approach to treatment of bipolar 
disorder in patients with alcohol or substance use disorder. One small trial in a relevant 
population supports the combination of valproate with lithium rather than lithium alone 
(Kemp et al., 2009). 
 
5. Treatment of borderline personality disorder 
 
There is very limited evidence on the treatment of borderline personality disorder 
especially when co-morbid with bipolar disorder. The NICE guideline on borderline 
personality disorder (https://www.nice.org.uk/guidance/cg78) understandably addresses 
the stigmatization and barriers to treatment of this patient group. However, it is dogmatic 
about the use of medication: ‘1.3.5.1 Drug treatment should not be used specifically for 
borderline personality disorder or for the individual symptoms or behaviour associated 
with the disorder (for example, repeated self-harm, marked emotional instability, risk-
taking behaviour and transient psychotic symptoms).’ And ‘1.3.5.6 Review the treatment 
of people with borderline personality disorder who do not have a diagnosed comorbid 
mental or physical illness and who are currently being prescribed drugs, with the aim of 
reducing and stopping unnecessary drug treatment.’ 
 
Despite these recommendations, patients with borderline symptoms are not uncommonly 
offered medication in part as an extrapolation from practice in bipolar patients or as 
treatment for depression. Such practice is supported by poor quality studies of 
lamotrigine, lithium, olanzapine, risperidone, aripiprazole and quetiapine, which suggest 
some symptomatic benefit in borderline samples (III, (Lieb et al., 2010)).  
 
The data from patients co-morbid for borderline and bipolar disorders, again very limited, 
also suggest improvement from lamotrigine and valproate on borderline symptoms 
(Frankenburg and Zanarini, 2002; Preston et al., 2004). In the lamotrigine study this 
appeared to be associated with, and so perhaps secondary to, improved control of bipolar 
symptoms. 
 
There are four approaches to psychological treatment of borderline personality; two are 
considered psychodynamic in nature: mentalization-based treatment and transference-
focused psychotherapy. The other two are considered to be cognitive-behavioral in 
nature: dialectical behavioral therapy and schema-focused therapy (Zanarini, 2009). They 
have been investigated in poor quality clinical trials (III or less). In terms of an evidence 
base, there is less to choose between medication and psychological treatment than the 
NICE guidance suggests.  
 
While the NICE borderline guideline acknowledges in passing that the condition is 
commonly co-morbid with bipolar disorder, and implicitly acknowledges that its 
treatment should continue, this probably needs emphasis so as to avoid a polarizing 
approach in the services caring for patients with borderline problems. In fact NHS audit 
suggests that borderline patients with bipolar disorder usually do receive appropriate 
medication as much as 80% of the time (Paton et al., 2015). 
 
6. Treatment of anxiety 
 
The NICE Bipolar disorder clinical guideline (185: 2014. p. 108) states  
“Offer people with bipolar disorder and coexisting disorders, such as personality 
disorder, attention deficit hyperactivity disorder, anxiety disorders or substance misuse, 
treatment in line with the relevant NICE clinical guideline, in addition to their treatment 
for bipolar disorder”….” be alert to the potential for drug interactions and use clinical 
judgement.” We recommend the corresponding BAP guidelines for attention deficit 
hyperactivity disorder (Bolea-Alamanac et al., 2014), anxiety disorders (Baldwin et al., 
2014) or substance misuse (Lingford-Hughes et al., 2012). 
 
Anxiety disorders should be routinely assessed alongside mood symptoms in patients 
with bipolar disorder. The anxiety co-morbidity in bipolar disorder is widely distributed: 
approximate proportions are social anxiety (22%), generalised anxiety disorder (18%), 
post-traumatic stress disorder (17%), panic disorder with / without agoraphobia (17%), 
obsessive compulsive disorder (10%), and agoraphobia without panic (9%) (McIntyre et 
al., 2006). The NICE and BAP guidelines for these primary anxiety disorders detail the 
specific pharmacological approaches. In bipolar patients there is need for caution in the 
use of dual action monoamine re-uptake inhibitors such as venlafaxine and duloxetine 
because of the risk of switch to mania: pregabalin may have advantages because of its 
mode of action (via calcium channels, not GABA receptors as its structure and name 
might lead one to expect). Specific anxiety-focussed psychological treatment – such as 
trauma-focussed CBT and CBT for social anxiety- are recommended rather than ‘generic 
CBT’. In general effect sizes for drug treatment of anxiety disorders appear to be greater 
than for psychological treatments (Bandelow et al., 2015). 
 
Psychological treatments do potentially offer adjunctive approaches for addressing 
anxiety in bipolar disorder where anxiety-specific medication is contra-indicated and/or 
in line with a patient’s preference. However, bipolar disorder is typically an exclusion 
criterion in the trials of psychological treatments so such recommendations represent 
extrapolation.  Moreover, only 22 psychological treatment studies had been published by 
2014 with an anxiety-related outcome measure in adults with bipolar disorders (Stratford 
et al., 2015). Thus, few psychological treatment studies have explicitly targeted anxiety, 
since historically depression has been the focus. Stratford et al conclude that preliminary 
data are promising for CBT for post-traumatic stress disorder and generalised anxiety 
disorder in bipolar disorders. There was no evidence that psychoeducation alone reduced 
anxiety. There is early evidence that when cognitive behavioural therapy (CBT) 
incorporated an anxiety treatment component, anxiety symptoms were reduced in 
cyclothymia, “refractory” and rapid cycling bipolar disorder, whereas standard bipolar 
CBT treatments had only a modest effect on anxiety. CBT during euthymic phases had 
the greatest weight of evidence, although still there is only relatively weak evidence and 
for limited benefit. The preliminary evidence for mindfulness-based cognitive therapy 
was mixed. Where reported, psychological therapy appeared acceptable and safe, but 
more systematic collection and reporting of safety and acceptability information is 
needed.  
 
Development of specific psychological models and treatment protocols for anxiety in 
bipolar disorders may help improve outcomes. However, separate parallel approaches to 
bipolar patients with different anxiety disorders will be unwieldy and restrictive. A 
current theme is that ‘bipolar anxiety’ is perceived to be a common clinical problem even 
if its intensity and structure do not make an anxiety diagnosis. Moreover, anxiety 
symptoms can be argued to have many core features across anxiety diagnoses. The 
challenge is how to develop such a generic approach for bipolar patients. One proposal is 
to take a highly patient-led approach based on qualitative interview and patient 
experience (Jones et al., 2013) from which, if effective, generalizability may be difficult.  
A more mechanistic approach might identify specific psychological treatment 
components responsible for reducing anxiety in bipolar disorder, like the intensity of  
imagery (i.e. experience like perception in the absence of a percept, such as intrusive 
images of traumatic events, or images of performing badly in a social situation, relevant 
to PTSD / social anxiety respectively) (Holmes et al., 2008; Holmes et al., 2011). Anxiety 
requires treatment in its own right, and since anxiety may exacerbate other mood 
symptoms, its treatment may contribute to overall improved mood stability.  There is 
wide consensus that research and development is required (Mitchell, 2015).  
 
As discussed above, in youth prodromes the earliest symptoms may be anxiety (NICE 
2014 p. 91). Further research is especially warranted for prodromal phases and youth 
populations in which anxiety is prominent.  We agree with the NICE guidelines 2014 (p. 
304) “it is important to know the form of psychological therapy that can benefit young 
people with bipolar disorder”. Evidence-based psychological therapy  - even for example 
within CBT - takes disorder-specific forms and may need to be targeted to bipolar 
specific features as well delivered in forms acceptable to youth. 
 
There is a widely perceived need for closer integration between psychological and 
pharmacological approaches, with psychological intervention a potential adjunctive 
treatment for anxiety in the context of long-term maintenance pharmacotherapy for mood 
symptoms. The NICE clinical guideline 185: 2014. p. 264: suggests that psychological 
therapists applying anxiety (or depression) treatment protocol to bipolar disorder “should 
have experience of bipolar”.  Further work needs to be done on standards of training and 
gaining experience of this clinical group. Reading these BAP guidelines should be part of 
this (see comment above in Scope of this Guidance). In addition it is recommended that 
psychological therapists and those prescribing maintain and active clinical links when 
working with the same patient.  
 
7. Treatment in special situations 
 
Children and young adults 
In previous versions of this guideline there was little attempt to make specific 
recommendations for children and young people, so one inference could have been that 
treatment options for this group should be extrapolated from adult data.  One worry has 
been such extrapolation to children falsely diagnosed with ‘bipolar disorder’.  In the 
absence of independent evidence of benefit and from appropriate trials in such children, 
the extrapolation could not be encouraged. A more conservative consensus about 
diagnosis has emerged and there has been some increase in information available since 
the last edition on both efficacy and adverse reactions. Most new studies were conducted 
in the USA and will have included patients with broadly defined bipolar disorder, so the 
diagnosis of mania may have had limited validity. There are studies showing advantages 
compared with placebo of aripiprazole, olanzapine, quetiapine, risperidone (and 
ziprasidone) and further evidence that effect sizes for these medicines is greater than 
lithium or valproate (Correll et al., 2010). Adverse effects on weight were very prominent 
for olanzapine, quetiapine and risperidone (in descending order of harm). Aripiprazole, 
lithium and valproate were better (Singh et al., 2010). 
 
Currently only aripiprazole (for 12 weeks) and lithium are licensed for treatment of 
mania in the UK (children of 12 years and older).  
 
Medications approved by the U.S. Food and Drug Administration (FDA) to treat youth 
with bipolar disorder are risperidone, aripiprazole, quetiapine and olanzapine. 
Specifically, ‘short-term treatment with risperidone can help reduce symptoms of mania 
or mixed mania in children ages 10 and up. Some research has indicated that risperidone 
is more effective in treating mania in young children than other medications. Aripiprazole 
and quetiapine are approved to treat mania symptoms in children 10–17 years old who 
have bipolar I, while olanzapine is approved for use in children ages 13–17.’ 
(http://www.nimh.nih.gov/health/publications/bipolar-disorder-in-children-and-
adolescents/index.shtml#pub7 ). 
 
Empirical data on the treatment of bipolar depression in children and young people are 
scarce. Thus, no trials of SSRIs have been conducted in bipolar depression, a study of 
quetiapine did not separate from placebo and there is only low quality evidence from 
open trials for lithium (Patel et al., 2006) and lamotrigine (Chang et al., 2006). 
 
NICE suggested a structured psychological intervention (individual cognitive behavioural 
therapy or interpersonal therapy) of at least 3 months’ duration for bipolar depression. 
This is a simple extrapolation from unipolar practice. Child and adolescent mental health 
professionals usually take a family-based approach (in the sense of non-specific support 
and psychoeducation) and we note a further need to support the education of these 
patients because manic episodes are easily misunderstood.  
 
Most of the trial data in young people come from family therapy or multi-family 
psychoeducation groups with a focus on relapse prevention so a more balanced view of 
this alternative would be appropriate.  Family focussed psychotherapy is currently the 
most relevant manualized approach to the problem (Miklowitz, 2015; Vallarino et al., 
2015).  
 
The recommendation to treat co-morbidities in accordance with other guidelines could 
imply additional treatment approaches. An integrated treatment that addresses multiple 
presentations of the illness may be more relevant in young people (IV).   
 
For bipolar depression that is moderate to severe, we would consider a pharmacological 
intervention that follows the recommendations for pharmacological interventions for 
adults with appropriate consideration of dosing and potential harms. 
 
Elderly patients 
Patients with bipolar disorder grow old, and older people may develop bipolar disorder de 
novo. Indeed, up to 10% of individuals develop bipolar disorder over the age of 50, an 
increasing number as population longevity increases (Sajatovic, 2002). Treatment follows 
the same principles as for other patient groups, although few studies have been directed 
specifically at the elderly. As a group they are more susceptible to adverse reactions, 
owing increased end-organ sensitivity, impaired circulation, and reduced hepatic and 
renal clearance. This may be especially the case with lithium (Sproule et al., 2000). In 
general treatment doses are lower than those used in younger adults and should be more 
carefully titrated (Naranjo et al., 1995). 
 Bipolar disorder and pregnancy 
 
Bipolar patients may wish to get pregnant. Some psychotropic medicines may reduce 
fertility. Thus, an increased incidence of polycystic ovarian syndrome (Joffe, 2007), 
putatively associated with valproate use, may reduce fertility but be reversible on 
stopping medication. Some dopamine antagonists may impair ovulation by causing 
hyperprolactinaemia and disruption of the hypothalamic-gonadal axis. Conversely, 
switching to a prolactin-sparing dopamine antagonist/partial agonist may cause return of 
fertility and unplanned pregnancy. Carbamazepine reduces the effectiveness of oral 
contraceptives (OC) by enzyme induction: double dosing of the OC is one practical 
solution. 
 
Risks of discontinuation of medication.  
There appears to be a high probability that women who are taking lithium and become 
pregnant will discontinue it. The figure from the UK Health Improvement Network 
primary care database was almost 70% by the 6
th
 week of pregnancy. There is a high risk 
of relapse in affective disorder if medication is discontinued. Thus, 52% of women who 
discontinued lithium during pregnancy relapsed and 70% of the women who remained 
stable after lithium discontinuation during pregnancy relapsed in the post-partum period 
(Meyer and Koro, 2004; Viguera et al., 2000). A systematic review of over 4000 women 
with bipolar disorder or post-partum psychosis confirmed that postpartum relapse rates 
were significantly higher among those who were medication free during pregnancy (66%, 
95% CI=57, 75) than those who used prophylactic medication (23%, 95% CI=14, 37) 
(Wesseloo et al., 2015). Risk of post-partum illness is especially high in women with a 
history of previous post-partum psychosis. Treatment may involve exposure to higher 
doses of psychotropic medicines than would be implied by long-term maintenance 
treatment. Maternal depression has a negative effect on child development (Rice et al., 
2007). 
 
Risk of medication harms. The risk of major congenital malformations in the general 
population is surprisingly high at 2-4% and increases with maternal age. Cohort studies 
have shown that the risk increases to 11% in valproate-exposed babies (II, (Kaneko et al., 
1999)), and 6% in those exposed to carbamazepine (II(Rosa, 1991)), and these risks are 
usually unacceptable. Of course, the great majority of women who conceive while taking 
either drug will still deliver a normal baby. Carbamazepine and valproate are associated 
with a range of congenital abnormalities, including neural tube defects (incidence 1% 
with carbamazepine and 1-2% with valproate (Omtzigt et al., 1992)) and the fetal 
hydantoin syndrome (facial dysmorphophobia, cleft lip and palate, cardiac defects, digital 
hypoplasia, and nail dysplasia), which was originally described with phenytoin. The risk 
of congenital abnormalities is dose related with valproate (blood concentrations over 70 
micrograms/ml are implicated) and increases with the number of antiepileptic agents 
prescribed (II, (Samren et al., 1999)). Valproate has been particularly singled out for 
concern because of apparently higher risks of developmental impairments when 
compared with women taking other anticonvulsants (for epilepsy) (see 
https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-abnormal-
pregnancy-outcomes ). The problems describe include lowered IQ and development 
disorders. 
 
Lamotrigine appears not to increase the risk of foetal malformation in the epilepsy 
population (Vajda et al., 2014). 
 
Lithium’s potential teratogenicity remains less well characterized, because it is a less 
common prescription (and is probably often avoided in pregnancy). In the past, lithium’s 
‘specific association’ with Ebstein’s anomaly was believed to represent a high risk. But 
recent analysis suggests that first trimester exposure to lithium is actually associated with 
a 0.05–0.1% risk of cardiovascular anomalies (a low absolute risk but perhaps still higher 
than in the general population) (I, (Cohen et al., 1994)). Some studies are still interpreted 
to justify echocardiography to check for cardiac problems in exposed babies (Diav-Citrin 
et al., 2014). However, studies have never been large enough (and so included too few 
cases) to be decisive (McKnight et al., 2012). 
 
Many of the risks for bipolar patients may be unavoidable, because population figures of 
30% are given for unplanned pregnancy, and this rate may be higher again in patients 
with mania. Most of the danger for organ development is in the first two months, which 
may be before a woman is aware that she is pregnant. Consequently, all female patients 
of childbearing age should be advised about the importance of effective contraception (II, 
(Smith and Whitfield, 1995)). Pregnancy should be planned in consultation with the 
psychiatrist and should include a full explanation of the treatment options and their 
benefit to harm balance. Treatment options include continuing the existing medication 
throughout pregnancy, switching to alternative medicines associated with lower foetal 
risk before conception, withdrawing some or all medication before conception, and 
reintroducing it either after the first trimester or immediately after birth. The chosen 
option will depend on the patient’s past history, response to treatment and the patient’s 
and clinician’s preferences. If lithium or valproate is continued during pregnancy, 
prescribing slow-release formulations twice or more times daily can minimize high peak 
concentrations. Some authorities consider withdrawal or reduction of lithium before 
(planned) delivery and re-establishing the original dose as before pregnancy immediately 
after delivery (see NICE2014). 
 
Patients who take lithium, valproate, or carbamazepine during the first trimester should 
be advised about prenatal diagnosis and offered maternal alpha-fetoprotein screening and 
a high resolution ultrasound scan at 16-18 weeks gestation. Folate supplementation is 
advised for all pregnant women, but it is unclear whether this reduces the increased risk 
of neural tube defects associated with carbamazepine and valproate. 
 
Maternal physiological changes during pregnancy may necessitate dosage adjustments. 
For example the glomerular filtration rate increases during pregnancy, causing many 
medications to be excreted more rapidly. As a result serum concentrations may fall and 
the mother may require higher doses to prevent a relapse. After birth these changes 
reverse and there is a risk that higher serum concentrations will results in adverse 
reactions, unless doses are reduced. These issues are most relevant to lithium, given its 
low therapeutic index. 
 
ECT can be administered to pregnant women without immediate adverse reactions or 
effects but primary data is very sparse and confounding prevents any comment about the 
safety for the unborn child (Leiknes et al., 2015). 
 
Neurotoxicity of maternal psychotropic medication after birth. In patients who have 
taken medicines up to childbirth, both toxic effects and withdrawal effects have been 
described in clinical case reports/series, although proving causality is often difficult 
(Ebbesen et al., 2000). Vigilance in caring for babies of mothers taking psychotropic 
agents is recommended. Pre-term babies are at particular risk if breast-fed due to reduced 
hepatic capacity. Benzodiazepines may depress neonatal respiration or cause drowsiness, 
hypotonia, or withdrawal symptoms. Dopamine antagonists/partial agonists can cause 
EPS. Tricyclics can cause urinary retention and functional bowel obstruction. Lithium 
has been associated with goitre, hypotonia, and cyanosis. Carbamazepine has caused 
neonatal bleeding and is an indication for prophylactic vitamin K. 
 
In the case of antidepressants, which are prescribed in as many as 6.5% of women 
delivering babies, revised class labelling has emphasized an increased risk of jitteriness, 
poor feeding, crying, and seizures. The mechanisms are unclear but are clearly 
attributable to toxicity, withdrawal, or a combination of factors (Haddad et al., 2005). 
Discontinuation in pregnancy, or a switch to fluoxetine, whose long half-life may reduce 
withdrawal effects, are management options. 
 
Breastfeeding requires an understanding by patients of the potential risks of toxicity to 
the neonate and the need for vigilance in their care. All maternal drugs enter breast milk, 
but the ratio between infant and maternal plasma concentrations varies greatly. The rate 
of adverse reactions attributable to maternal psychotropic medicines is most uncertain 
and depends on sporadic reports of, for example, toxicity due to lithium, hepatic 
dysfunction due to carbamazepine, and thrombocytopenia or anaemia attributed to 
valproate. These risks need to be balanced against the benefits of breast feeding (I, 
(Austin and Mitchell, 1998)). Owing to its narrow therapeutic index lithium is generally 
regarded as being a relative contraindication to breast feeding (I, (Chaudron and 
Jefferson, 2000)) because it is present in breast milk at 40% of the maternal serum 
concentration (American Academy of Paediatrics Committee on Drugs, 2000). 
 
In general, the risks to the infant are the same as those for any patient exposed to the 
medicine, so clozapine is usually regarded as contraindicated because of the risk of 
agranulocytosis. Lamotrigine will carry the possibility of rash. Antidepressants are 
usually present in breast milk in low concentration but there is large individual variation 
and some infants have developed plasma concentrations higher than maternal plasma 
concentrations. Abrupt withdrawal of sertraline may have caused neonatal withdrawal 
effects. 
 
The BUMPS website provides a useful resource for clinical staff and pregnant mothers 
themselves concerned about the use of medicines: http://medicinesinpregnancy.org. 
NICE have revised their guidelines for antenatal and postnatal mental health 
(http://www.nice.org.uk/guidance/cg192 ). 
 
 
Bottle feeding 
A pragmatic alternative to breastfeeding is bottle feeding. This obviously avoids concerns 
about drugs in breast milk and means adherence to drug treatment may be more likely. It 
also has the advantage that responsibility for night feeds may be shared. This may in turn 
protect against the deleterious impact of sleep deprivation on bipolar mood at a critical 
time for mother and infant. Unfortunately, patients may encounter an over-zealous 
approach to breast-feeding advice which assumes they ought to do so.  Common sense 
may well dictate otherwise and women should feel confident to make an informed 
decision that suits them (IV). 
 
The risk of relapse 
Childbirth increases the risk of relapse in patients with bipolar I disorder in the post-
partum period (Robertson et al., 2005). In fact, this effect is most striking in first babies 
and for first psychiatric admissions (I, (Terp and Mortensen, 1998)). The potential 
benefits of adherence to long-term treatment for a mother with bipolar affective disorder 
are to remain free of symptoms, enjoy normal bonding with her child, and facilitate 
neonatal development.  Failure to control symptoms will risk harm to the mother/child 
relationship directly or via co-morbid alcohol, drug, and nicotine consumption. Against 
the benefits there are some risks. These include teratogenesis, neonatal adverse reactions 
that may reflect drug toxicity, and withdrawal effects. 
 
Patients with bipolar II disorder are at an increased risk of mood episodes in general (and 
during pregnancy) but not particularly in the post-partum periods. A history of child-hood 
sexual abuse is associated with an increased risk of post-partum depression (Robertson et 
al., 2005). 
 
Suicide is a major cause of maternal death in developed countries (Oates, 2003) and is 
sometimes associated with infanticide. It is a sombre note on which to conclude, but 
perhaps helps underline just how fatal a disease bipolar disorder sometimes is. 
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Annex: Additional information about medicines  
 
For newer medicines, clinicians may wish to consult Summaries of Product 
Characteristics (SmPCs). However, there is some question about their accuracy and 
utility, certainly for adverse drug reactions (Ferner et al., 2005). Many Trusts will have a 
medicines information service. 
 
Unexpected adverse reactions in bipolar patients should be reported to the relevant 
licensing authority. There is much accumulated experience to guide the use of lithium. 
Nevertheless, it is potentially toxic and there is an important potential for litigation if 
accepted procedures are not followed. Experience with the anticonvulsants is growing in 
bipolar patients and is extensive from the epilepsy field. 
 
Lithium 
 
Initial workup  
• General medical history, physical examination and weight. 
• Blood creatinine concentrations, e-GFR, thyroid function (Kripalani et al., 2009). 
• Pregnancy test (in women of childbearing age) 
 
Dosing 
• Lithium is available in a confusing variety of formulations: immediate or modified 
release, tablet or liquid. The pharmacokinetics are not very different but the doses may 
be. It is probably best to prescribe as a proprietary brand to avoid confusion.  
• Lithium is usually best given as a single dose at night, to facilitate adherence. Twice a 
day dosing may be associated with a higher risk of renal side effects.  
• If possible start at a dose that will allow some calibration for renal function: e.g. 400mg 
(as lithium carbonate) if normal renal function. Check lithium serum concentration after 2 
weeks. 
• Titrate the dosage further upward if necessary (generally to serum concentrations of 
0.6 to 0.8 mmol/L) according to response and adverse reactions. 
• The commonest dose for younger patients is 800 mg/day, which can be tapered at the 
clinician’s discretion. 
• Check lithium concentration after later dosage increases (steady-state concentrations are 
likely to be reached about 5 days after a dosage adjustment). 
• The “optimal” maintenance dose is the highest tolerated without significant adverse 
reactions. It will vary from patient to patient. 
• Older patients, and others with reduced renal function, will require lower doses. 
• In acute mania, higher serum concentrations (1.0 to 1.5 mmol/L) are claimed to be more 
efficacious, but this approach should be reserved for unusual circumstances where 
alternative treatments are contra-indicated or have failed. 
 
Long-term monitoring of laboratory values 
• Measurement of lithium concentrations is primarily to avoid doses leading to toxicity 
(over 0.8 mmol/l), rather than as a strict guide to efficacy (concentrations over 0.6 mmol/l 
appear best). 
 • As long as lithium heparin is not used as an anticoagulant, plasma can be used to 
measure the lithium concentration; plasma and serum lithium concentrations are 
identical. 
• Blood for estimation of lithium concentration should be drawn 12 hours after the last 
dose. 
• Serum lithium concentrations should be checked whenever the patient’s clinical status 
changes, for example during intercurrent illnesses, such as infections, when it is thought 
that renal function may be changing, and when other drugs that may interact with lithium 
are introduced. The most important drug interactions are with diuretics, ACE inhibitors 
and non-steroidal anti-inflammatory drugs. 
• If it has not been necessary to check the lithium concentration otherwise, it may be 
checked every 3-6 months in stable patients, if only to reassure the clinician that the 
treatment is still adequate. Monitoring at this frequency appears to be recommended 
because it is feared that less frequent monitoring will lead to no monitoring at all. In fact, 
less frequent (annual) but assured monitoring of every patient would probably be more 
rational and cost effective. Rapid decline in renal function would be unlikely to be 
detected unless monitoring was more frequent than 3 monthly, and is anyway very rare. 
• Renal and thyroid function should be checked every 12 months in patients with stable 
renal thyroid function (and no change of lithium dose) or whenever the clinical status 
changes. 
 
Adverse reactions 
• Adverse reactions include tremor, polyuria, polydipsia, weight gain, cognitive 
problems, sedation or lethargy, impaired coordination, gastrointestinal distress, hair loss, 
benign leukocytosis, acne, and edema. 
• The common adverse reactions can usually be reduced or eliminated by lowering the 
lithium dose or changing the dosage schedule. 
• During long-term lithium treatment (>10 years), 10–20% of patients develop 
morphological kidney changes. These changes are not generally associated with renal 
failure, although there are case reports of renal insufficiency attributed to lithium. 
• Fluid restriction is contraindicated. Troublesome polyuria can be reduced by amiloride 
(check other electrolytes). 
• Lithium can cause hypothyroidism; if the serum TSH rises consider adding 
levothyroxine. 
• For persistent tremor consider adding propranolol (asthma is a contra-indication). 
 
• Most patients experience toxic effects with concentrations above 1.5 mmol/L; 
concentrations above 2.0 mmol/L are associated with life-threatening toxicity and require 
urgent treatment: haemodialysis may be needed to minimize toxicity. 
• Lithium toxicity should also be suspected even when concentrations are in the usual 
target range in compromised patients with symptoms that are consistent with toxicity. 
 
Lithium discontinuation 
• Abrupt discontinuation of lithium provokes manic relapse in Bipolar I patients (50% in 
the next 12 weeks). Accordingly, lithium should always be tapered over at least 4 weeks 
or longer except in medical emergency or overdose.    
 
 
Valproate 
 
Initial workup 
• General medical history, with special attention to hepatic, haematological, and bleeding 
abnormalities, physical examination, and weight. 
• Liver function tests. 
• Pregnancy tests in women of childbearing age 
• Earlier estimated risks for development of polycystic ovarian syndrome appear to have 
been misleading for valproate (Duncan, 2001). 
•  
 
 
Dosing 
• Valproate formulations are closely similar: 
 
 
 
• Doses will be given for valproate semisodium because almost all the controlled data 
was obtained with this formulation. For hospitalized patients with mania, valproate 
semisodium can be administered at an initial dosage of 20 to 30 mg/kg per day in 
inpatients. A serum valproate concentration between 50 and 125 microg/mL has been 
associated with an acute response. 
• For outpatients, elderly patients, or patients with hypomania or euthymia, start at 500 
mg valproate semisodium at night. Titrate the dose upward by 250 to 500 mg/day every 
few days, depending on adverse reactions. The SmPC suggests divided doses, but in 
practice a single dose can often be given at night. The maximum adult daily dosage is 60 
mg/kg/day, but all patients taking daily doses higher than 45 mg/kg should be carefully 
monitored. However, a total dose of 1250 mg/day is the highest usually well tolerated by 
outpatients. 
. 
Long-term monitoring of laboratory values 
• Repeat liver function tests may be indicated in the first six months of treatment, 
although clinical vigilance is more important. Severe reported complications have 
occurred early in treatment and usually in children in treatment for epilepsy. 
 
Adverse reactions 
• Common adverse reactions to valproate include gastrointestinal pain, rises in hepatic 
aminotransferases, tremor, and sedation. 
• Patients with past or current hepatic disease may be at increased risk of hepatotoxicity. 
• Mild, asymptomatic leukopenia and thrombocytopenia occur less frequently and are 
reversible on drug discontinuation and sometimes with dose reduction. 
• Other adverse reactions include hair loss, increased appetite, and weight gain. 
• Rare, but potentially fatal adverse reactions include irreversible hepatic failure, 
hemorrhagic pancreatitis, and agranulocytosis; patients should contact their physician 
immediately if severe symptoms develop. 
 
Drug-drug interactions 
• Many drug interactions have been reported for valproate due to protein binding 
displacement, other kinds of pharmacokinetic interactions, some pharmacodynamics 
effects and even a combination of these effects. Seek expert advice if in doubt. 
• Valproate inhibits the metabolism of lamotrigine, which must be initiated at half the 
usual dose when added to valproate. Accordingly, lamotrigine dosage should be reduced 
when valproate is added to it. 
• Valproate can significantly lower plasma levels of olanzapine when co-prescribed. 
 
Carbamazepine 
 
Initial workup 
• General medical history with special attention to blood dyscrasias or liver disease. 
• Complete blood count (CBC) with differential and platelet count, liver function tests, 
and creatinine. 
• Serum electrolytes in the elderly, who may be at higher risk of hyponatraemia. 
 
Precautions 
Similar to valproate, carbamazepine is associated with multiple drug-drug interactions. 
Induction of enzymes can reduce the effectiveness of co-prescribed medications 
including antipsychotics, antidepressants, and oral contraceptives. 
 
Dosing 
• Carbamazepine is usually started at a dose of 400 mg at night for outpatients with acute 
mania. 
• In hospitalized patients with acute mania, the dosage may be increased in increments of 
200 mg/day up to 800-1000 mg/day or higher if tolerated. 
• Maintenance dose ranges from 200 to 1600 mg/day in routine clinical practice and 
should be as high as possible without producing adverse reactions. 
 
Long-term monitoring of laboratory values 
• CBC, platelet count, and liver function tests may be performed during the first 2 months 
of treatment. 
• Monitoring is less important than clinical vigilance for potentially serious adverse 
reactions (see below). 
 Adverse reactions 
• The most common dose related adverse reactions include fatigue, nausea, and 
neurological symptoms such as diplopia, blurred vision, and ataxia. 
• Less frequent adverse reactions include rashes, mild leukopenia, mild rises in liver 
enzymes, mild thrombocytopenia, hyponatremia, and (less commonly) hypo-osmolality. 
• Rare, idiosyncratic, but serious and potentially fatal adverse effects include 
agranulocytosis, aplastic anemia, thrombocytopenia, hepatic failure, Stevens-Johnson 
syndrome, toxic epidermolysis, and pancreatitis. 
• Awareness of the possible significance of fever, sore throat, rash, mouth ulcers, and 
bruising or bleeding is essential in view of the rare but severe adverse reactions. 
Patients should be encouraged to seek urgent medical attention if they occur. 
• Other rare adverse reactions include systemic hypersensitivity reactions; alopecia; 
cardiac conduction disturbances; psychiatric symptoms, including sporadic cases of 
psychosis; and, very rarely, renal effects, including renal failure, oliguria, hematuria, and 
proteinuria. 
• The carbamazepine analogue oxcarbazepine may be a useful alternative to 
carbamazepine based on its superior adverse reactions profile. 
 
Lamotrigine 
 
Dosing 
• Doses of lamotrigine should be increased slowly, and starter packs are available for this 
purpose, giving 25 mg/day for the first 2 weeks, then 50 mg/day for weeks 3 and 4. After 
that, 50 mg/day can be added at weekly intervals as clinically indicated up to doses of 
400 mg/day. 
• In patients who are receiving valproate, or other inhibitors of hepatic metabolism, the 
dose or the dosage schedule should be halved (i.e., 12.5 mg/day or 25 mg every other day 
for 2 weeks, then 25 mg/day during weeks 3 and 4). 
• Concurrent treatment with carbamazepine, or other inducers of hepatic metabolism, will 
lead to increased metabolism of lamotrigine and will require that dosing be doubled. 
 
Adverse reactions 
• The most serious early risk is a rash associated with influenza-like symptoms and 
hypersensitivity. It is not established that early rashes “progress” to Stevens-Johnson 
syndrome and toxic epidermal necrolysis, even when the early rash is erythema 
multiforme. Nevertheless, there have been reports of Stevens-Johnson syndrome and 
toxic epidermal necrolysis and drug withdrawal is therefore recommended. In early 
clinical trials with patients with epilepsy, rapid titration of lamotrigine dosage was 
associated with an incidence of approximately 0.3% in adults and approximately 1% in 
children. A slow dosage titration schedule (as above) reduces the risk of serious rashes in 
adults to 0.01% (comparable to other anticonvulsants). Patients should be informed of the 
risk of rashes and of the need to contact the psychiatrist or primary care physician 
immediately if any rash occurs. 
• At rash onset, since it is difficult to distinguish between a serious and a more benign 
rash, lamotrigine should always be discontinued. If the rash is trivial and disappears, 
lamotrigine can be reintroduced even more slowly. 
•If rashes are accompanied by fever or sore throat, are diffuse and widespread, or show 
prominent facial or mucosal involvement, all possible provoking agents should be 
stopped and re-introduction should be extremely cautious if attempted at all. 
• Rashes may be more likely if lamotrigine and valproate are administered concomitantly, 
primarily because the half-life of lamotrigine is effectively doubled or tripled because of 
inhibition of its hepatic metabolism by valproate. 
  
Figure 1. The problem for early detection of bipolar disorder.  
Adapted from (Berk et al., 2007). 
 
   
Table 1. Traditional evidence categories. 
Randomized Controlled Trials (RCTs) must have an appropriate control treatment arm; 
for primary efficacy this should include a placebo condition although for psychological 
treatments this may not be met. BAP: British Association for Psychopharmacology. 
Evidence categories Treatment studies Observational studies 
I Meta-analysis of RCTs, at least 
one large, good quality, RCT 
or replicated, smaller RCTs 
Large representative population 
samples 
II Small, non-replicated RCTs, at 
least one controlled study 
without randomization or 
evidence from at least one 
other type of quasi-
experimental study 
Small, well designed but not 
necessarily representative 
samples 
III Non-experimental descriptive 
studies, such as uncontrolled, 
comparative, correlation and 
case-control studies 
Non-representative surveys, 
case reports  
IV Expert committee reports or opinions and/or clinical experience of 
BAP expert group. 
 
  
Table 2. Grades of recommendation and their relationship with supporting levels of 
evidence 
 
Grade of 
recommendation 
Underlying methodology Symbol 
High RCTs or double upgraded 
observational studies 
**** 
Moderate Downgraded RCTs or 
upgraded observational studies 
*** 
Low Double downgraded RCTs or 
observational studies 
** 
Very low Triple downgraded RCTs or 
downgraded observational 
studies or case series/reports 
* 
 
  
Table 3. Treatment of different phases of bipolar illness: summary and grade. 
NMA: Network meta-analysis 
 
 
Phase of 
illness 
Modality and  
Format 
Underlying 
methodology 
Recommended 
Treatments 
GRADE 
Manic 
episode 
 
Medication: 
hierarchy of 
effective 
treatments 
Coherent 
plausible NMA; 
RCTs 
Dopamine 
antagonists, 
valproate, 
lithium 
**** 
Depressive 
episode 
 
 
Medication: 
choice of 
alternative 
treatments (NMA 
not likely to be 
stable) 
Downgraded 
RCTs (risk of 
unblinding) 
Quetiapine *** 
Downgraded 
RCTs (small size) 
Olanzapine, 
Olanzapine plus 
fluoxetine 
Antidepressants 
*** 
RCTs Lurasidone 
Lamotrigine as 
combination 
**** 
Psychotherapy (as 
add on to 
medication) 
Downgraded 
RCTs 
FFT, CBT, ISPT ** 
Psychotherapy 
alone 
Extrapolation 
from unipolar 
depression 
CBT * 
Long term  Medication: 
hierarchy of 
effective 
treatments (NMA 
supportive not 
decisive) 
RCTs; double 
upgraded 
observational 
studies 
Lithium 
(Mania, 
depression, 
suicide) 
**** 
Downgraded 
RCTs; double 
upgraded 
observational 
studies 
Dopamine 
antagonists and 
partial agonists,, 
valproate  
(mainly mania) 
**** 
RCTs; double 
upgraded 
observational 
studies 
Lamotrigine 
(depression) 
**** 
Psychotherapy (as 
add on to 
medication) 
RCTs Psychoeducation
FFT 
**** 
Downgraded 
RCTs 
CBT, IPSRT ** 
 
 
 
 Table 4. Recommendations for audit in bipolar patients 
 
Diagnosis 
 
Is there a structured patient-completed (or structured interview) record? 
Is there a record of the manic symptoms in mania? 
Is there a record of the depressive symptoms in depression? 
Have symptoms of borderline personality disorder been recorded as present or absent? 
Is there a record of anxiety symptoms? 
Has the history of alcohol and drug use (including caffeine) been documented? 
Has impairment of memory and executive function (or functional impairment) been 
considered? 
 
Risk assessment 
 
Is suicide risk recorded? 
Is neglect of self and dependents, exploitation by others considered? 
Is risk of violence or offending considered? 
 
Physical health 
 
Is a physical health screen conducted annually? 
weight, blood pressure, lipids, fasting glucose 
renal and thyroid function, calcium concentration if taking lithium 
Has appropriate treatment been offered for physical health problems? 
 
Treatment 
 
Lithium 
Has lithium been offered for maintenance treatment?  
Is the use of lithium safe? 
(baseline eGFR, lithium concentrations, thyroid function, calcium) 
Are serum concentrations of lithium measured regularly? 
Are serum concentrations of lithium maintained above 0.6 and below 0.8mEq/l? 
 
Dopamine antagonists/partial agonists.  
Are doses within accepted limits? 
Are multiple dopamine antagonists/partial agonists being prescribed together? 
Is long-term use justified? 
 
Drugs for bipolar depression 
Is prescription of antidepressants for depression or anxiety? 
Is there evidence of treatment response to the antidepressant? 
Is use justified? 
Have options with a better evidence base for treating depression been considered (e.g 
lamotrigine, quetiapine) 
 
Valproate 
Is valproate being used in women of childbearing age? 
If so, is a written justification recorded in the case notes? 
Has the patient clearly understood the risks? 
Has effective contraception been offered?  
 
 
Psychological interventions 
 
Has psychoeducation been offered? 
Is there a mechanism in place for regular mood monitoring? 
Is there a plan which anticipates the actions required when the patient relapses with 
mania, develops a worsening of depressive symptoms or expresses suicidal ideas? 
Is the person delivering the psychological intervention linked to other members of the 
care team?  
  
  
Table 5. Comparison of emphasis in planning service provision for bipolar patients. 
The items where benefit is uncertain, or based on no formal evidence for bipolar disorder, 
are marked with an asterisk. 
 
  
 
 
NICE BAP 
Access to early intervention for 
psychosis 
Access to early intervention from experts 
in bipolar disorder(S). For mania, always 
consider admission to hospital or 
intensive community management (S). 
Care programme approach*  
Continue in specialized service or 
integrated CMHT but offer those stable 
the option of a return to primary care* 
Long-term specialist services with a 
consistent flexible alliance (S) with a 
specifically trained psychiatrist(S) 
Discuss self-management and 
engagement 
Help patient and carers recognize early 
signs of relapse 
Intensive case management for those 
likely to disengage.  Crisis 
management* 
Disorganised patients need assertive 
management  
Offer a structured psychological 
intervention 
Offer family intervention 
Offer supported employment 
programme* 
Consider offering enhanced psychological 
and social support 
 
  
Table 6. Comparison with NICE guidelines: bipolar depression 
 
NICE2014 BAP 
Offer fluoxetine combined with 
Olanzapine (OFC), or quetiapine 
monotherapy. 
Consider quetiapine, lurasidone or 
olanzapine monotherapy 
Consider either olanzapine 
(without fluoxetine) or 
lamotrigine monotherapy. 
Consider initial treatment with 
lamotrigine, … usually as an 
addition to agents preventing 
recurrence of mania  
If there is no response to OFC or 
quetiapine, consider lamotrigine 
monotherapy. 
Consider the use of an 
antidepressant with an antimanic 
drug in bipolar I patients 
ECT noticed but not 
recommended. 
Consider ECT in severe or 
refractory depression 
Offer a psychological 
intervention that has been 
developed specifically for bipolar 
disorder.  
 
Consider family-focused, cognitive 
behavior therapy or interpersonal 
rhythm therapy as an additional 
treatment (not as a primary 
treatment option) 
Within 4 weeks of resolution of 
symptoms, discuss …whether to 
continue treatment for bipolar 
depression or start long-term 
treatment 
Consider the strategy for long-term 
treatment as patient recovers 
 
 
  
Table 7. Comparison with NICE guidelines: long-term treatment 
 
NICE BAP 
Offer lithium as a first-line 
Consider lithium as first line treatment 
in adherent patients 
If lithium is ineffective, consider 
adding valproate 
If lithium alone is ineffective consider 
combination treatment (depression 
predominant: ADD lamotrigine, 
quetiapine or lurasidone to lithium; 
mania predominant: ADD valproate or a 
dopamine antagonist/partial agonist to 
lithium) 
if lithium is poorly tolerated or 
unsuitable, consider valproate or 
olanzapine or (if acutely effective) 
quetiapine 
If lithium is poorly tolerated or 
unsuitable, consider other options: 
valproate, dopamine antagonists/partial 
agonists 
 
Consider lamotrigine as monotherapy in 
bipolar II disorder when depression is 
the major burden 
 
Within 4 weeks of resolution of 
symptoms, discuss …. whether to 
continue psychological or 
pharmacological treatment for bipolar 
depression or start long-term treatment 
Consider the strategy for long-term 
treatment as patient recovers 
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